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SUMMARY
Improvements in living standards and health care 
have caused a great increase in the number of elderly 
individuals in our community. The problems associated 
with age are many, but one in particular is of interest 
in this thesis: bone loss and the problems of metabolic
bone disease, leading to various studies concerned with 
their effects on bone and bone metabolism.
Organ culture preparations of neonatal mouse calvaria
were used to look at several aspects of bone metabolism.
By preparing standard cultures of neonatal mouse calvaria,
45but with the bone prelabelled with Ca and the culture
47medium labelled with Ca, it was possible to look at the 
effects of human serum from patients suffering from 
metabolic bone disease on bone turnover in vitro. The 
results of this study proved interesting, suggesting that 
such sera act on bone to produce particular patterns of 
formation and resorption, reminiscent, in general, of the 
symptoms of the bone disease in vivo. Although there 
are other and better ways of diagnosing metabolic bone 
disease, such as serum biochemistry and bone histology, 
this method could be useful in assessing the development 
of any disorder. Human serum is abundant and easy to 
obtain, unlike human bone, and the cultures are easy to 
prepare; the effects of any drug therapy on bone turnover
10.
can be seen quickly, by monitoring ^^Ca and ^^Ca in the 
culture medium, and by constant monitoring of serum 
biochemistry, it may be possible to understand how 
particular drug therapies affect bone.
The enzyme alkaline phosphatase stimulated a lot of 
interest. First of all the relationship between serum 
alkaline phosphatase and the level of the enzyme within 
bone itself was studied, showing a strong correlation between 
the two parameters and supporting the study of serum alkaline 
phosphatase levels as a tool in the diagnosis of metabolic 
bone disease. Dialysis osteomalacia is thou#it to be 
caused by the inhibition of alkaline phosphatase, through 
the build-up of aluminium. By studying the effect of 
aluminium in vitro, it was found that it does inhibit 
alkaline phosphatase, the inhibition of which is accompanied 
by high.levels of free calcium in the culture medium, showing 
a strong inverse relationship between alkaline phosphatase 
and calcium and supporting the role of the enzyme in 
mineralisation. This relationship was also supported 
when alkaline phosphatase and free calcium levels were 
compared'in cultures containing foetal calf serum and with 
human se rum.
Other studies concerned with metabolic bone disease 
involved the assay of two different and unrelated enzymes: 
collagen prolyl hydroxylase and creatine kinase.
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Collagen is the main structural component of bone 
and collagen prolyl hydroxylase is the enzyme responsible 
for the hydroxylation of proline, without which the classic 
triple helix structure cannot be formed. By assaying 
homogenates of bone obtained by biopsy of the iliac crest, 
it was hoped to discern any differences in collagen 
metabolism between the different metabolic bone diseases. 
Unfortunately, for a variety of reasons, it was not possible 
to pursue this line of study as much as was desired.
The assay of creatine kinase was more successful. 
Creatine kinase is the enzyme involved in the breakdown of 
the high energy molecule creatine phosphate to form ATP 
and is particularly abundant in skeletal muscle. Normal 
serum has little or no creatine kinase content, but the level 
has been found to change with different disorders, 
particularly those related to muscle weakness. As many 
metabolic bone diseases are severely debilitating, it was 
decided, looking at homogenates of striated muscle, to 
see if there is any pattern of creatine kinase activity in 
different metabolic bone diseases. Results showed no 
difference in creatine kinase levels in striated muscle 
in different metabolic bone diseases, but showed higher 
levels in the muscle of males than in females and ‘ 
increasingly high levels of the enzyme, for both sexes, 
with increasing age. Previous work, looking at serum
12.
creatine kinase levels, related the sex-difference to the 
inhibition of the enzyme by oestrogen in pre-menopausal 
women.
The culture of human bone fragments is possible, but 
not desirable as long as uniform samples, containing 
equivalent amounts of cells and bone, of a suitable size
are difficult to obtain. Human bone cell cultures are more
desirable as they would be easier to reproduce and control. 
Although unsuccessful here, new technology will aid the
culture of human bone cells and these cultures will play
an important role in the study of metabolic bone diseases.
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GENERAL INTRODUCTION
The recent advances made in the field of modern 
medicine have produced many important improvements in the 
lives and life expectancy of countless thousands of people; 
however these advances themselves may lead to new or 
previously unconsidered problems, for example, those related 
to metabolic bone diseases. As individuals age they lose 
bone, becoming evident in men over 50 and women over 40, and 
once bone loss has begun it proceeds linearly with age. Until 
recently, in this country, the life expectancy of the average 
individual was only 40 or 50 years and bone loss with 
increasing age posed few problems, but with today's aging 
population: a 14% increase in the number of women over 80
(1971-1977, Scotland ) (Boyle, 1981), this is no longer the 
case and we have many elderly people suffering from the 
consequences of prolonged bone loss. The increasing 
significance of metabolic bone diseases makes them a very 
relevant topic of study, because of both social and medical 
aspects. This thesis is concerned with studies of bone 
metabolism in metabolic bone diseases, using various biological, 
biochemical, chemical and histological means in an attempt to 
understand the basis of these clinical problems.
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Bone is a complex organ, well known for its 
supportive role in providing the skeleton, but also very 
important in maintaining mineral homeostasis within the 
body through its constant formation and resorption 
(Vaughan, 1965; Jackson, 1967; Rasmussen, et al. 1974).
Frost (1981) has hypothesised that bone is made up of bone 
modelling units (B.M.U.), whereby specific areas of bone 
are undergoing constant turnover in an attempt to maintain 
the strength of the skeleton, as well as answering the 
need for minerals throughout the body. Changes through 
the process of bone remodelling, where formation follows 
resorption and takes place at sites of previous resorption, 
are fundamental to most metabolic bone diseases and can often 
result in serious dysfunction of the bone.
The basis of all bone function relates to the complex 
arrangements of cells and matrix within the bone , with each 
type of bone cell: osteoclasts, osteoblasts and osteocytes,
performing specific tasks in the maintenance of bone, bone 
matrix and ground substance. The spacial arrangements of 
these cells, as well as their differing shapes and sites, 
can be seen in FIGURE A.
Osteoclasts are the largest cells found in bone and 
can be easily recognised as they may contain up to 20 
nuclei; vacuolated cytoplasm contains those enzymes, chiefly 
acid phosphatase, so important in their role as bone-resorbing 
cells (Smith, 1979). Circulating monocytes have been found
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FIGURE A
Histological section showing osteocytes in 
bone lacunae, or chambers, osteoblasts at 
the bone-forming surface and multinucleate 
osteoclasts in Howship’s lacunae.
1 osteocyte
2=osteoblasts
3=osteoclast
to be attracted to sites of bone resorption, as well as 
being capable of resorbing bone, leading Mundy, et al.
(1977, 1978) to suggest that these cells may be the origin 
of osteoclasts found in bone.
Biochemical changes produced by osteoclasts during 
bone resorption have been studied by Wong, et al. (1977), 
who noted increased levels of hyaluronate, a matrix 
component, and increased acid phosphatase activity; acid 
phosphatase is involved in the breakdown of bone matrix 
(Marks, 1974). Osteoclasts, as well as monocytes, 
phagocytose any bone fragments produced during bone 
resorption (Kahn, et al, 1978). Chambers (1980) describes 
the origin and role of osteoclasts, with evidence supporting 
their origin from circulating monocytes and their production 
of lysosomal enzymes during bone resorption.
Bone resorption occurs in the general maintenance of 
bone structrue, but also occurs in response to biochemical 
stimuli from throughout the body, such as parathyroid hormone, 
the vitamin D metabolite 1,25(011)203 (Wong, et al. 1977) and 
prostaglandins (Bookman, 1980). It would seem that para­
thyroid hormone acts directly on the osteoclasts to promote 
bone resorption, increasing their numbers (Rowe, et al. 1977), 
while prostaglandins act by stimulating 3-lymphocytes, which 
in turn produce an osteoclast-activating factor (O.A.F.) 
(Bookman, 1980). Vitamin D metabolites, it would seem, 
act generally to stimulate bone turnover (Mittleman, et al.196 8 ;
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Raisz et al. 1972; Boyle, 1974; Stern, et al. 1976;
Peacock, et al. 1976; Wong, et al. 1977). Interestingly, 
recent work by Howard, et al. (1981) would seem to suggest 
that osteoclasts may be involved in the extra-renal 
synthesis of vitamin D metabolites in patients suffering 
from chronic renal failure, where the patient cannot 
synthesise these metabolites in the normal way and the number 
of osteoclasts is found to be increased.
Osteoblasts are the bone-forming cells: small cells
with single nuclei, rich in the enzyme alkaline phosphatase, 
which is believed to increase local phosphate concentrations 
for the formation of calcium phosphate and the deposition of 
bone mineral (Jackson, 1967; Scott, et al. 1980); these 
cells are also important in bone matrix formation. There 
are several different views as to the origin of osteoblasts. 
Owen (1977) holds the opinion that, while osteoclasts are 
derived from circulating monocytes, osteoblasts are derived, 
separately, from reticular cells of the reticulo-endothelial 
system; Rasmussen, et al. (1973,1974) believe that they 
are derived from osteoclasts. Osteoblasts form a single 
layer on the surface of bone, lying parallel to the underlying 
collagen 'fibres, which form the basis of the bone structure.
Osteocytes are osteoblasts which have become 
encapsulated within bone during its formation and can be 
found within small chambers, or lacunae (Jackson, 1967).
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From within these lacunae osteocytes send out cytoplasmic 
processes of up to 100 pm in length, connecting with 
similar processes from other osteocytes and with the 
circulatory system (Rasmussen, et al. 1974), allowing them 
to respond to chemical changes throughout the body and 
forming an organised network between the cells of bone 
(Parfitt, 1976). When osteocytes die and contact between 
bone cells and their environment is lost, bone can no 
longer function effectively (Aaron, 1976).
Various groups have studied the relationship between 
age and bone cell function. The famous American 
endocrinologist Albright (Albright, et al. 1948) provided 
what is now regarded as the classic view on bone loss in 
elderly women, concentrating on osteoporosis, the most 
prevalent disorder in aging bone. He believed, like 
Rasmussen, et al. (1973, 1974), that osteoblasts are derived 
from osteoclasts and that the increasing loss of bone with 
increasing age is due to a decrease in the number of bone- 
forming cells. Through a lack of progression from
osteoclasts to osteoblasts, or because the number of cells 
which could derive from osteoclasts became decreased, 
osteoclasts in osteoporotic bone averaging only 2.5 nuclei 
per cell as opposed to 4 nuclei per cell in normal age- 
matched bone, the ability to form bone decreases with age; 
at the same time, though, the number of osteoclasts and the 
degree of bone resorption remains unchanged, leading to 
net bone loss.
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Two other, independent, studies of bone histology 
by Mert, et al. (1969) and Bordier, et al. (1972) note 
an increased accumulation of bone resorption surface, 
while the rate of active bone resorption remains the 
same; the number of osteoblasts, also in accordance with 
Albright, et al. (1948), was found to decrease. It would 
seem, therefore, that bone loss with age occurs through 
decreased bone formation, with no compensatory change in 
bone resorption, leading to progressive loss of bone.
Collagen is the major extracellular protein found 
in the body and more than 50% of it is found in bone, 
forming the basis of the extracellular bone matrix 
(Grant, et al. 1972). Osteoblasts, the bone-forming cells, 
produce procollagen precursors, a-chains, which are 
extruded into the extracellular matrix and formed into 
collagen bundles, triple helices (Rasmussen, et al. 1974; 
Smith, 1979). In a study of the role of collagen in 
mineralisation, Strates, et al. (1957) successfully induced 
calcification in collagen from tissues which do not normally 
calcify, while Bachra, et al. (1959) found that the lamellar 
organisation of collagen is important as a 'local factor' 
in initiating mineralisation. Rasmussen, et al. {1974) 
supported the idea of some cellular involvement in the 
mineralisation of bone, with Miinzenberg, et al. (1975) 
believing that the calcium phosphate crystals and collagen
2 0 .
matrix in bone form a specific spacial interaction by 
which calcification can take place and Vaughan (1975) 
claiming that the mucopolysaccharides in the matrix 
also have some role to play. It would seem then that 
collagen could be important, perhaps along with other 
factors, in bone mineralisation. In this thesis collagen 
is studied with respect to the enzyme collagen prolyl 
hydroxylase, involved in the hydroxylation of a- 
for the formation of the triple helices; this enzyme is 
discussed in greater detail in a later chapter.
Abnormalities in bone metabolism can give rise to 
several clinical pictures: osteoporosis, rickets or
osteomalacia, hyperparathyroidism and, perhaps, Paget's 
disease of bone, among many others. Patients suffering 
from these disorders have formed the basis of this study.
The most widespread disorder of bone affecting the 
elderly, particularly women, is osteoporosis. This 
disorder is characterised by a continuous loss of bone 
with age, although the biochemistry and pathology of the 
bone present is absolutely normal (Albright, et al. 1948). 
Albright and Reifenstein, as mentioned above, found that 
this continuous bone loss resulted mainly from an inability 
to form sufficient bone in reply to normal bone resorption. 
The clinical consequences of osteoporosis are characterised 
by femur and fore-arm fractures, as well as crush fractures 
of the vertebrae (Smith, 1979).
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Coupron (1972) has suggested that those persons 
suffering most from the effects of osteoporosis had, in 
general, less bone than normal to begin with. However, 
Chalmers, et al. (1970), in their comparative study of the 
incidence of vertebral crush fractures in Oriental and 
European women, found that the former, with their smaller 
skeletons, showed no greater tendency towards fractures.
Doyle (1972) has suggested that Oriental women perform 
more physical labour, which has been shown to increase bone 
mass and calcification (Harell, et al. 1977), thus counter­
acting normal bone loss with age (Geiser, et al. 1958).
A study by Jensen, et al. (1980) has shown that 44% of all 
Danish women suffer from fractures.
Possible clinical cures for osteoporosis have been 
studied. Reeve, et al. (1976) found that parathyroid 
hormone (PTE), administered to post-menopausal women, 
stimulated bone turnover, with more formation than resorption 
Calcitonin, a strong inhibitor of bone resorption, was 
studied by Shamonki, et al. (1980); they found that post­
menopausal women show progressively lower levels of serum 
calcitonin with increasing age. Calcitonin acts by 
inhibiting the proliferation of osteoclasts and fibroblasts 
and inhibits the loss of bone matrix (Raisz, et al.- 1968) 
and so we can see how its progressive loss would enhance 
progressive bone loss. In addition to these treatments,
Marx (1980) supports some role for the vitamin D metabolite
2 2 .
1 ,25~diliydroxycholecalciferol ( 1 ,25-(OH)pDg) in the 
management of osteoporosis. All of these factors are 
discussed in more detail later in this introduction.
Oestrogen is thought to hold the key to the.prevention 
or cure of osteoporosis, as the condition is predominant 
among post-menopausal females whose oestrogen levels have 
become drastically reduced. Atkins, et al. (1972) showed 
that oestrogen inhibits the bone-resorptive activities of 
parathyroid hormone, suggesting that the loss of oestrogen with 
the menopause causes a decrease in the control of bone 
resorption. Wink, et al. (1980) showed the induction of 
osteoporosis in castrated rats, again suggesting the 
involvement of the sex-hormones. Robin, et al. (1980) 
found that a conjugated natural oestrogen preparation.
Premar in prevented heparin-induced accelerated bone loss, but 
Coope, et al. (1980) found that a synthetic steroid produced 
no change in the osteoporotic condition. It would seem 
then that oestrogen could play an important role in the 
prevention or cure of osteoporosis, but this treatment can 
have unpleasant side-effects, such as cancer of the uterine 
endometrium or the inconvenience of an elderly woman 
continuing her menstrual cycle. Orloff, et al. (1980) have 
described the preventive or curative agent required in the 
treatment of osteoporosis: any agent which influences the
balance between bone deposition and resorption, which can 
control the time-dependent evolution of trabecular bone loss.
2 3 .
Osteomalacia, along with its juvenile form of 
rickets, is another common metabolic disorder of bone 
(Smith, 1979). This disorder is characterised mainly 
by a lack of calcification in the organic osteoid bone 
matrix, leading to distortion of bone, pseudofractures 
and severe bone pain. There are several well-known 
causes of this disorder which, unlike osteoporosis, is 
not an age-related complaint.
The problems of osteomalacia and rickets have 
largely been eradicated in the native population of this 
country, but it has been found with increasing regularity 
among Scotland’s Asian immigrant population. In 1962 the 
Scottish Medical Journal published a report by Dunnigan, 
et al. (1962) concerning the incidence of osteomalacia and 
rickets in Glasgow's Asians, followed by studies from 
Ford, et al. (1972) and Denman (1979). Felton, et al. (1966) 
noted its occurrence during pregnancy, leading to its 
appearance in newly-born Asian children (Ford, et al. 1973).
The high occurrence of osteomalacia and rickets 
among the Asian population was thought to be associated 
with high gluten and phytate content of the traditional 
Asian bread. Studies by Moss, et al. (1965), Van de Berg, 
et al. (1972) and Holmes, et al. (1973) showed that gluten, 
phytate and hydrolysates of phytate all inhibit resorption 
of calcium in the gut by means of the formation of 
insoluble calcium salts, but interestingly, orally-
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administered phytate can be readily digested in the gut. 
Wills, et al. (1972) however claim some success in curing 
rickets by reducing dietary phytate. The role played 
by phytates and gluten in the incidence of osteomalacia 
is therefore inconclusive, leading to the study of other 
factors.
Dietary or environmental lack of vitamin D, through 
inadequate supplies in food or insufficient exposure to 
sunlight, have also been implicated in the occurrence of 
osteomalacia. Various studies have shown that the vitamin 
D metabolites: 25(0H)Dg, the main circulating form, and
l,25(0H)2Dg, the active form, are important in the 
prevention and cure of osteomalacia (De Luca, 1977; Kanis, 
et al. 1977; Frame, et al. 1978; Ahmed, et al. 1979; 
Offerman, et al. 1979). The mechanisms of these metabolites 
will be discussed in more detail later in the introduction.
It could be that osteomalacia and rickets occur purely 
through a lack of vitamin D. Those Asians in Scotland 
suffering from the effects of osteomalacia and rickets did 
not suffer to the same extent in their native countries, 
where they had the same diet and a lot more,exposure to 
sunlight. Patients on long-term anti-convulsant therapy 
show a high incidence of osteomalacia (Hoikka, et al. 1980), 
but they are usually institutionalised and lack exposure to 
sunlight, as well as a healthy diet; children of mothers 
on anti-convulsant therapy and suffering from osteomalacia
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show no increased tendency towards the disorder themselves 
(Christiansen, et al. 1980). The importance of diet, 
sunlight and vitamin D in the prevention and cure of 
osteomalacia and rickets are also emphasised by Parfitt, 
et al. (1979).
An abnormal serum calcium level is the main disorder 
resulting from hyperparathyroidism and is the result of 
increased calcium absorption from the gut (Avioli, et al. 
1965), increased bone turnover, particularly resorption 
(Harris, et al. 1969), and increased tubular resorption 
of calcium from the kidneys. Clinical bone disease is 
not common in this disorder, but the bone is nearly always 
histologically abnormal (Byers, et al. 1971), with 
excessive osteoclastic resorption, marrow fibrosis and 
increased bone formation, accompanied by a woven collagen 
matrix (Smith, 1979). Apart from bone disease, clinical 
problems manifest themselves in increased cardiac problems 
(Hargreaves, et al. 1980), increased tumour development 
(Wajngot, et al. 1980), muscle weakness, malaise and severe 
dementia (Heath, et al. 1980b).
Like most other metabolic bone diseases, hyperpara­
thyroidism tends to increase in incidence with age (Heath, 
1980a, Mannix, et al. 1980), although Jason, et al. (1981) 
report a case of this disease in an 18 month-old child. 
Similar to hypophosphatasia, mentioned later, hyperpara­
thyroidism may occasionally have a familial incidence, often
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associated with other endocrine disorders, manifesting 
themselves in adulthood (Orwall, et al. 1981), although 
Sandler, et al. (1980) discuss the occurrence of the disease in 
a mother and her 12-year-old son.
Hyperparathyroidism takes two main forms. The usual 
stimulus to parathyroid overactivity is low serum calcium, 
found particularly with chronic renal failure or intestinal 
malabsorption, with prolonged overactivity of this type 
classed as secondary (2°) hyperparathyroidism (McCarron, 
et al. 1981). Primary (1°) hyperparathyroidism occurs 
through overproduction of the hormone, parathyroid hormone, 
through the presence of an adenoma in one or more of the 
parathyroid glands (O'Riordan, et al. 1972). Cure or 
prevention of hyperparathyroidism has, understandably, 
been under study for many years now, with surgery providing 
a common means of removing the adenoma which cause 1° 
hyperparathyroidism (Heath, et al. 1980b; Sandler, et al.
1980; McCarron, et al. 1981). Various drugs have been 
used to combat the disorder, with a lot of attention 
recently focusing on Cimetidine. This drug is capable 
of blocking the synthesis or release of the excess para­
thyroid hormone causing the disease (Sherwood, et al. 1980a), 
without affecting serum levels of calcium, phosphorus or 
magnesium (Jacob, et al. 1980).
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The enzyme alkaline phosphatase, found in great 
abundance in osteoblasts, is thought to be very important 
in bone mineralisation, or calcification, and dramatically 
high or low levels of the enzyme have been found to result 
in equally dramatic changes in bone structure and composition. 
Hypophosphatasia is an inherited recessive genetic disorder 
affecting alkaline phosphatase and bone (Smith, 1979); a 
condition of hyperphosphatasia was thought to exist, but is 
now regarded as a form of Paget's disease of bone, discussed 
later (Eyring, et al. 1968). Hypophosphatasia is 
characterised by very low levels of bone-related alkaline 
phosphatase in the serum, with any enzyme present originating 
from its other major sources: the liver and the gut
(Warshaw, et al. 1971; Inglis, et al. 1972). This disorder 
manifest itself in defectively-mineralised bone, similar to 
that found in osteomalacia, with the age of onset determining 
the severity of the effects, decreasing with age (Fraser, 
1957). O'Duffy (1970) also found the disorder to be 
related to cartilage calcification. The lack of 
mineralisation found with the absence or very low levels 
of alkaline phosphatase in this disorder emphasises the 
importance of the enzyme in calcification, discussed in a 
later chapter.
Hypophosphatasia is a very rare disorder, but 
deserves mention here as it became possible to include two 
hypophosphataemic patients in this study.
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Although those bone diseases already described may 
be regarded as the results of changes in metabolic processes, 
metabolic bone disease may appear as a result of non- 
biological factors. Renal bone disease, or renal osteo­
dystrophy, appears as one or all of several bone diseases: 
osteitis fibrosa, osteomalacia and osteosclerosis (Ellis, 
et al. 1973), with one condition tending to predominate.
Bone disorders accompanying chronic renal failure tend to 
show themselves in increased bone formation, increased 
osteoid and increased mineralised bone, compared to age- 
matched controls, although bone problems accompanying 
chronic renal failure are not inevitable (Malheche, et al.
1976). One of the main factors thought to enhanœ renal 
osteodystrophy is aluminium (Ward, et al. 1978).
Ellis, et al. (1979) found that patients suffering 
from chronic renal failure, and receiving regular dialysis 
treatment, had abnormally high levels of aluminium in their 
bones, which could be associated with osteomalacia and 
dialysis encephalopathy, a mental disorder. Changes in 
bone histology associated with osteomalacia, dialysis 
and high levels of aluminium have been found to be common 
(Stanbury, 1972; Malluche, et al. 1976; Alfrey, et al.
1976; Elliot, et al. 1978; Wing, et al. 1980; Boyce, 
et al. 1981). Experimental studies with laboratory animals, 
along with some of my own studies, have shown that aluminium
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is readily taken up by bone (Berlyne, et al. 1970) and that 
prolonged administration leads to decreased calcification 
and increased osteomalacia (Ellis, et al. 1979).
The origin of the aluminium involved is probably the 
dialysate water used in renal dialysis (Platts, et al. 1977; 
Drueke, 1980; Boyce, et al. 1981), with increased incidence 
of renal osteomalacia in areas where the level of aluminium 
in the local water supply is high. The effects of 
aluminium on bone mineralisation is of particular interest 
in this study and is discussed in greater detail in a later 
chapter.
Albright, et al. (1948) described Paget's disease of 
bone as a local bone disease, not a metabolic bone disease, 
characterised by very high levels of serum alkaline phosphatase 
and urinary hydroxyproline, indicative of high rates of bone 
turnover, noted by Nagant de Deuxchaines, et al. (1964). This 
bone disease is fairly common, with 3% of all people over 40 
suffering from it (Smith, 1979) and, although it is not a 
metabolic bone disease as such, it has been used in several 
comparative studies within this thesis and so requires 
description. Paget's disease of bone is characterised by 
gross macroscopic and microscopic changes in bone (Singer,
1977) , with enlargement and deformation of the skull and 
long bones following the deposition of woven, disorganised 
bone, as opposed to normal, organised lamellar bone (Smith, 
1979; Krane, 1980), through increased bone turnover.
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The increased levels of serum alkaline- phosphatase 
characteristic of this disorder are known to originate from 
the bone (Woodward, et al. 1969), suggesting increased 
osteoblastic activity. Cheung, et al. (1980) noted that, 
in addition to increased alkaline phosphatase production, 
pagetic osteoblasts also synthesised more collagen and 
protein than other osteoblasts, while pagetic osteoclasts 
are found to be bigger and more numerous, indicative of 
increased, bone resorption (Rowe, et al. 1977) and, as 
discussed before, providing the source of more osteoblasts. 
All of this increased bone turnover leads to the formation 
of dense, highly disorganised and deformed bone (Khairi, et 
al. 1973; Franck, et al. 1974).
The incidence of Paget's disease of bone has been found 
to follow interesting geographical patterns. Smith (1979) 
noted that it never occurs in Scandinavia, Japan or the 
Tropics, but is common in Australia and Western Europe, 
leading to a general assumption that it is a disorder of 
Anglo-Saxon populations. A particiiarly interesting study 
by Barker, et al. (1980) has shown that certain communities 
can exhibit unusually high incidences of Paget's disease of 
bone, particularly in Lancashire. Rebel, et al. (1980) and 
Singer (1980) have noticed a measles-like viral inclusion 
in the genetic material contained within the nuclei of 
osteoclasts from Paget's disease of bone and such antigens
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could, it seems, explain the course of the disease: the lack
of an immune response, indicative of a slow virus infection, 
and the incidence of the disease within families and 
communities.
Various drugs have been used in the treatment oT 
Paget's disease of bone. Mithramycin, a cytotoxic 
antibiotic which has been shown to inhibit the bone- 
resorbing activities of parathyroid hormone (Engracio, et 
al. 1972; Minkin, 1973), has produced effective results.
On administration to patients, Mithramycin relieved all 
types of pain, more effectively than any synthetic drug, 
and decreased all types of bone cellular activity (Condon, 
et al. 1971; Hadjipavlou, et al. 1977). Diphosphonates, 
thought to be naturally-occurring inhibitors of bone turn­
over in their natural form of pyrophosphate, discussed in a 
later chapter, were also studied in association with Paget's 
disease of bone. Bijvoet, et al. (1980) used dichloro- 
methylidene diphosphonate and (3-amino-l-hydroxypropylidene)-1, 
1-diphosphonate and found that they produced a total 
biochemical and histological cure of the disease within 
6 months. Calcitonin has proved less successful, initially 
decreasing bone turnover, but becoming ineffective after 
only 4 months (Gattereau, et al. 1980 ).
Metabolic bone diseases can, therefore, take several 
forms, each associated with the dysfunction of one or more
32 .
of the systems involved in the formation and maintenance 
of normal calcified bone . There are a few hormones and 
metabolites of particular importance in the normal functioning 
of bone, some of which have already been mentioned, which 
bear further discussion.
Parathyroid hormone (PTH) has been widely researched 
over the years: normal physiological levels of the hormone
producing no net gain or loss of bone (Malluche, et al. 1981), 
while severe variations result in those bone disorders 
characteristic of hyperparathyroidism, already discussed, 
and hypoparathyroidism, which has opposite effects. The 
main effects of PTH are known to result in increased bone 
resorption (Rosenbac.h, et al. 1967; Vaes, 1968; Shubina, et 
al. 1969; Chu, et al. 1971; Messer, et al. 1973a; Minkin, 
1973; Peck, et al. 1976; Reeve, et al. 1976; Langeland,
1977; ïïong et al, 1977; Luben, et al.1977; Maria, et al. 
1977; Ibbotson, et al. 1978; Krieger, et al. 1980; Malluche, 
et al. 1981), with the mechanisms of this action under 
investigation.
Under normal conditions PTH production is stimulated 
by low serum calcium levels, with high serum calcium levels 
resulting in a decrease in the available PTH (Birkenhager, 
et al. 1973; Pitkin, et al. 1980; Weinstein, et al. 1980; 
Blum, et al. 1981). Krieger, et al. (1980) maintains the 
existence of a Na-Ca exchange mechanism for this regulation
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of serum calcium levels under the influence of PTH, fuelled 
by glucose (Fenton, et al. 1978; Zamboni, et al. 1980).
It has been shown that PTH effects the release of calcium 
from bone by stimulating the production of acids and enzymes, 
mainly lactate and citric acids (Nisbet , 1968; Heersch,
et al. 1969; Stern, et al. 1970; Messer, et al. 1973b; Luben, 
et al. 1976), resulting in decreased calcification and the 
breakdown of bone matrix; increased bone resorption is 
also accompanied by increased levels of cAMP within osteo­
blasts (Peck, et al. 1973; McPartlin, et al. 1976; Wong, 
et al. 1977; Peck, et al. 1977; Marcus, et al. 1977). The 
role of osteoclasts in this PTH-stimulated bone resorption 
has been supported by the discovery that calcitonin (CT) 
inhibits PTH-stimulated bone resorption by inhibiting 
osteoclastic activity (Feldman, et al. 1980), while other 
studies have shown that PTH acts through inhibiting collagen 
formation (Dietrich, et al. 1976; Kream, et al. 1980), 
increasing serum calcium by inhibiting bone formation.
One interesting point, related to the severe bone loss 
experienced by many post-menopausal women, is the relationship 
between PTH and the steroid sex hormones : these hormones
decline with the menopause and recent studies have shown that 
they are effective in inhibiting PTH-stimulated bone 
resorption (Stern, 1969; McPartlin, et al. 1976; Reeve, 
et al. 1976; Langeland, 1977).
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Calcitonin has the opposite effect to PTH, inhibiting 
bone resorption (Raisz, et al. 1967; Reynolds, et al. 1968; 
Raisz, et al. 1968; Nisbet, et al. 1968; Mittleman, et al. 
1968; Binderman, et al. 1972; Gozariu et al. 1973 ;, Geusens, 
et al. 1980; Maier, et al. 1980; Stevenson, et al. 1981). 
Many studies have shown that although CT produces results 
contrary to PTH, it does not work directly against PTH 
itself, only against its effects: it does not inhibit PTH-
inhibition of collagen formation (Dietrich, et al. 1976), 
it has been found to act on the cells of the periosteum, 
where PTH works on sub-periosteal cells (Peck, et al. 1977); 
it does not inhibit PTH-induced inhibition of citrate 
metabolism, although it does inhibit hyaluronate synthesis 
and déminéralisation (Luben, et al. 1976). CT acts by 
inhibiting the proliferation of osteoclasts and fibroblasts 
and inhibits the loss of bone matrix (Raisz, et al. 1968), 
effects which are enhanced by the presence of fluoride 
(Messer, et al. 1973b).
The important association between steroid hormones,
CT and post-menopausal bone loss has been followed in recent 
years. It has been shown that the purpose of CT would seem 
to be the prevention of excessive bone loss, rather than the 
formation of new bone, as it acts only to reverse any bone 
resorption which may have already occurred (Mittleman, et al. 
1968). In post-menopausal women we find serum CT levels
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drastically different than those in younger women, 
decreasing with age (Shamonki, etal. 1980; Padilla, et al. 
1980). Oestrogens have been found to stimulate CT 
secretion (Woloszczuk, et al. 1980; Stevenson, et al.
1980; Morimoto, et al. 1980; Cressent, et al. 1980; 
Stevenson, et al. 1981), suggesting that lack of oestrogens, 
through the menopause, would lead to loss of control over 
bone resorption and accumulated bone loss over the years 
(Geusens, et al. 1980). This situation would suggest 
that a suitable treatment for post-menopausal osteoporosis 
would be the administration of CT; CT is already used to 
control bone turnover in Paget’s disease of bone (Singer, 
et al. 1980; MacIntyre, et al. 1980), but it has been 
found that patients soon become resistant to the effects 
of the drug and it becomes ineffective.
Vitamin is involved in bone mineralisation and 
resorption, promoting both (Mittleman, et al. 1968;
Raisz, et al. 1972; Boyle, 1974; Stern, et al. 1976; 
Peacock, et al. 1976; Wong, et al. 1977) through the action 
of its metabolites, mainly 25-hydroxycholecalciferol 
(25(0H)Dg) and 1,25-dihydroxycholecalciferol (25(0H)2Dg). 
Cholecalciferol, or vitamin D^, can be synthesised in the 
skin from 7-dehydrocholesterol or can be ingested from food 
in the small intestine (Smith, 1979). 25(0H)Dg, the main
circulating form, is synthesised from vitamin in the
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liver microsomes and subsequently converted to l,25(0H)gDg, 
the active form, in the kidneys (Boyle, 1974; DeLuca, et 
al. 1978). Two specific cases resulting from defects in 
this procedure occur, in one case, with chronic renal 
failure, where 1,25(011)2^2 cannot be synthesised (Boyle, 
1974; Weinstein, et al. 1980), and in elderly people where 
reduced stores of 7-dehydrocholesterol mean decreased 
ability to produce vitamin Dg (Holick, et al. 1981); these 
ailments contrast with osteomalacia and rickets, where lack 
of exposure to vitamin D in the environment or the diet 
is the problem.
Metabolites of vitamin Dg are widely used in the 
treatment of metabolic bone diseases, treating osteoporosis 
(DeLuca, 1977; Wandless, et al. 1980; Cohen, et al. 1980) 
and osteomalacia, as discussed earlier, promoting bone 
strength and decreasing pain. One novel point to note 
is the recent work by Howard, et al. (1981), which suggests 
that osteoclasts may be involved in the extra-renal 
synthesis of vitamin D metabolites, their numbers increasing 
during chronic renal failure.
Fluoride has been the subject of a lot of controversy 
in recent years, with evidence suggesting that it is 
effective in reducing the incidence of dental caries when 
added to drinking water (Jackson, 1967), through its action 
in promoting bone matrix/tooth formation (Smith, 1979) and
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inhibiting bone resorption (Messer, et al, 1973), However 
excesses of fluoride would appear to have severe effects on 
bone, not differing greatly from those found with osteo­
malacia (Arnala, et al. 1980; Christie, 1980) and 
osteoporosis (Alhava, et al. 1980; Robin, et al. 1980; 
Laitenen, et al. 1980), meaning that the use of this 
element must be strictly controlled.
We can see that bone is a very complex organ, subject 
to the influences of many drugs, hormones and environmental 
factors and not solely responsible for providing mechanical 
skeletal support. The purpose of this study is to 
investigate further aspects of bone metabolism to try to 
aid our understanding of metabolic bone diseases, with 
particular interest being placed on alkaline phosphatase 
and calcification, the effects of aluminium on alkaline 
phosphatase and calcification, changes in muscle creatine 
kinase and collagen prolyl hydroxylase activities in 
different metabolic bone diseases and the effects of human 
serum on bone turnover in vitro. Each particular subject 
has been described in greater detail within each chapter 
and the results would seem to suggest that we still have a 
lot to learn about metabolic bone diseases.
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CHAPTER ONE : PRELIMINARY STUDIES IN THE ORGAN CULTURE OF BONE
The in vitro culture of foetal and neonatal mouse 
calvaria has, for many years, been important in the study of 
the mechanisms of bone metabolism, particularly bone resorption 
These studies, some of which will be described here, serve to 
illustrate the most valuable aspect of in vitro cultures : 
they allow the effects and interactions on bone of hormones, 
drugs and other metabolites to be seen directly, independent 
of other, complex, systemic factors.
General studies in bone resorption have been performed 
by Reynolds, et al, (1970) and Messer, et al. (1972). who 
looked at PTH, which increased bone resorption, CT and 
fluoride, which inhibited bone resorption, in in vitro 
cultures with mouse calvaria. Susi, et al. (1966);
Nisbet (1968) and Nisbet, et al. (1970) found using such 
cultures that PTH-stimulated bone resorption is accompanied 
by intense acid phosphatase activity and the accumulation 
of lactate and citric acids. Minkin (1972) used this bone- 
resorbing activity of PTH to study the effects of the 
antibiotic Mithramycin on in vitro bone cultures, finding 
that it inhibited bone resorption, while Maria,et al. (1977) 
studied the effects of Verapamil, a drug involved in calcium 
homeostasis, on the same system. Many studies have been 
performed using in vitro bone culture, looking at various 
steroid hormones (Nisbet, et al. 1969; Messer, 1977), 
vitamin D metabolites (Herrmann-Erlee, et al. 1978), hyperoxia
39.
(Goldhaber, 1958) and collagenase (Stern, et al. 1970),
for example. Although these examples serve to illustrate
the wide use of this system, it must always be remembered
that it is only a model system and not an absolute replica
of in vivo bone systems (Reynolds, 1975):
’’One of the most important experimental
advantages of organ cultures of bone and cartilage
is the ability to isolate tissue under study from
systemic effects, and to be able to test the actions
of substances under controlled conditions. However,
this can also be one of the disadvantages of the
method unless care is taken to integrate the organ
culture results with in vivo findings."
One important example which illustrates the differing
effects a substance may exhibit in vivo and in vitro is
that concerning vitamin D . DeLuca (1978) demonstrated
that vitamin D is metabolised in the liver to 25(0H)Dg and
then in the kidney to l,25(0H)2Dg, before it has any effect
on bone, increasing calcification. When vitamin D is
added to bone culture medium in vitro it can undergo no
such transformations and is therefore unable to reflect the
effects of vitamin D in vivo.
Of particular interest in this study is the relationship
between the enzyme alkaline phosphatase (AP) and the level
2+of free ionised calcium (Ca ) found within the culture 
medium supporting mouse calvaria in vitro. The possible
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involvement of AP in bone mineralisation is discussed in
greater detail later in this thesis, however the basic
studies will be outlined here. Robison (1923) noted that
AP was readily found in localised areas where calcification
was occurring, or would soon occur, as did Bevelander, et al.
(1950) and Morse, et al. (1951). The suggestion resulting
from these discoveries was that AP was present to facilitate
the precipitation of calcium phosphate, by causing a local
supersaturation of phosphate esters, the precipitation of
the calcium phosphate would in turn cause a decrease in the 
2 +Ca present. By looking at the relationship between AP 
2 +and Ca in the culture medium supporting the mouse calvaria, 
it is hoped here to find any possible correlation between 
these two parameters.
The means of mouse calvaria culture employed in this 
study, as in many others, was that developed by John Reynolds 
in the Strangeways Laboratory in Cambridge. This method 
of bone culture can be found in Reynolds and Dingle (1970), 
Reynolds (1972) and Reynolds (1975) and generally involves 
the very careful dissection of calvaria from 6-7 day old 
mice and their culture under optimum conditions. In this 
study mouse calvaria have been cultured and quantified for 
viability, both histologically and biochemically, as a 
preliminary to organ culture of human bone samples and the 
culture of mouse calvaria with human serum. It is hoped 
to discern any relationship between AP and Ca^”*" using all 
of those culture systems mentioned.
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FIGURE (i)
Organ culture dish with central well for 
culture medium. The stainless steel grid 
sits over the well, supported by its walls. 
Each dish is approximately 5 cm in diameter.

FIGURE (ii)
Mcintosh-Fildes jar, which can hold up to 
24 culture dishes at any time. This is 
a glass jar, commonly known as an aneorbic 
jar, which can be made air-tight by means 
of a tightly-fitting, rubber-lined lid, 
with the inlet and outlet taps allowing 
gassing with 5% CO^ in air.
Lab-line tissue culture box, which can hold 
up to 64 cultures at a time. This is a 
perspex box, which can be made air-tight by 
means of a tightly-fitting, rubber-lined lid, 
again with inlet and outlet taps for controlling 
the inner atmosphere.


Materials and Methods:
1. All organ cultures of bone were maintained in organ 
culture dishes (Falcon Plastics, 3037. Becton, 
Dickinson and Co., Cockeysville, M.p. USA). These 
dishes (FIGURE ( i )) are approximately 5 centimetres 
in diameter and have a central well, to which bone 
culture medium is added, and an outer moat, which 
may contain a sterile filter paper ring soaked in 
sterile distilled water, to stop or reduce evaporation 
of the culture medium. In those cases where no 
paper ring was used, a sterile tissue soaked in sterile 
distilled water and wrapped in foil would be placed in 
the tissue culture jar or box.
2. In initial studies, Mclntosh-Fildes anaerobic jars 
(Anaerobic culture jar. A. Gallenkamp and Co. Ltd., 
London) were used for the incubation of cultures; 
each jar held up to 24 cultures and, here, filter 
paper rings were used to provide humidity. Latterly 
these jars were replaced by tissue culture boxes 
(Lab-line Instruments, Inc.; Melrose Park, Illinois, 
USA) which hold up to 64 cultures each; sodden tissue 
paper provides a humid environment here. Both of 
these vessels can be seen in FIGURE (ii).
It is important that such air-tight containers 
are used to house the bone organ cultures, as the 
cultures must be maintained in an atmosphere of 5%
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COg in air, which is added through inlet tubes each 
time the boxes have been opened for changing of 
culture medium or when the cultures are set up.
3. Sterile disposable pipettes (Falcon Plastics; Becton, 
Dickinson and Co., Cockeysville, M.D. USA) were used 
in the transfer of all culture media and other sterile 
solutions throughout each experiment.
4. Various types of culture media were used: Medium 199
with Hanks salts, Medium 199 with Earle's salts, BGJb 
Original medium and BGJb Modified medium, with the 
Fitton-Jackson modification (Gibco Bio-cult Ltd., Paisley) ; 
P^ medium, another modification, was supplied by J.
Reynolds (Strangeways Laboratory, Cambridge). Each
type of culture medium, except in particular cases which 
will be mentioned, was supplemented with 15% foetal calf 
serum (Gibco Bio-cult Ltd., Paisley), or by 5% rabbit 
serum, in the case of the P^ medium. To reduce any 
incidence of contamination, penicillin-streptomycin 
solution (Gibco Bio-cult Ltd., Paisley) was added to 
the culture medium: 1 ml of solution containing 5000
units of penicillin and 5000 meg. of streptomycin was 
added, to each 100 ml of culture medium. Glutamine 
is an essential factor in bone culture medium and 
was added to those culture media which did not .already 
contain it : BGJb Original and Modified; 1 ml of
glutamine (Gibco Bio-cult Ltd, Paisley), containing 
29.2 mg, was added to each 100 ml of culture medium.
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5. Before and during dissection, bone was supported in 
Hanks BSS (Gibco Bio-Cult Ltd., Paisley) with added 
penicillin-streptomycin or Medium 199 (Gibco Bio-cult 
Ltd., Paisley) with added penicillin-streptomycin.
The latter maintains a steady pH over a longer period 
of time and was used mainly in the transport of human 
bone biopsies, which may take as long as one hour.
6 . Bone in culture was supported over the central well
of the tissue culture dish, allowing uniform access between 
bone and culture medium, while holding the bone out of 
the culture medium and allowing culture medium to be 
changed without disturbing the bone. Various means of 
support were tested in an attempt to find the best way 
of holding the bone over the culture medium: stainless
steel mesh grids (Falcon Plastics; Becton, Dickinson 
and Co., Cockeysville, M.D. USA), nylon mesh grids 
(supplied by Professor A Curtis, Department of Cell 
Biology, University of Glasgow), and filter paper rafts 
(Reynolds, 1972). Both the nylon mesh grids and the 
filter paper rafts failed to support the bone, each 
becoming waterlogged and collapsing into the culture 
medium. Stainless steel grids, however, provided 
strong support while still allowing diffusion and 
passage of nutrients and waste to occur between‘bone 
and culture medium as well as being easily sterilised.
From this point all organ cultures of bone were prepared 
using stainless steel grids.
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7. Organ culture dishes containing a stainless steel grid 
and the appropriate culture medium were always prepared 
before bone was made ready.
8 . For organ cultures of mouse calvaria, mice were killed 
instantly by decapitation and the head placed in sterile 
Hanks BSS with added penicillin-streptomycin.
Using sterile scissors and forceps, and in a sterile 
petri dish (Falcon Plastics; Becton, Dickinson and Co., 
Cockeysville, LÎD. USA) containing sterile Hanks solution, 
calvaria were carefully dissected from each mouse, being 
particularly careful not to damage the bone. Following 
the lines of the frontal and parietal bones, these bones 
were dissected-out, cleansed of all tissue and placed in 
a fresh dish of Hanks solution. Again, being very 
careful, the two parietal bones, or calvaria, were cut out 
and each was placed, separately, in prepared culture 
dishes, concave side down.
It was also suggested that single mouse vertebrae 
could be used in organ cultures of bone, since they 
are intact pieces of bone of a uniform size, suitable 
for organ culture. However, after several unsuccessful 
attempts, it proved impossible to remove all of the 
surrounding muscle and tendons from these bones 
sufficiently quickly to keep the bone alive for culture.
9. Human bone organ cultures were prepared from biopsies
of the iliac crest . When an iliac crest bone biopsy ...
was talien from the patient it was placed immediately 
in Medium 199 solution, which is specially buffered
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to maintain a more constant pH, contained in a sterile 
universal container (Falcon Plastics; Becton, Dickinson 
and Co., Cockeysville, MD. USA) on ice. As soon as 
possible, usually within 45 minutes after the removal 
of the biopsy from the patient, the biopsy was placed 
in a sterile petri dish and all muscle removed, the 
bone was then placed in fresh Medium 199 solution to 
remove any blood.
Using sharp scissors and forceps, under sterile 
conditions, the bone biopsy was cut horizontally into 
two pieces. Generally the bone biopsy would be a 
cylinder of bone, mainly trabecular bone, but with an 
end-plate of cortical bone at the top. and bottom; by 
cutting the bone horizontally it became possible to gain 
access to the trabecular bone. Using sharp scissors, it 
was quite a simple matter to pare away at the trabecular 
bone and obtain small fragments suitable for culture. 
These small fragments of trabecular bone were placed in 
organ culture in the same way as the mouse calvaria.
10. All bone cultures, as described, were placed in 
Mclntosh-Fildes jars or tissue culture boxes and gassed 
with 5% COg in air.
11. Culture medium was removed and replaced as required, 
usually daily, but always within 3 days.
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12. In those experiments where the effects of serum from 
patients suffering from metabolic bone disease were 
studied, 15% human serum replaced 15% foetal calf 
serum in the standard culture medium. Human serum 
was sterilised using multipore filters (Swinnex-25, 
Millipore S.A., France).
13. In some cases, to obtain control bone samples, sample 
calvaria were killed by thrice freezing and thawing 
and subsequently treated as live cultures.
14. Alkaline phosphatase assays on the culture medium were
performed by means of kits (Boehringer Diagnostics, 
London) for total alkaline phosphatase in serum, but 
proved suitable for use here. This assay for alkaline 
phosphatase incorporates paranitrophenol phosphate as 
the substrate.
15. Ionised calcium (Ca^^) measurements in the culture
rpedium were performed by means of a Nova 2 ionised
calcium analyser (American Hospital Supply (U.K.)
Ltd., Oxon).
Initially, to allow the viability of the calvaria 
in culture to be assessed, sample calvaria were removed 
from culture and fixed for histological studies. For 
comparison, calvaria of the same age as the bone in 
culture were removed from mice and assessed in the same 
manner.
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16. All bone studied was fixed in the following buffered 
formalin solution:
formalin 10 ml
acid sodium phosphate monohydrate 0.4g 
anhydrous disodium phosphate 0.65g
distilled water to 100 ml
Samples were fixed in buffered formalin solution for 
at least 48 hours. Later, when it was realised that 
the fine calvaria were difficult to discern during 
embedding and sectioning procedures, red acid fuchsin 
dye was added to the formalin, making the calvaria red; 
the dye was readily removed from the calvaria during 
the staining procedures.
17. Décalcification of the calvaria became necessary as it 
was found that, although quite thin and delicate, the 
mouse calvaria did not become completely embedded in 
the paraffin wax used and parted company with the wax 
during sectioning. When bones had been fixed in 
buffered formalin for at least 48 hours, they were then 
placed in 10% formic acid overnight, this decalcified 
the bone, and then into a solution of 50% saturated 
lithium carbide solution and 50% tap water, to 
neutralise the acid.
18. Embedding of samples was by the standard paraffin- 
embedding technique.
19. Three main histological stains were used on the 
6 pm sections of calvaria produced:
A. Standard haemalum and eosin. This stain highlights
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the nucleus and cytoplasm of each cell: the 
nucleus is blue and the cytoplasm pink.
B, Masson's acid fuchsin aniline blue trichrome.
This stain shows the nuclei to be.black, cytoplasm 
a range of reds, muscle fibres bright red and 
collagen an intense blue, mucin is also blue.
This stain was chosen to highlight the presence
of collagen in the calvaria sections, the major 
component of the organic phase of bone.
C. Schmorl's method for compact bone. This stain
shows the cells to be blue to black, while the
bone matrix is light blue. As with the previous 
stain, this stain was chosen to highlight the 
matrix component of the mouse calvaria sections.
20. All photographs were taken on Ektachrome 50 film
using a tungsten lamp.
21. Human serum from a variety of metabolic bone disorders 
were used in this study.
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Results :
Stained sections of both cultured and non-cultured 
calvaria have allowed us to see whether the bone in 
culture is being maintained, using the criterion that 
living nuclei are large and round, while dead nuclei are 
small and dilated, pyknotic. The various staining methods 
were employed to let us see if the sections of cultured 
calvaria compared favourably with sections of calvaria taken 
directly from mice.
FIGURE lA shows a section of a 6-day-old mouse calvaria 
which has been in culture for 2 days, the section is stained 
using haemalum and eosin. In this photograph we can see 
the large nuclei of the cells, the cell cytoplasm and the 
bone matrix stain pink, indicating that cells are alive. 
FIGURE IB shows a section of 6-day-old mouse calvaria, which 
has been cultured for 2 days, stained using Masson's 
trichrome stain; here again we see the large dark-stained 
nuclei and healthy collagen matrix, indicating that the 
bone is both alive and. maintaining its structure.
Later, looking at sections of calvaria kept in 
culture for 4 days (FIGURES 1C and ID) we can see that the 
nuclei are still large and densely-stained; the staining 
methods used here are haemalum and eosin and Masson's 
trichrome, respectively. Even after 6 days in culture 
(FIGURES IE and IF) we still see large dark nuclei, with 
these sections comparing favourably with sections of
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FIGURE lA
A histological section of 6 day-old mouse 
calvaria which has been cultured for two 
days. This section is stained with 
haemalum and eosin.
FIGURE IB
A histological section of 6 day-old mouse 
calvaria which has been cultured for two 
days. This section is stained with 
Masson's trichrome stain.

FIGURE 1C.
A histological section of 6 day-old mouse 
calvaria which has been cultured for 4 
days. This section has been stained with 
haemalum and eosin.
FIGURE ID
A histological section of 6 day-old mouse 
calvaria which has been cultured for 4 
days. This section has been stained with 
Masson’s trichrome stain.

FIGURE IE
A histological section of 6-day-old mouse 
calvaria which has been cultured for 6 days. 
This section has been stained with haemalum 
and eosin.
FIGURE IF
A histological section of 6-day-old mouse 
calvaria which has been cultured for 6 days 
This section has been stained with Masson's 
trichrome stain.

calvaria taken from a 13-day old mouse (FIGURE IG).
After 9 days in culture the bone is still alive and
maintaining its structure (FIGURE IH).
Haemalum and eosin staining and Masson's trichrome
stain produced the clearest results, although for ease
and simplicity haema um and eosin staining was preferred.
Schmorl's stain for compact bone produced poor and
indefinite results. This histological study of mouse
calvaria in culture showed that bone can be successfully
maintained by the culture regime described, with all
culture media tested producing healthy calvaria. From
this point, however, only BGJb Original medium was used,
allowing accurate comparisons to be made between cultures.
2 +Alkaline phosphatase and Ca assays were performed
daily on the culture medium supporting the mouse bones,
noting first of all that both methods of assay chosen:
the Nova 2 ionised calcium analyser and the Boehringer-
Mannheim kit for total A P , gave reproducible results, with
the appropriate quality controls. Fresh culture medium
contains no AP but has a 1.1 mM concentration of Ca ; the
results produced in culture medium when bone is cultured
are shown in FIGURE II. These results show that, initially,
2the AP level in culture medium rises and the Ca level falls,
only to decrease and increase, respectively, as the cultures 
proceed. The general trends for AP and Ca^’*' levels would 
seem to suggest an inverse relationship between the two
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FIGURE IG
A histological section of a 13 day old mouse 
calvaria, taken directly from a 13-day-old 
mouse and not cultured. This section has 
been stained with haemalum and eosin.
FIGURE IH
A histological section of a 6-day-old mouse 
calvaria which has been cultured for 9 days. 
This section has been stained with haemalum 
and eosin.

FIGURE II
2 +Levels of alkaline phosphatase and Ca in 
culture medium supporting 6-day-old mouse 
calvaria in culture, on each day of culture.
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parameters, which will be studied in more detail later.
Biochemical tests equivalent to those performed on
mouse calvaria culture medium were carried out on culture
medium supporting small fragments of human bone. Results
2 +of AP assays and Ca assays performed are shown in
FIGURES IJ and IK, respectively. These results would
suggest that the amount of AP released by calvaria in culture 
2 4-and the Ca levels in the culture medium, again, show some 
kind of inverse relationship. The results, however, do not 
show any particular trends for any of the bone disorders 
studied, except that bone from a patient with Paget's 
disease of bone releases more AP than the others, reflecting 
serum AP levels in vivo.
Looking at the results for AP and Ca^^ levels in culture 
medium supporting human bone fragments, and taking some 
other factors into consideration, it was decided not to 
continue preparing cultures of human bone. It is very 
difficult to produce fragments of human bone of a uniform 
size and content, in terms of cortical and trabecular bone 
and cellular distribution, making accurate comparisons very 
difficult. The complex structure of bone also makes it 
difficult to get a uniform distribution of nutrients 
throughout the bone, as well as a uniform release of enzymes 
and metabolites, again making accurate comparisons' difficult.
However, mouse calvaria cultures were prepared using 
serum from patients suffering from metabolic bone disease.
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FIGURE IJ
Results of alkaline phosphatase assays performed 
on culture medium supporting fragments of bone 
from patients suffering from metabolic bone 
diseases.
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FIGURE IK
Results of Ca^ **' assays performed on culture 
medium supporting fragments of bone from 
patients suffering from metabolic bone 
diseases.
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substituting 15% human serum for 15% foetal calf serum.
2 +Alkaline phosphatase and Ca assays were performed on 
the culture medium each day and the results are shown in 
TABLES lA(i),(ii).
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By rearranging the results shown in TABLES lA, to show
the levels on the first day calculated as 100%, we can gauge
2-1-
the changes in AP and Ca concentrations over the culture
period. The results of this exercise are shown in TABLES IB.
PERCENTAGE ALKALINE PHOSPHATASE LEVEL 
+ DAY OF CULTURE
TABLE lB(i) DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY 1
Foetal calf serum 100 32 31 35 51 17
Osteoporosis 100 36 14 6 5l 15
Primary Hyperparathyroid­- 100 48 12 23 46 32
ism
Paget's Disease of Bone 100 33 5 0 0 0
Pseudohypoparathyroidism 100 100 100
Hypochondroplasia 100 2 0 0 0 0
Normal human serum 100 45 27 41
Malignant Hypercalcaemia 100 32 28 34
Osteogenesis Imperfecta 100 30 6 5 6
PERCENTAGE Ca^ LEVEL + DAY OF CULTURE
TABLE IB(ii) DAY 1 DAY 2 DAY 3 DAY 5 DAY 6 DAY
Foetal calf serum 100 105 104 47
Osteoporosis 100 105 94 104
Normal human serum 100 100 70 81
Paget's Disease of Bone 100 108 78 87
Hypercalcaemia 100 100 78 104
Malignant Hypercalcaemia 100 107 70 93
Hypophosphatasia 100 104 67 96
Chronic Renal Failure 100 115 129 119
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Discussion :
From the results of histological studies made
concerning the maintenance of mouse calvaria in culture, we
can see that the culture regime which has been developed
successfully supports the calvaria in culture, as well as
maintaining their structural integrity. This method of
culture may now be used with confidence in other studies.
Results of biochemical studies also appear to be
promising, with the Ca^^ and AP parameters easily measurable
in the culture medium. Standard culture medium, containing
foetal calf serum, contains no AP but a 1.1 mlî Ca
concentration. When the medium is placed in culture with
bone we see a dramatic increase in the level of AP and
changes in the Ca^ * level, which can increase or decrease,
but the trends would seem to suggest an inverse relationship 
2 +between Ca and A P .
Robison (1923), Bevelander, et al. (1950) and Morse,
et al. (1951) suggest that AP is present in areas preparing
for calcification and, as such, one might expect to find
some sort of relationship between Ca^* and AP. As AP
stimulates or engenders mineralisation through the
precipitation of calcium phosphate, one would expect the
2 +levels of free Ca to decrease, increasing again when levels 
of AP decrease. Further studies in this thesis will attempt 
to clarify this relationship.
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Mouse calvaria cultures are very simple to replicate: 
6-day-old mice from a standard litter are of similar size, 
making their calvaria of similar size and allow: 
accurate comparisons to be made between different calvaria 
in culture. Cultures of human bone are a different 
matter: Meunier trephine biopsies of the iliac crest are
cylinders of bone, 1 cm in diameter and 2.5 cm in length, 
but the amount of bone contained in each biopsy may vary 
a great deal, depending on the condition of the patient. 
Osteomalacic bone is soft and poorly calcified, osteoporotic 
bone is fine and fragments easily, while bone from a patient 
with Paget's disease of bone is dense and strongly calcified.
3
This comparison shows that a 2 mm piece of bone from each 
type of patient would vary a great deal, as it also can 
within disorders, where severity may vary. It is fairly 
clear then that many factors may combine to make comparisons 
between results produced by human bone fragments in culture 
very suspect and inaccurate. Prom this point no further 
human bone cultures were prepared.
However, human serum from patients suffering from a 
variety of metabolic bone disorders was used in culture 
with mouse calvaria: 15% human serum replacing the standard
15% foetal calf serum in the medium. The results of Ca^^ 
and AP assays performed on the culture medium of such 
cultures are shown in TABLES lA(i),(ii) and TABLES lB(i),(ii)
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These results show no particular pattern of progressive
2 +  *increase or decrease in AP or Ca over the culture period,
2 +with the AP and Ca levels inherent in the patient's
serum interfering with those produced by the effects of
the serum on the bone itself, making comments on the
effects of the serum difficult.
What has been learned from the work carried out in
this chapter is that the culture system used is keeping
the calvaria alive and healthy in culture and that AP 
2 +and Ca , of particular interest in this thesis, are 
easily measurable in the culture medium, with the suggestion 
of some kind of inverse relationship between the two 
parameters. Such results allow further studies with 
calvaria in culture to be carried out with confidence.
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CHAPTER T W O : STUDIES IN BONE RESORPTION USING
^^Ca AND 4?Ca WITH HUMAN SERUM
Over the past 20 years calcium radioisotopes have been
used in many studies concerned with the effects of various
drugs, hormones or metabolites on bone resorption and, it
45is generally agreed, the release of Ca from prelabelled
bones in culture is an accurate means of assessing bone
resorption. These various substances have been tested,
either individually or in combination, allowing the effects
of the drugs on in vitro bone resorption to be assessed.
One of the main bone resorbing agents to be studied
has been parathyroid hormone, which has been shown, after
causing an initial uptalee of calcium by bone, to promote
bone resorption and serum calcium levels (Parsons, et al.
1971). Changes in bone resorption on the addition of other
substances may also be assessed. Engracio, et al. (1972)
and Minkin (1973) studied the effects of the antibiotic
45Mithramycin on parathyroid-hormone-induced release of Ca 
from prelabelled bone in culture, finding that the drug 
inhibits the action of the hormone. Stern (1969) had 
followed a similar line of enquiry, looking at the effects 
of corticosteroids on parathyroid hormone-induced resorption 
of bone, also finding that the hormone was inhibited. 
Calcitonin is an effective inhibitor of bone resorption 
(MacIntyre, et al. 1971) and also inhibits the in vitro 
resorption of bone by parathyroid hormone (Raisz, et al. 1967)
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Raisz, et. al. (1969) also studied the effects of phosphate,
calcium, magnesium, parathyroid hormone and calcitonin,
in combination, on bone resorption in culture, providing
some interesting results. Phosphate inhibits the release 
45of Ca from bone, particularly in the presence of para­
thyroid hormone, with the effects of phosphate and calcitonin 
appearing to be additive. Increasing the concentration of 
magnesium ions has no effect on bone resorption, but 
decreasing the concentration results in decreased bone 
resorption, particularly in the presence of parathyroid 
hormone. Calcium concentration has apparently no effect 
on bone resorption in vitro. These studies, among many 
others, serve to indicate the wide acceptance of this technique 
as a means of assessing bone resorption.
Experimental bones may be labelled for study by one of
several methods. Some workers prelabel young bones in
45utero, injecting up to 500 yCi of CaClg into a pregnant
rat or mouse on the 18th day of gestation, using foetal
bones in culture a day or two later (Raisz, et al, 1967;
Vaes, 1968; Raisz, et al. 1968; Stern, 1969; Raisz, et al,
1969; Engracio, et al. 1972; Stern, et al, 1976; Rowe, et al.
1977; Holtrop, et al. 1978; Horton, et al. 1978). Other
researchers prefer to inject 2 day old mice subcutaneously,
45with doses of between 10 pCi and 12.5 pCi of CaCl^ each, 
using their labelled calvaria in culture 4 days later 
(Reynolds, et al. 1970; Pang, et al. 1971; Minkin, et al.
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1972; Minkin, 1973; Gozariu, et al. 1973; Marks, 1974).
The prelabelled bones are dissected out from the freshly-
killed young animals and placed in sterile culture with
either control medium or experimental medium, the latter
containing some test substance. The effects of the test
substance are gauged by intermittent monitoring of the 
45Ca levels in the culture medium.
As in the previous chapter, thrice frozen and thawed
dead bone cultures were sometimes used as experimental
controls. Reynolds, et al. (1970) have shown that the
degree of actual cell-mediated resorption in bone, as
opposed to diffusion or active transport, of calcium may
45be calculated by subtracting the level of Ca released
by dead bones from that released by living bones. In
45addition to the Ca released by bone in culture, changes 
45in the Ca content of the prelabelled bones themselves
may also be assessed: Vaes (1968) dissolved labelled calvaria
in 1 ml of 1 Normal hydrochloric acid, while Fang, et al.
(1971) used 0.5 ml of concentrated formic acid, assessing 
45the Ca content of the dissolved bone on 3-scintillation 
counter.
In this study, after various preliminary experiments, 
the effects of various substances were examined. Many 
studies have been made concerning the effects of para­
thyroid hormone, calcitonin, oestrogen and vitamin D 
metabolites, separately or in combination, on bone in 
culture and so it was decided to use these as trial
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substances for the experimental system used here, using
the doses of these substances tested in previous studies
(Nisbet, et al. 1969; Heersche, 1969; Messer, et al.
1973; Peck, et al. 1976; Jones, et al. 1976; Reynolds,
1977; Messer, 1977; Jones, et al. 1977; Herrmann-Erlee,
et al. 1977; Hermann-Erlee, et al. 1978).
The main point of this study, however, was to look
at the effects of human serum, taken from patients
suffering from a variety of metabolic bone diseases, on
bone turnover in vitro. Mice were prelabelled by
45subcutaneous injection of CaCl^ at 2 days old and their
calvaria placed in culture at 6 days old, but on each
45occasion, in addition to prelabelling the bone with Ca,
47the culture medium was prelabelled using CaCl^. These 
isotopes of calcium have distinct half-lives, which allow 
them to be used together, while still allowing them to be 
assessed separately. Once test serum has been added to 
the culture medium, samples of medium are removed daily and
assessed, initially for ^^Ca and ^^Ca content and after
45 47four weeks for Ca content alone. Ca has a half-life
45of only 4.7 days, decaying within 4 weeks, with the Ca, 
with a half-life of 160 days, remaining. It was hoped 
that by using both isotopes of calcium, bone turnover, 
and not just bone resorption, in the presence of the 
different sera could be assessed.
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Materials and Methods :
1. Preparation of cultures. Two-day-old BKW mice
4*5were injected subcutaneously with 10 pCi of CaClg,
4-5
in initial studies, or 0.5 pCi of CaCl^ in all
subsequent studies with patient serum. At six-days-
old the mice were killed by decapitation and their
calvaria placed in culture, as described in the previous
chapter. In those experiments where it is specified,
470.25 pCi of CaClg were added to the culture medium. 
Each day of culture the medium was removed and replaced 
with fresh medium of the same type and, occasionally, 
bone was removed from culture and dissolved in 1 ml 
of concentrated formic acid, to allow the isotope 
content of the bone to be assessed.
2. Radio-active assay of samples. All samples, after
initial trial experiments, were counted for 5 minutes 
on a 3-scintillation counter (Packard TRI-CARB, Model 
3375), each vial containing 5 ml of instagel, a 
scintillation cocktail, and 25 pi of the sample.
The culture medium used, as in the previous chapter, 
contained phenol red indicator and it was thought that 
this may produce a colour-quenching effect on the 
activity recorded, reducing the counts per minute 
(CPM) detected. To test this effect, some samples 
were treated with 0.2 mis of hydrogen peroxide and 
incubated at 40^C for & houv; samples without bleach 
were also treated in this way. The results showed
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that the phenol red produces no colour-quenching
effect and bleaching of samples is unnecessary.
3. To look at the effects of parathyroid hormone (PTH) and
45calcitonin (CT) on the release of Ca from prelabelled
bone in culture, cultures were prepared as normal, but
with either 0.5 U/ml of PTH or 50 mU/ml of CT (Sigma,
London) added to the experimental cultures; control
cultures contained no test substance. The PTH and
CT were not added to the experimental cultures until
day 2, allowing the calvaria to 'acclimatise' themselves
45in culture. The release of Ca in the presence of each 
substance was assessed by 3-scintillation. Dead control 
cultures were also prepared. Results are shown in TABLE 
2A. (ECS = Eoetal Calf Serum Control).
TABLE 2A
DAY OE
CULTURE CULTURES COMPARED p
TEST
ÎTANC]
NOW
1 PTH (860+ 350) + PCS (1120+160) 0
CT (1570+ 90) + ECS (1120+160) 0
PTH (860+ 350) + CT (1570+ 90) 0
ECS (1120+160) + ECS Dead (940±180) 0
ID
2 PTH (1190+400) + ECS (2680+120) 0. 01
CT (2540+940) + ECS (2680+120) 0
PTH (1190+400) + CT (2540+100) 0
ECS (2680+120) + ECS Dead (1420+100)0.001
3 PTH (450+77) + ECS (1700+60) 0.001
CT (1640+40) + ECS (1700+60) 0
PTH (450+77) + CT (1640+40) 0.001
ECS (1700+60) + ECS Dead (960±240) 0
4 PTH (380+92) + ECS (1160+40) 0.001
CT (760+320) + ECS (1160+40) 0
PTH (380+92) + CT (760+320) 0
ECS (1160±40) + ECS Dead (700+60) 0. 02
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The results demonstrate that PTH strongly inhibits
bone resorption in vitro, while CT only slightly inhibits
bone resorptiono Dead bone in culture releases less
45Ca than corresponding living control cultures.
FIGURE 2A demonstrates the general trends.
45 474. Ca and Ca in Culture Medium. On each day that
4 7fresh medium was placed in culture, 0.25 yCi CaClg were 
added to the medium. It was hoped that by using two 
distinct calcium isotopes that the passage of calcium 
into and out of bone, throughout the duration of each
45culture could be studied: looking at the release of Ca
47by bone and the uptake of Ca by bone. Results in
TABLE 2B, looking at ^^Ca and ^^Ca levels in the culture
medium on each day of culture show that the culture
medium in each case contains both calcium isotopes, where
47it had originally contained only Ca. The level of 
45Ca in the medium seems to remain fairly constant,
although it falls towards the end of the given culture
47 47period, the level of Ca rises. The values of Ca
have been corrected, taking into account the short half-
life and the rapid decay of the isotope. At the end
of the given culture period the bone, on dissolution with
concentrated formic acid, can be seen to contain a mixture
of both ^^Ca and ^^Ca, where it had originally contained 
45only Ca.
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FIGURE 2 A
45Results of comparisons between Ca levels in 
culture medium in the presence of parathyroid 
hormone and calcitonin, as well as in control 
medium. These results demonstrate that, 
generally, less ^^Ca is released in the 
presence of parathyroid hormone or calcitonin 
than with control medium.
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It is possible to use two isotopes of calcium 
together in such a manner, and detect them separately, 
as they have distinct half-lives. In the initial count 
made on the culture medium, and dissolved bone samples,
we obtain a total count for all ^^Ca and ^^Ca present,
47 47
however Ca has a half-life of 4.7 days and all Ca
decays to a stable form within 4 weeks; assessment of
45the culture medium after 4 weeks will show only the Ca 
45present, Ca having a half-life of 160 days. The activity 
47of Ca in the samples was obtained by subtracting the bone 
^^Ca level from the combined ^^Ca and ^^Ca level obtained
4 weeks previously. 
TABLE 2B
DAY OF CULTURE 45Ca (CPM) 
X + S
47Ca (CPM) 
X + S
1 1304 + 544 5887 + 1214
2 1494 + 637 7638 + 1448
3 1401 597 8723 + 1899
4 1489 + 665 11877 + 1137
5 1421 + 565 13520 3572
6 1344 + 463 14421 + 3403
7 1141 + 380 15610 + 2804
ON DAY 7 8726 4 4815 43745 + 7833
Results of Ca and Ca activities present in bone 
culture medium on each day of culture and in acid- 
dissolved bone at the end of the culture period. 
These results show that both bone and culture medium 
contain a mixture of the 2 calcium isotopes, where 
each had previously contained only one.
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To give a better impression of how ^^Ca and ^^Ca levels
in bone are affected on each day of culture, sample
calvaria were removed from culture on each day and dissolved
in concentrated formic acid. As controls, cultures were
set up using dead calvaria, killed by thrice freezing and
thawing, to let us see whether the exchange of calcium
isotopes between bone and culture medium is active or
passive. The results of this study are shown in TABLE 2C
and FIGURE 2 B , showing us that as cultures progress the 
47amount of Ca in the bone itself rises then falls again, 
suggesting that ^^Ca is lost from bone. ^^Ca levels also 
seem to show a lot of variation, probably due to differing 
uptake at the time of injection. The ^^Ca and ^^Ca levels 
in both living and dead bones seem to fluctuate, with no
great differences in the levels of isotopes on each day.
TABLE 2C. (C.P.M . = Counts per minute).
DAY BONE REMOVED CONTENT OF LIVING BONE CONTENT OF DEAD BONE
FROM CULTURE 45„ , „ .T \ 47^ 47Ca ( C ,P.M.) Ca Ca (C. P.M.) Ca
. 1 4263 5491 4704 3626
2 3654 9118 2929 7021
3 2892 12990 2886 12540
. 4 2409 20599 2337 19921
5 3578 23740 42 46 14390
6 3751 19019 4930 18181
7 4237 19805 3370 35488
Results of Ca and Ca activities in bone removed from 
culture each day and dissolved in concentrated formic acid, 
showing that the ±^Ca and '^’^Ca in both living and dead bone 
fluctuates greatly.
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FIGURE 2B
Results of and ^^Ca assays performed
daily on pre-labelled calvaria. The 
calvaria were removed from culture on each 
day, dissolved in concentrated Formic acid 
and assayed for ^^Ca and ^^Ca content.
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Looking at the levels of and ^^Ca released by
living and frozen dead control bones into the culture medium,
TABLE 2D FIGURE 2C, we see that dead bones tend to release 
45less Ca into the culture medium than living bones. The
47uptake of Ca by living and dead bone following a similar 
pattern, decreasing then increasing, but with living bone
tending to take up slightly less 
TABLE 2D
47Ca.
(i)
LIVING
BONE
CULTURE
MEDIUM
DAY OF CULTURE ^^Ca (C.P.M.) ^'^Ca (C.P.M.)
X + S X + S
1 734 + 207 6114 + 941
2 859 + 226 8720 + 1338
3 864 + 311 9967 + 1260
4 86 3 + 219 12157 1618
5 1001 + 294 14732 2988
6 1055 273 12925 + 1820
7 677 + 16 11285 + 358
(ii) DAY OF CULTURE ^^Ca (C.P.M.) 
X + S
4?Ca (C.P.M.) 
X + S
DEAD 1 596 + 128 6805 + 2254
BONE 2 596 + 83 7638 + 1540
CULTURE 3 593 + 73 9496 + 995
MEDIUM 4 644 + 77 10763 + 1561
5 640 + 62 12874 + 1548
6 598 + 395 10019 + 1740
7 650 + 7 12068 + 985
Results of Ca and Ca activities in culture 
medium supporting living and dead calvaria on 
each day of culture. These results show that 
dead bone releases less 45c& than living bone 
and the release of 45^^ from dead bone is at an 
almost constant rate, suggesting a passive process. 
The results also show that living bone tends to take 
up less 47ca than dead bone, but the amount taken up 
fluctuates.
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FIGURE 2C
Results of and ^^Ca assays performed
daily on bone culture medium supporting
living and dead calvaria; medium is 
45
labelled with Ca.
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45Reynolds (1970) used the release of Ca from 
prelabelled living and dead calvaria to give a measure of
the actual cell-mediated resorption (C*M.R«), by subtracting
45 45the Ca released by dead calvaria from the Ca released
45by living calvaria, the release of Ca from dead bone
being caused by diffusion. However, results from cultures
containing both ^^Ca and ^ ^Ca suggest that ^^Ca, originally
taken up by bone in culture, may be released by bone towards
45the end of the culture period, replacing Ca which would 
normally be released. This trend suggests that when both 
calcium isotopes are used we cannot get a true measure of 
the C.M.R., making the use of dead calvaria controls 
unnecessary.
From this point in the study of bone turnover in culture,
the levels of the ^^Ca and ^^Ca isotopes in the culture
medium will be used in comparative studies. The short 
47half-life of Ca makes it unsuitable for long-term cultures
and so all cultures will be maintained for only 4 days, with 
47the Ca levels on each day being corrected for decay.
The main point of this investigation is the study of 
the effects of serum, from patients suffering from metabolic 
bone disorders, on bone turnover in vitro. We have already 
seen that many groups have studied the effects of bone-
related substances, such as parathyroid hormone, on bone
45resorption in culture, using Ca alone; these substance 
parathyroid hormone, oestrogen, calcitonin and vitamin D
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45metabolites have been, studied in relation to Ca and 
47Ca bone turnover in vitro. By looking at the effects
of these metabolites in culture with this experimental
system, we can look at the usefulness of this system
45compared with studies in bone turnover using Ca alone.
Cultures were prepared containing 15% human serum,
from patients or normal individuals, replacing 15% foetal
calf serum ; the normal serum is pooled. For those
cultures where PTH or some other substance is studied,
the test substance, in the concentration given, is added
to the standard culture medium, containing 15% foetal
calf serum, at the beginning of the culture period.
Control cultures, containing standard culture medium with
15% foetal calf serum, were prepared with each set of
experimental cultures. Between 3 and 16 cultures of each
type were prepared, depending on the availability of the
serum or metabolite. On each day of culture, the culture
medium was changed, being replaced by fresh medium of the
same type, as before. The culture medium removed was
assayed by g-scintillation for ^^Ca and ^^Ca content,
45 47by the method described; the average Ca and Ca 
levels in each set of control and experimental cultures 
are given in TABLES 2E-2U.
Initially, the ^^Ca and ^^Ca levels found in culture 
medium in the presence of any test substance, whether 
serum or metabolite, are compared with those levels found
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in control medium, control medium acting as the standard,
producing a ratio: EXPERIMENTAL x . By comparing
CONTROL X
these ratios between different sets of experimental 
cultures, we can see how ^^Ca release and ^^Ca uptake 
compare in the presence of each test substamce. Results 
for days 3 and 4 only, where bone has ’acclimatised' in 
culture, are given.
Results :
TABLE 2E . Pooled normal human serum
TYPE OF CULTURE
45ca
DAY 3 
(C.P.M.,)^^Ca 45ca
DAY 4 
(C.P.M) 4?Ca
EXPERIMENTAL x 79 485 85 454
S 14 192 8 152
CONTROL X 87 547 82 665
S 13 119 17 222
EXPERIMENTAL x 
CONTROL X
0.91 0.89 1.04 0.68
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TABLE 2F. Serum from hypoparathy-roid patients.
(i)
(ii)
(iii)
(iv)
TYPE OF CULTURE
45ca(C 47.P.M) Ca
DAY 4 
^^Ca(C.P.M) ^^Ca
EXPERIMENTAL X 489 16662
S 24 3305
CONTROL X 596 24312
S 17 . . . . 4529
EXPERIMENTAL X
CONTROL X 0.82 0.69
EXPERIMENTAL X 161 4308 210 4769
S 86 354 135 490
CONTROL X 178 3025 144 3311
S 35 730 70 513
EXPERIMENTAL X
CONTROL X 0.9 1.42 1.46 1.44
EXPERIMENTAL X 211 4034 280 4345
8 111 600 83 341
CONTROL X 178 3025 144 3311
8 35 730 70 513
EXPERIMENTAL X
CONTROL X 1.18 1.33 1.94 1.31
EXPERIMENTAL X 481. 9072 526 10167
S 45 686 73 863
CONTROL X 506 5525 630 6199
8 44 572 63 825
EXPERIMENTAL X 0.95 1.64 0.84 1.64
CONTROL X
(i) Female, age 37. Serum Ca 1.65; serum AP 246.
(ii) Female, age 37. Serum Ca 1.95; serum AP 127. On 3 yg
l(OH)Do per day.
(iii) Female, age 46. Serum Ca 2.4 ; serum AP 205; serum PTH 
280. On 1.25 yg calciferol per day.x iO V J . W U p  C H . JLC JL Jl
(iv) Female, age 67. Serum Ca 1.95 ; serum AP 211.
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TABLE 2G. Serum from patients with Paget's Disease of Bone
(i)
(ii)
(iii)
(iv)
TYPE OE CULTURE
.
DAY 3
(C.P.M) 4?ca
DAY 4 
^^Ca (C.P,.M) 4?ca
EXPERIMENTAL X 906 24863 1195 31054
S 58 2571 0 0
CONTROL X 997 23985 964 26494
S 92 924 0 0
EXPERIMENTAL X
CONTROL X 0.91 1.03 1.24 1.18
EXPERIMENTAL X 291 2547
S 55 215
CONTROL X 269 1688
S 28 299
EXPERIMENTAL X
1.08 1.51CONTROL X
EXPERIMENTAL X 580 13243
S 81 1550
CONTROL X 628 10955
S 29 1460
EXPERIMENTAL X 0.92 1.21
CONTROL X
EXPERIMENTAL X 849 8590 730 10377
8 23 1520 89 1045
CONTROL X 509 6821 546 9021
S 13 706 99 466
EXPERIMENTAL X 1.67 1.26 1.34 1.15
CONTROL X
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TABLE 2G (continued)
( v)
(vi)
TYPE OE CULTURE
45ca
DAY 3
47
(C.P.M) ^'Ca ^^ca
DAY 4 
(C.P.M. )
EXPERIMENTAL X 427 16432 498 18086
S 29 194 24 2311
CONTROL X 346 18121 410 21538
S . 44 ...... 1424 26 1067
EXPERIMENTAL 
CONTROL X
X 1.23 0.91 1.21 0.84
EXPERIMENTAL X 410 7954 432 10187
S 68 1296 101 3637
CONTROL X 486 5474 453 8580
S 104 1077 92 167
EXPERIMENTAL 
CONTROL X
X
0.84 1.45 0.95 1.19
(i) Male, age 59. Serum Ca 2.25; serum AP 353.
(ii) Female , age 55. Serum Ca 2.3; serum AP 82 8,
(iii)Eemale, age 71.
(iv) Male , age 51. Serum Ca 2.3; serum AP 265.
(V) Male, age 72 . Serum Ca 2.5 ; serum AP 142.
(vi) Male, age 78. Serum Ca 2.35; serum AP 1542 . On
calcitonin, last injection 98 hours previously.
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TABLE 2H. Serum from patients with primary hyperparathyroidism,
TYPE OF CULTURE
45ca
DAY 3 
(C.P.M) 4?Ca ^^Ca
DAY 4 
(C.P.M.) 4?ca
) EXPERIMENTAL X 477 10465 393 18128
S 0 0 0 0
CONTROL X 587 6680 606 9906
S 0 0 79 1131
EXPERIMENTAL 
CONTROL X
X
0.81 1.56 0.65 1.83
i) EXPERIMENTAL X 262 4730 342 5090
S 176 553 35 401
CONTROL X 178 3025 144 3311
S 35 730 70 5l3
EXPERIMENTAL 
CONTROL X
X
1.47 1.56 2.37 1.53
i) EXPERIMENTAL X 198 4190 369 4228
S 163 927 74 535
CONTROL X 178 3025 144 3311
S 35 730 70 513
EXPERIMENTAL 
CONTROL X
X 1.11 1.38 2.56 1.27
v) EXPERIMENTAL X 378 440 2 32 538
S 0 7 14 89
CONTROL X 662 347 476 431
S 0 0 34 147
EXPERIMENTAL 
CONTROL X
X 0.57 1.27 0.49 1.24
(i) Male,. (ii) Male, age 79
(iii) Female, age 66.(iv) Male.
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TABLE 21. Serum from patients with malignant hypercalcaemia
TYPE OE CULTURE 47.P.M) 'Ca
45 DAY 4 
4^Ca (C.P, 47,M) *'Ca
(i) EXPERIMENTAL
CONTROL
X
8
X
132
30
72
390
115
321
150
10
75
449
129
300
Male. 
Serum AP 
1040 
(mostly 
liver
8 12 81 4 178
iso­
enzyme )
EXPERIMENTAL 
CONTROL X
X 1.83 1.21 2.0 1.5
(ii) EXPERIMENTAL X
8
150
14
457
163
129
16
174
70
Male. 
Serum AP 
274.
CONTROL X 75 321 75 300
8 12 81 4 178
EXPERIMENTAL 
CONTROL X
X 2.0 1.42 1.72 0.58
(iii) EXPERIMENTAL X 119 415 116 196 Male.
8 13 70 7 87
CONTROL X 75 321 75 300
8 12 81 4 178
EXPERIMENTAL 
CONTROL X
X 1.59 1.29 1.55 0.65
(iv) EXPERIMENTAL X 170 439 118 293 Male.
8 38 113 34 124 Serum AP
CONTROL X
8
75
12
321
81
75
4
300
178
2200
(mostly
liver
EXPERIMENTAL 
CONTROL X
X
2.27 1.37 1.57 0.98
iso­
enzyme)
(v) EXPERIMENTAL X 712 3613 585 4554 Female.
8 66 747 116 273
CONTROL X 671 3692 740 5197
8 412 904 48 790
EXPERIMENTAL 
CONTROL X
X 1.06 0.98 0.79 0.88
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TABLE 2J. Serum from patients suffering from carcinoma, 
but with a normal serum calcium.
(i)
(ii)
(iii)
(iv)
TYPE OE CULTURE DAY
^^Ca(C.P.
3
M)4?ca
DAY 4 
. ^^Ca(C.P.M) 4?ca
EXPERIMENTAL X 345 1888
S 70 534
CONTROL X 269 1688
8 28 299
EXPERIMENTAL 
CONTROL X
X 1.28 1.09
EXPERIMENTAL X 356 2223
8 45 297
CONTROL X 269 1688
8 28 299
EXPERIMENTAL 
CONTROL X
X 1.32 1.32
EXPERIMENTAL X 185 150 170 343
8 56 105 67 138
CONTROL X 75 321 75 300
8 12 81 4 178
EXPERIMENTAL 
CONTROL X
X 2.47 0.47 2.27 1.14
EXPERIMENTAL X 103 425 103 250
8 9 125 9 28
CONTROL X 75 321 75 300
8 12 81 4 178
EXPERIMENTAL 
CONTROL X
X 1.37 1.32 1.37 0.83
(i) Male. Serum PTH <300. (ii) Male.
iii) Male. (iv) Male.
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TABLE 2K. Serum from patients suffering from hypercalcaemia
(i)
(ii)
(iii)
TYPE OF CULTURE
, ^^Ca(C^ ^ N 47 P.M) ^'Ca
45 d a y  
*^Ca(C.P. ^ 47 ,M) 'ca
EXPERIMENTAL x 300 2547
8 29 591
CONTROL X 269 1688
8 28 299
EXPERIMENTAL x 
CONTROL X
1.11 1.51
EXPERIMENTAL x 206 2148 176 2564
8 15 182 9 212
CONTROL X 167 3947 183 3826
8 19 216 17 14
EXPERIMENTAL x 
CONTROL x
1.23 0.54 0.96 0.70
EXPERIMENTAL x 726 17663 657 20663
8 53 2307 44 1054
CONTROL X 748 15255 348 19890
8 99 904 337 1082
EXPERIMENTAL x 
CONTROL X 0.97 1.16 1.89 1.04
(i) Female, age 72. Serum Ca 2.65; Serum AP 296
(ii) Female, age 66. On diabetic drugs.
(iii) Male, age 63.
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TABLE 2L. Serum from patients suffering from
hypervitaminosis D.
(i)
(ii)
TYPE OF CULTURE
45ca(C.P,
DAY 3 
.M) 4?ca
DAY 4 
^^Ca(C.P M)
EXPERIMENTAL X 520 4208 698 4468
S 130 421 489 1055
CONTROL X 671 3692 740 5197
S 412 904 48 790
EXPERIMENTAL 
CONTROL X.
X 0.77 1.14 0.94 0.86
EXPERIMENTAL X 492 3940 579 4927
S 2 31 544 41 1250
CONTROL X 671 3692 740 5197
S 412 904 48 790
EXPERIMENTAL 
CONTROL X
X 0.73 1.07 0.78 0.95
(i) Female. Serum 25(0H)Dg 1940 nm/litre
(ii) Male. Serum 25(0H)Dg 1760 nm/litre.
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TABLE 2M. Serum from patients suffering from osteoporosis
(i)
(ii)
TYPE OF CULTURE DAY
45ca(C.P
3
.M) 4?Ca
DAY 4
45ca(C.P.M)4?Ca
EXPERIAŒNTAL X 142 1290 263 1179
8 99 72 70 0
CONTROL X 349 774 304 890
8 76 63 61 0
EXPERIMENTAL 
CONTROL X
X 0.41 1.67 0.87 1.32
EXPERIMENTAL X 266 4206 291 4311
8 87 451 87 675
CONTROL X 178 3025 144 3311
8 35 730 70 513
EXPERIMENTAL 
CONTROL X
X 1.49 1.39 2 .02 1.30
EXPERIMENTAL X 366 3360 290 5043
8 131 595 56 559
CONTROL X 236 3092 410 4020
8 67 493 99 429
EXPERIMENTAL 
CONTROL X
X 1.55 1.09 0.71 1.25
EXPERIMENTAL X 552 4207 459 5446
8 45 667 100 1242
CONTROL X 671 3692 740 5197
S 412 904 48 790
EXPERIMENTAL 
CONTROL X
X 0.82 1.14 0.62 1.05
(i) Female.
(ii) Female, age 51. Serum Ca 2,3; Serum AP 171.
(iii) Female, age 58.
(iv) Female, on oestrogen tablets for 3 weeks.
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TABLE 2N. Serum from a patient suffering from
osteogenesis imperfecta
TYPE OF CULTURE DAY
45ca (C.P.M)
3
4?Ca
DAY 4 
^^Ca (C.P .M) 4?Ca
EXPERimNTAL X 493 4225 794 4810
8 71 228 48 560
CONTROL X 671 3692 740 5197
8 412 904 48 790
EXPERIMENTAL x 
CONTROL X
0.73 1.14 1.07 0.94
Male, age 31. Serum Ca 2.5; Serum AP 436.
uE 20. Serum from a patient suffering from
hypophosphatasia
TYPE OF CULTURE DAY 3 
45ca (C.P.M) 4?Ca
DAY 4 
4^Ca (C.P. M) ^^Ca
EXPERIMENTAL x 254 2507
8 58 400
CONTROL X 269 1688
S 28 299
EXPERIMENTAL x 
CONTROL X
0.94 1.49
Female, age 21. Serum Ca 2. 8 ; no AP.
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t a b l e 2P. Serum from patients suffering from
rickets/osteomalacia
(i)
(ii)
(iii)
TYPE OF CULTURE
4Sca
DAY 3 
(C.P.M) 4?Ca
DAY 
4^ca (C,
4
47.P.M) *'ca
EXPERIMENTAL X 263 4436 181 5150
S 118 289 85 416
CONTROL X 178 3025 144 3311
S 35 730 70 513
EXPERIMENTAL 
CONTROL X
X 1.48 1.47 1.26 1.56
EXPERIMENTAL X 436 15518 466 15127
S 34 2883 20 3470
CONTROL X 402 16655 407 18123
S 139 4619 51 2077
EXPERIMENTAL 
CONTROL X
X 1.08 0.93 1.14 0.83
EXPERIMENTAL X 355 3805 294 4671
8 63 1091 84 786
CONTROL X 178 3025 144 3311
8 35 730 70 513
EXPERIMENTAL 
CONTROL X
X 1.99 1.26 2.04 1.41
(i) Male. Nutritional rickets
(ii) Male, age 79. Serum Ca 1.3; Serum AP 619
(iii) Female, age 18. Serum Ca 2.25; Serum AP 302;
Serum PTH 230,Phosphaturic rickets.
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TABLE 2Q. 1 ng/ml
TYPE OE CULTURE DAY 3 
^^Ca (C.P.M) 4?ca
DAY 4
45
Ca (C.P.M) 4?Ca
EXPERIMENTAL X 129 1633 155 2987
S 24 273 38 796
CONTROL X 175 1186 200 3068
S 29 335 39 493
EXPERIMENTAL 
CONTROL X
X 0.74 0.71 0.78 0.97
5R. 100 ng/ml 25(0H)Dg
TYPE OF CULTURE 45 d a y
4^Ca (C.P
3 47 
.M) 'Ca
45 d a y  4 
Ca (C.P.M) 47ca
EXPERIMENTAL X 120 1432 132 1422
s 18 245 19 408
CONTROL X 175 2286 200 3068
s 29 335 39 493
EXPERIMENTAL_ x 0.63 0.66 0.46
CONTROL X
TABLE 28. 0.5 U/ml parathyroid hormone
TYPE OF CULTURE DAY 3 
(C.P. M) 4?ca
DAY 4 
4^Ca (C.P.M) 4?Ca
EXPERIMENTAL X 62 12 8 62 129
S 11 54 10 74
CONTROL X 87 547 82 665
S 13 119 17 222
EXPERIMENTAL X 0.71 0.23 0.76 0.19
CONTROL X
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TABLE 2T. 50 mU/ml calcitonin
TYPE OF CULTURE
4Sca
DAY 3 
(C.P.M) 4Sca
DAY 4 
(C.P.M) 4?ca
EXPERIMENTAL x 61 379 74 418
S 10 79 13 62
CONTROL X 87 547 82 665
S 13 119 17 222
EXPERIMENTAL x
CONTROL X 0.70 0.69 0\90 0.63
TABLE 2U. 100 yg/ml oestrogen
TYPE OF CULTURE
45c&
DAY 3 
(C.P.M) ^^Ca
DAY 4 
(C.P.M) 4?Ca
EXPERIMENTAL X 62 118 60 131
S 7 43 7 45
CONTROL X 87 547 82 665
S 13 119 17 222
EXPERIMENTAL 
CONTROL X
X
0.71 0.22 0.73 0.20
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FIGURE 2D (i), (ii), (iii)
Results of e x p e r t MENT A L j .^Ca calculations
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CONTROL Ca
made for control medium, containing foetal 
calf serum, and experimental medium, 
containing either 15% human serum, from a 
patient with a metabolic bone disorder, or 
some other bone-related test substance.
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Discussioa:
As was described in the introduction to this chapter,
45bone pre-labelled with Ca has been very useful, in in
vitro culture, in the study of the effects of various metabolites
or other test substances on bone resorption. However, as
well as knowing the effects a substance may have on resorption,
it is sometimes of interest to know the effect of the same
47substance on bone formation, involving the use of a Ca
label in the culture medium. In this chapter, the effects
of various standard test substances: PTH, C T , oestrogen
and the vitamin D metabolites 25(0H)Dg and l,25(0H)2Dg,
and of various human sera on bone resorption and formation
45 47have been studied. By comparing Ca and Ca levels in 
the presence of control culture medium, containing 15% 
foetal calf serum, with the levels in experimental medium, 
containing added test substance, we can see any effect 
the substance may have on bone turnover. The effects of 
medium containing 15% serum from patients suffering from 
metabolic bone disease are compared in the same way, with 
control medium, and then compared with the effect of 
medium containing normal human serum.
There are two basic ways by which the results produced 
in this study can be assessed. Firstly, the effects of 
the standard test substance: PTH, C T , oestrogen and the
vitamin D metabolites, on ^^Ca and ^^Ca bone turnover
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in vitro can be compared with the effects found in previous
45studies, of the same substances on Ca bone resorption in 
vitro. Secondly, the effects of the different human sera 
on bone turnover in vitro can be studied, with the effects 
of any in vivo drug therapy, such as calcitonin treatment 
for Paget's disease of bone, on bone turnover being assessed.
As has already been mentioned, PTH is a powerful 
stimulator of bone resorption. In the condition of hyper­
parathyroidism, with a high serum PTH (Harris, et al. 1969), 
we find increased bone turnover, particularly resorption, 
through increased osteoblastic activity (Rosenbach, et al. 
1967; Vaes, 1968; Shubina, et al. 1969; Byers, et al.
1971; Chu, et al. 1971; Messer, et al. 1973a; Minkin,
1973; Peck, et al. 1976; Reeve, et al. 1976; Langeland,
1977; Wong, et al. 1977; Luben, et al. 1977; Maria, et al.
1977; Ibbotson, et al. 1978; Krieger, et al. 1980,
Malluche, et al. 1981), although accompanied by increased 
bone formation (Smith, 1979). Using pre-labelled bone 
to study bone resorption, it was found that PTH acts on 
bone in vitro by inhibiting bone resorption, for the first 
few days of culture, followed by a stimulation of bone 
resorption (Raisz, et al. 1967, 1969; Stern, 1969;
Parsons, et al. 1971; Engracio, et al. 1971; Minkin, 1973)
With ^^Ca-prelabelled bone and ^"^Ca-prelabelled culture 
medium it was found that, over the 4 day culture period,
PTH decreased bone resorption, as compared to control 
medium with no added PTH, but increased calcium uptake
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from the labelled culture medium. The inhibition of bone
resorption in these cultures compares favourably with these
45results found with Ca-labelled bone alone, with the
47increased uptalce of Ca from the prelabelled medium
supporting the role of PTH in increasing bone formation,
although to a lesser extent than promoting resorption.
These trends are also promising in that the comparable
results would seem to suggest that the uptake and re-release 
47of Ca from bone, mentioned earlier, may not significantly 
interfere with the experiment.
Calcitonin inhibits bone resorption (Raisz, et al. 1967; 
Reynolds, et al. 1968; Raisz, et al. 1968; Nisbet, et al. 
1968; Mittleman, et al. 1968; Binderman, et al. 1972;
Gozariu, et al. 1973; Luben, et al. 1976; Geusens, et al. 
1980; Maier, et al. 1980; Stevenson, et al. 1981),by 
inhibiting the loss of bone matrix and mineral. Looking 
at the effect of CT on PTH-induced bone resorption, and on 
bone in general, it has been found that CT acts on prelabelled 
bone in culture to inhibit bone resorption (Raisz, et al. 1967, 
1969; MacIntyre, et al. 1971). In this study, using pre­
labelled bone and pre-labelled culture medium, it was found 
that CT does indeed inhibit bone resorption, also 
increasing calcium uptake. This role of CT in the control 
of bone turnover is of particular interest in the study of 
post-menopausal osteoporosis, a condition of accumulated 
bone loss accompanied by normal bone formation, as serum 
CT levels fall drastically with the menopause (Shamonki, 
et al. 1980; Padilla, et al, 1980). As CT falls one
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would expect the effects of bone resorption to increase, 
with no effect on bone resorption; with this experiment 
it has been found that high levels of CT in the culture 
medium result in decreased bone resorption, a result which 
compares favourably with that found in vivo and already 
researched in vitro.
The most common metabolic bone disease affecting
post-menopausal women is osteoporosis and with the onset
of the menopause comes the disappearance of oestrogen.
Oestrogen has been shown to inhibit PTH-stimulated bone
resorption (Atkins, et al. 1972; Robin, et al. 1980;
Wink, et al. 1980), as well as being able to stimulate the
production of CT (Woloszczuk, et al. 1980; Stevenson,
et al. 1980; Morimoto, et al. 1980; Cressent, et al. 1980;
Stevenson, et al. 1981) which, as we have seen, also
inhibits bone resorption, the loss of both oestrogen and
CT leading to accumulated loss of bone (Geusens, et al.
1980). The inhibition of bone resorption by oestrogen
45has been demonstrated, looking at Ca-labelled bone (Stern, 
1969). Using ^^Ca-labelled bone and ^^Ca-labelled culture 
medium, it was found that oestrogen decreased bone resorption 
in vitro, while stimulating the uptake of calcium. Again, 
we have results which compare favourably with those found 
in previous studies, with added information concerning the 
effect of oestrogen on calcification.
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Metabolites of vitamin D have-, in general, been found
to promote both bone resorption and formation (Mittleman,
et al. 1968; Raisz, et al. 1974; Boyle, 1974, Stern, et al
1976; Peacock, et al. 1976; DeLuca, 1977; Wong, et al.
1977; Cohen, et al. 1980), promoting bone strength.
Looking at the effects of the metabolites 25(0H)Dg and
45l,25(0H)2Dg on bone turnover, using Ca-labelled bone 
47and Ca-labelled culture medium, it was found that both 
inhibited bone resorption, with no apparent effect on 
calcification.
Those experiments relating to the effects of PTH, CT,
oestrogen and the vitamin D metabolites on bone turnover
45 47in vitro, using Ca-labelled bone and Ca-labelled
medium, have proved promising, generally reflecting those
45trends found using Ca-labelled bone alone, but providing
additional information concerning bone formation under the
same conditions. Just as important, however, is that
47these results show that any re-release of Ca taken up 
by bone in the early stages of culture has no detrimental 
effect on the results. . It will now be interesting to 
look at the effects of the various human sera on bone 
turnover in vitro.
Looking at the effect of serum from osteoporotic 
patients on bone turnover in vitro, there are indications 
of a general trend towards increasing resorption and 
decreasing formation, as compared with normal human serum.
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One patient, being treated with oestrogen, shows decreased 
resorption and decreased uptake of calcium, as compared to 
other osteoporotic patients. Osteoporosis is the most 
widespread bone disorder affecting the elderly and is 
characterised by an accumulated loss of bone, although the 
biochemistry and pathology of the remaining bone is normal 
(Albright, et al. 1948). As the biochemistry and pathology 
of the bone are normal, one may expect to find that serum 
from osteoporotic patients and normal individuals would 
produce the same effects, concerning bone turnover, on bone 
in vitro, however we find that osteoporotic serum promotes 
bone resorption over formation, reflecting the osteoporotic 
condition. The ’normalising’ effect of the administration 
of oestrogen to an osteoporotic patient, reducing bone 
resorption, is interesting to note, with oestrogen being 
seen as a potential cure for osteoporosis.
Serum from patients suffering from osteomalacia/rickets 
would seem to enhance resorption of bone, accompanied by 
decreased calcification. The osteomalacic/ricketic condition 
is characterised by soft bones, with a lot of uncalcified 
bone matrix (Smith, 1979). The effects of serum from such 
patients would seem to reflect the situation in vivo, with 
resorption and lack of mineralisation being the rule.
Parathyroid hormone, as we have already seen, acts 
in vitro by inhibiting bone resorption, initially, but 
promoting it as cultures get older (Raisz, et al. 1967, 1969; 
Stern, 1969; Parsons, et al. 1971; Engracio, et al. 1972;
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Minkin, 1973). Serum from patients suffering from 1^ 
hyperparathyroidism, where there is an abnormally high 
serum PTH level, acts on ^^Ca-labelled bone and ^^Ca-labelled 
medium by decreasing uptake of calcium and, in general, 
stimulating bone resorption. These results differ from 
those found using standard PTH, in that here calcium uptake 
is decreased and bone resorption is stimulated more quickly. 
This result suggests that, similar to vitamin D, PTH may 
act slightly differently in vivo and in vitro.
Hypoparathyroidism, as the name would suggest, is a 
condition where PTH is absent and bone resorption is 
severely decreased. Looking at the effects of hypopara- 
thyroid serum on bone turnover in vitro, we see that the 
effects, as compared with normal human serum, suggest
47decreased calcification, through decreased uptake of Ca 
from the culture medium. Results concerning bone resorption 
are unconvincing. It could be that decreased resorption, 
in vivo, is counteracted to some extent by decreased 
mineralisation, in an attempt to keep the amount of bone 
present as normal as possible. The vitamin D metabolite 
la(OH)Dg has, as far as this study is concerned, little 
effect on bone turnover.
Although not a metabolic bone disease, Paget’s disease 
of bone is used here in a comparative role. Serum from 
patients suffering from P.D. would seem to increase bone
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resorption, while showing decreased mineralisation compared 
to normal human serum. Treatment with C T , as seen with 
one patient, is effective in decreasing bone resorption, as 
well as 'normalising' calcification. As P.D. is 
characterised by increased bone turnover, leading to the 
deposition of disorganised woven bone (Smith, 1979; Krane, 
1980), the increased bone resorption in vitro reflects 
that found in vivo, however increased mineralisation may have 
been expected. The effect of CT in reducing bone resorption 
and 'normalising' calcium uptake indicates its importance 
in treating this disorder. When the standard test CT was 
added to ^^Ca-labelled bone and ^^Ca-labelled medium we 
saw that it increased the uptake of calcium to a more normal 
level, suggesting a normalising effect in vivo.
A group of patients suffering from malignant hyper-
calcaemia provided a special interest in this study, such
patients having very high serum Ca levels which were thought
to originate from bone ; their serum was placed in culture
45to test this theory. Prom the results of Ca-resorption
47and Ca-uptake, we can see that serum from patients with 
malignant hypercalcaemia promotes bone resorption and 
decreases calcification, suggesting that some factor in 
the serum indeed promotes bone resorption. However, when 
we look at the effects of serum from patients suffering from 
carcinoma but with no elevated serum Ca, we see a very
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similar pattern of calcium uptake and release. More,
specific, investigations would be necessary to explain this
action of serum from malignant patients.
Two patients suffering from hypervitaminosis D, who
had each taken a massive overdose of 25(0H)Dg, also provided
particular interest in this study. Despite the very high
25(0H)Dg levels in their serum, the Ca and AP levels in their
45serum remained normal. When placed in culture with Ca-
47labelled bone and Ca-labelled culture medium, their serum
caused decreased bone resorption, as compared with normal
human serum, in much the same way as the two test vitamin D
47metabolites. Mineralisation, or Ca-uptake, was slightly 
less than that found with normal human serum and with the 
test vitamin D metabolites.
Hypophosphatasia is a rare, inherited, disorder affecting 
AP and bone (Smith, 1979), where there is no, or very little, 
bone AP. As this disorder is so rare, it was fortunate 
that serum from a hypophosphataemic patient became available 
for this study. In culture with labelled bone and medium, 
hypophosphataemic serum caused decreased calcification, with 
no effect on bone resorption, as compared with normal human 
serum. This result may support the positive relationship 
between AP and mineralisation, discussed elsewhere in this 
thesis.
Serum from patients suffering from hypercalcaemia, 
apart from the malignant hypercalcaemic patients, produced 
increased bone resorption in culture, with no effect on 
calcification. This result suggests that the increased serum
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calcium originates from bone. Osteogenesis imperfecta is
characterised by decreased bone mass, accompanied by
multiple fractures (Teitelbaum, 1981), with serum from such
a patient producing decreased calcification, with no effect
on resorption, in culture. As with osteomalacia, this
decreased calcification and softening of the bone would
lead to the accumulation of pseudofractures, as have been
found in vivo.
From these results we can see that this method of
observing bone turnover in vitro has certain attractions.
With previous studies it was possible to look at the effects
of substances on bone resorption in vitro, but now it is also
possible to look at the effects of substances on bone formation
45in vitro. Previous studies using Ca-labelled bone have
shown how various standard test substances: PTH, C T ,
oestrogen, 25(0H)Dg and l,25(0H)gDg affect bone resorption,
45effects which have been repeated here, using Ca-labelled 
47bone and Ca-labelled culture medium; any effects of such 
substances on bone formation in vitro can be accepted 
confidently in view of the duplicated resorption effects. 
Additional information concerning bone formation in vitro 
gained from this study of C T , PTH, oestrogen and the vitamin 
D metabolites is that, as in 1^ hyperparathyroidism, PTH 
stimulates calcium uptalee in vitro, CT normalises 
calcification while oestrogen promotes calcification. It 
would have been interesting to look at the effects of
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fluoride, thought to promote strong bones and teeth 
(Jackson, 1967; Messer, et al. 1973; Smith, 1979) on bone
turnover in vitro, however time did not allow.
47Although Ca has been used here to demonstrate the 
uptake of calcium by bone in the presence of different test 
substances, the uptalee of labelled calcium from the gut has 
previously been used to demonstrate bone mineralisation 
(Spencer, et al. 1978). The advantage of using this in 
vitro system as opposed to any in vivo system is that this 
system is much less complicated, with the many systemic 
effects found in experimental animals being removed. Another 
advantage of this in vitro system is that it allows 
investigation of the effects of various human sera on bone 
turnover in vitro; the administration of human serum to an 
experimental animal would be complicated by its immune response.
From the limited number of human sera studied here, it 
is still possible to discern particular patterns of bone 
formation and resorption accompanying particular bone 
diseases, as well as their treatment. Human serum is, of 
course, a very complex mixture of enzymes, metabolites, nutrients 
and other factors and the main problem in using serum in 
any study is that any effect cannot, without further analysis, 
be linked to any particular factor. With those sera used 
here, for example, no link between serum AP or Ca levels 
and bone resorption or formation in vitro can be found.
As far as the study of the effects of human sera on bone 
turnover in vitro is concerned, this system could be important.
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first of all, in indicating the severity of bone loss or 
formation in a disorder, and, secondly, in determining 
the effects of any drug therapy on the patient's condition, 
the latter being the most important aspect of this system.
NOTE: The work contained within this chapter was
presented, in poster form, at the joint 
meeting of the Scottish Society for Experimental 
Medicine and the Medical Research Society in 
Edinburgh on 9th, 10th July, 1982.
Abstract: McGowan, P., Boyle, I.T. (1982)
In vitro Bone Turnover in Neonatal Mouse Calvaria: 
The Influences of Serum from patients with a 
Variety of Metabolic Problems. Clinical Science, 
63, 24p.
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CHAPTER THREE : HOW SERUM ALKALINE PHOSPHATASE LEVELS RELATE
TO BONE ALKALINE PHOSPHATASE LEVELS IN 
METABOLIC BONE DISEASE.
The enzyme alkaline phosphatase (AP) has, for many 
years, been of great interest in the study of the mechanisms 
of bone mineralisation and many groups have looked at various 
aspects of its distribution and activity, in attempts to 
understand its association with calcification. The purpose 
of this study is to look at the relationship between serum 
AP levels and AP measurements in bone from patients suffering 
from metabolic bone disease.
Early work on the role of AP in calcification was performed 
by Robison (1923,1932), who looked at AP activity in rachitic 
cartilage. Robison found that the enzyme is detectable in 
the cytoplasm of hypertrophic cells located in areas of 
imminent calcification, leading him to postulate that AP 
is responsible for the localised increase in phosphate 
esters at these sites, which eventually react within calcium 
to precipitate as calcium phosphate. Bevelander, et al.
(1950) and Morse, et al. (1951) followed the same line of 
Histological study and suggested that AP dissipates 
following this localised build-up of phosphate esters and 
before mineralisation occurs, playing no part in mineral­
isation itself. When they studied the mineralisation of 
bone in relation to the underlying collagen fibres, Bachra, 
et al. (1959) also found evidence that AP acts on inorganic
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phosphates as a * local' factor, but suggested that it had 
some role in calcification itself. All of these results 
suggest a specialised build-up of AP for mineralisation, 
although there seems to be some controversy about the part 
played by the enzyme.
In an attempt to understand the changes produced by 
AP and, therefore, the part it plays in the calcification 
process, the relationship between the enzyme and the 
inorganic phosphate, pyrophosphate, was studied. Fleisch, 
et al. (1962) proposed that AP removes a layer of pyro­
phosphate, covering inactive bone surfaces, allowing 
mineralisation to proceed, showing that pyrophosphate in 
normal physiological concentrations stabilises both bone 
formation and resorption (Fleisch, et al. 1966; Nordin, 
et al. 1969; Fast, et al. 1977). These results lead to 
the conclusion that pyrophosphate, in a layer covering 
inactive bone surfaces, is a naturally-occurring regulator of 
bone turnover, preventing unnecessary formation and resorption 
and that, acting locally, AP removes the layer and allows 
bone turnover to proceed (Fleisch, et al. 1970; Russell, 
et al. 1970; Thomas, et al. 1978; Smith, et al. 1979).
This conclusion would seem to support the localised activity 
of AP without any involvement in the mineralisation process 
itself, as suggested by Robison (1923, 1932), Bevelander, 
et al (1950) and Morse, et al. (1951).
The role of AP in relation to pyrophosphate and 
mineralisation is therefore fairly well understood, but
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where does the enzyme originate? Osteoblasts, the bone- 
forming cells are known to be rich in AP (Jackson, 1967;
Smith, 1979) and are the most likely source of the AP 
involved in mineralisation. Khairi, et al. (1973) and 
Franck, et al. (1974) found that they could relate 
increased AP activity with increased osteoblast activity 
and the level of calcification in bone from patients suffering 
from Paget's disease of bone. Burks, et al. (1978) also 
found a visible rise in AP during bone cell proliferation, 
looking at cells in culture. It would seem then that the 
AP involved in the localised calcification of bone arises from 
increased osteoblast activity, as would be expected: increased 
bone formation requiring increased mineralisation under normal 
circumstances. One point to note, however, is that the 
osteoblasts which produce AP are often separated from the 
mineralisation front by a layer of osteoid tissue ; one 
might expect then that the osteoid nearest to the osteoblasts 
would calcify first, but this does not happen: the AP would
seem only to interact with the surface of mineralised bone; 
could this be a measure to prevent unwanted calcification?
The level of AP in human serum has been used as a 
diagnostic index in several metabolic bone diseases, varying 
between different disorders (Rasmussen, et al. 1974;
Smith, 1979). An increase in serum AP is often to be 
found related to osteomalacia and rickets, renal osteo­
dystrophy, Paget's disease of bone and hyperparathyroidism.
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although it may remain normal with each of these disorders, 
as it does with osteoporosis and osteomalacia as a result 
of renal tubule disorders. The level of serum AP is 
always very low in hypophosphatasia, a rare disease where 
there is a congenital lack of AP in most tissues, resulting 
in gross defects in mineralisation and, therefore, providing 
support for the importance of AP in the calcification process.
Although the level of serum AP is used in the diagnosis 
of metabolic bone disease, not all circulating AP originates 
from bone: it derives from gastro-intestinal mucosa, placenta,
bone and liver, with the last two providing the bulk of the 
enzyme (Smith, 1979); the level of liver derived AP in the 
serum remains constant, while the level of bone-derived enzyme 
tends to fluctuate. Pritchard (1952) found AP located in 
'soft' tissue, which does not normally calcify, and in 
mesenchymal cells, which earlier workers found difficult to 
reconcile with the role of AP in mineralisation but, as 
discussed earlier, the lack of mineralisation in these tissues 
may be due to the lack of a calcification front.
The diverse origins of serum AP must, therefore, place some 
doubt as to whether the level of serum AP genuinely reflects 
the level of AP and therefore calcifcation, in bone 
(Rasmussen, et al. 1974). We will see from the study of 
creatine kinase in muscle, that enzyme levels in serum may 
not always reflect enzyme levels in the organ of origin 
itself; in this study, therefore, the levels of alkaline 
phosphatase in various bone samples have been assessed and 
the relationship to serum AP determined.
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Materials and Methods :
1. Transiliac Meunier trephine biopsies were frozen 
immediately after removal from the patient and stored 
deep-frozen until required. Shortly before the assay 
was due to be performed, the bone was cut on a 
Cryostat, a microtome in a -20°C refrigerated cabinet, 
to slices of 12 yra thickness. These sections were 
stored deep-frozen until required.
2. To prepare bone homogenates, O.Olg of bone flakes were 
added to 1.0 ml of distilled water and homogenised at 
setting 5 on a TRI-R homogeniser (Model 563C. TRI-R 
Instruments, Rockville Centre, New York, USA) for 5 
minutes, on ice. The homogenates were then left, on 
ice, to settle and the supernatant was assayed for 
total alkaline phosphatase.
3. Alkaline phosphatase assay was by means of a Boehringer- 
Mannheim Diagnostic Kit for total alkaline phosphatase, 
substituting 100 pi of bone homogenate for the 100 yl 
of serum required by the assay. Four assays were 
carried out on each sample, producing a measure of 
alkaline phosphatase in U/L.
4. Serum alkaline phosphatase levels were determined in 
the hospital laboratories.
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Results ;
1, TABLE 3A shows several bone disorders and the levels 
of serum AP and bone AP found for each patient 
suffering from each disorder.
BONE DISORDER + PATIENT SERUM AP 
U/L
BONE AP 
U/L
OSTEOPOROSIS H.W. 184 18.6
I .K. 1609 81.4
A.K. 5.8
E.R. 258 25.6
E.O. 200 25.5
C.R. 289 11.5
A.B. 211 6 .0
1° HYPERPARA M.T. 598 158.9
M.D. 322 16.4
HYPOPHOSPHAT. D.R. 15 3.8
OSTEOMALACIA J.S. 327 54.4
E.I, 470 85.0
C.R.E. M.R. 202 24.4
G.R. 110 16.4
M.H. 264 24.8
J.B. 281 26 .0
J.B. 270 7.0
R.K. 15 .0
A.P. “ Alkaline Phosphatase
1° HYPERPARA = Primary Hyperparathyroidism 
HYPOPHOSPHAT. = Hypophosphatasia
C.R.E. = Chronic Renal failure
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FIGURE 3A
Results of serum alkaline phosphatase versus 
bone homogenate alkaline phosphatase, with 
line of regression y = 2.9x + 170. 
Correlation co-efficient 0.893.
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2. Using all of the paired data for serum AP levels
and bone AP levels, the co-efficient of correlation 
(r) between these two parameters was found to be 
0.893, showing a strong correlation between the 
level of AP in the serum and the AP level in bone.
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Discussion :
It is generally assumed that changes in the level of 
serum AP reflect both pathological and physiological changes 
in those organs rich in the enzyme, namely liver and bone 
(Rasmussen, et al. 1974; Smith, 1979). Serum AP levels 
are used in the diagnosis of metabolic bone disease, but 
as the enzyme originates from other organs, apart from bone, 
it cannot accurately be assumed that changes in serum AP 
levels reflect those in bone (Rasmussen, et al. 1974). In 
addition to this, it has b e e n '  found, in the case of 
creatine kinase discussed in the next chapter, that the 
circulating level of an enzyme may not reflect the level 
of enzyme in the organ of origin, the muscle, as in that 
particular case the levels of enzyme in the organ were so 
high that changes were difficult to detect. The purpose 
of this study was to clarify the relationship between serum 
AP levels and bone AP levels, to let us see whether or not 
serum AP accurately reflects metabolic bone disease.
Assays for AP were performed on human bone homogenates, 
using longitudinal slices of Meunier trephine biopsies, 
incorporating both trabecular and cortical bone; a measure 
of the enzyme present in each bone homogenate was obtained 
and compared with the level of AP in the corresponding serum 
This comparison showed a correlation co-efficient of 0.893, 
indicating that even a measure of total serum AP clearly 
reflects the level of enzyme activity in bone and proving
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that a measure of serum AP is a good indicator of the level 
of active calcification in bone. Alkaline phosphatase, it 
would seem, is produced by bone only when required, it is 
not continuously abundant, as is creatine kinase, which 
suggests a specialised role, probably related to calcification
106 .
CHAPTER FOUR. COLLAGEN PROLYL HYDROXYLASE ACTIVITY IN
HUMAN BONE
In the past the biosynthesis of collagen has been
studied with particular reference to the occurrence of a
proline-rich precursor, which is converted by hydroxylation
to collagen; the enzyme involved in this hydroxylation is
collagen prolyl hydroxylase. This enzyme was first
demonstrated in chick embryo microsomal fractions
(Peterkopsky and Udenfriend, 1962), with activity also being
detected in foetal rat skin, adult rat liver and guinea pig
granuloma (Stone and Meister, 1962; Hutton, et al. 1966).
A rapid assay for collagen prolyl hydroxylase activity was
developed by Hutton, et al (1966) based on the measurement
3 3of tritiated water formed when 3,4- H-L-proline { H = tritium}
3
in specially prepared substrate is converted to 3- H-L- 
hydroxyproline. This assay has been found to be suitable 
for crude enzyme preparations, as will be used here.
Proline constitutes 20% of all amino acids in collagen 
and any failure in proline hydroxylation leads to the failure 
to form the triple helix structure which is so characteristic 
of collagen. Steps involved in the hydroxylation of proline 
to hydroxyproline are illustrated in FIGURES 4A, 4B. Various 
groups, particularly Prockop, et al. (1963, 1964), Juva and 
Prockop (1964, 1966) and Meister, et al. (1964) have shown 
that this reaction involves the loss of only one tritium 
atom, the release of this atom and its assessment giving
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FIGURE 4A
The proposed mechanism for the coupled oxygenation 
of hydroxyproline and a-ketoglutanate by collagen 
prolyl hydroxylase.
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FIGURE 4B
The hydroxylation of tritium-labelled proline 
to hydroxyproline, with the liberation of 
tritiated water. This also incorporates the 
inclusion of molecular oxygen as the reaction 
proceeds.
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an accurate measure of enzyme activity, while Fujimoto
and Tamiya (1962), using molecular have demonstrated
that the reaction cannot occur in anaerobic conditions.
Hutton, et al. (1966) have shown that u-ketoglutarate
is an essential co-factor, but its function as a reactant
or as a catalyst in the hydroxylation of proline is not
clear, since 50% of it disappears during the reaction
(Hutton, et al. 1967). Work by Flanagan and Nichols (1962)
had already suggested that intermediates in glycolysis may
play some part in proline hydroxylation. Ascorbic acid and 
2 +iron, in the Fe ionic form, are also essential to the
reaction: ascorbic acid acting as a reducing agent, which
can be replaced by tetrahydropteridine (Peterkofsky and
2 +Udenfriend, 1965), Fe is unique in its role as an electron- 
transferring agent (Hutton, et al. 1967), although it can 
be chelated by a, a'-dipyridyl (Hurych and Chvapil, 1965).
All of these important factors and co-factors reflect the 
complexity of the enzyme reaction involved in the hydroxy­
lation of proline and our understanding is reflected in 
the accuracy of the assay itself.
The incorporation of labelled proline and the formation 
of labelled hydroxyproline are found to be unaffected in 
the presence of unlabelled hydroxyproline. Granuloma 
minces and cell-free supernatants from chick embryo homogenates 
are unable to use free hydroxyproline for incorporation 
into collagen (Hutton, et al. 1966), although Mitamo, et al 
(1959) claimed some success in incorporating hydroxyproline
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directly into collagen. The former, however, is generally 
held to be the case and the presence of labelled hydroxy­
proline indicates collagen synthesis.
Collagen is one of the main structural components of 
bone and as such any changes in bone metabolism, such as 
are found in osteoporosis, osteomalacia, or renal osteo­
dystrophy, for example, may be reflected in changes in 
collagen metabolism. In this study, using a method for 
assay of collagen prolyl hydroxylase activity based on that 
developed by Hutton, et al. (1966), human bone homogenates 
have been examined to assess any changes in collagen 
metabolism with different metabolic bone diseases.
Materials and Method:
1. Bone from Meunier trephine, biopsies of the iliac crest 
was frozen immediately after removal from the patient 
and stored deep-frozen until required. Shortly before 
the assay was due to be performed, bone was cut on a 
Cryostat, a microtome contained in a -20^C refrigerated 
cabinet, to slices 12 pm in thickness. These sections 
were stored deep-frozen until required for homogenisation
2. To prepare the substrate, 14 dozen six-day-old chick 
embryos were decapitated and the bodies placed in 
buffer, with constant gassing with 5% COg in air. 
Hydroxylation of proline depends on molecular oxygen 
and is prevented by imposing anaerobic conditions 
(Hutton, et al. 1967), preventing spontaneous formation
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of hydroxyproline in the substrate. The bodies were washed 
three times, using 200 ml of buffer each time, and once the 
buffer was clear it was decanted-off. The tissue was then 
divided into 5g aliquots and added to 100 ml beakers along 
with 5 ml of buffer and 0.1 ml of 0.1 Molar a, a'-dipyridyl 
in absolute alcohol, to inhibit collagen formation by
O ^
inhibiting Fe (Hurych and Chvapil, 1965). This mixture 
was incubated at 37°C, with constant gassing with 5% CO^ in 
air and constant shaking, for 20 minutes. Following 
incubation & mCi H^O was added to each of the beakers, which 
were then incubated under the same conditions as before for a 
further two hours. This two hour incubation was followed 
by spinning at 15,000 r.p.m. on a Superspeed 50 centrifuge 
for 20 minutes, after which the supernatant was removed and 
discarded. Each pellet formed was extracted with 10 ml 
of 0.5 Molar CHgCOOH overnight, forming extract I, which 
was further centrifuged at 15,000 r.p.m. for another 20 
minutes. The supernatant obtained from this last centrifuga­
tion was placed in a dialysis bag and dialysed against 5 litres 
of chilled distilled water for approximately 3 hours, then 
two changes of 1 litre of 0.01 Molar tris buffer, pH 7.5 .
The pellet produced by this extraction was also dialysed 
with 10 ml of 0.5 Molar CH^ COOH, forming extract 2; extract I 
was further dialysed against tris buffer, with both extracts 
forming the enzyme substrate.
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Buffer for substrate preparation:
0.3 Molar KCl 10 ml
1.2 Molar MgSO^ 7E^0 1 ml
1.22 Molar NaCl 100 ml
1.3 Molar CaCl^ 6HgO 1 ml
0.4 Molar KH^PO^ 1 ml
0.25 Molar NaHCO^ 100 ml
D-glucose to 0.01 Molar
Distilled water up to 1 litre.
Buffer X for preparation of bone homogenates:
0.5 Molar tris buffer, pH7.2 10 ml
lOT^Molar E.D.T.A. 1 ml
0.25 Molar Sucrose up to 90 ml.
—2Before use add 1/10 volume of 10 Molar dithiothreitol.
Bone homogenates were prepared from 0.3 g of frozen 
bone slices, added to 5 ml of Buffer X plus 1/10 volume 
of Dithiothreitol, and homogenised at setting 5 on a 
TRI-R STIR-R homogeniser {Model S63C. TRI-R Instruments, 
Rockville Centre, New York, USA} for 5 minutes. This 
homogenate, kept on ice throughout its preparation, was 
allowed to settle before use.
The reaction mix for each assay tube was made as follows:
0.5 Molar Tris buffer, pH 7.2. 0.1 ml
—2
10 Molar Ferrous Ammonium Sulphate 0.1 ml
(ANALAR GRADE)
50 mMolar Na Ascorbate 0.1 ml
1% Bovine Serum Albumin 0.2 ml
Catalase 0.02 ml
“210 Molar a-ketoglutaric acid 0.1 ml
10 ^Molar Dithiothreitol 0.01 ml
Distilled water ■ 0.07 ml.
The total volume of this reaction mix is 0.7 ml and the 
amount required is obtained by multiplying all constituents 
by the number of samples used in the assay.
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7. The contents of each reaction tube are as follows;
Reaction mix 0.7 ml
Substrate 0.05 ml
Homogenate as specified.
Distilled water making homogenate up to 300 pi, with 
300 pi of distilled water, only, forming the 
experimental blank.
8. All reaction tubes were sealed and incubated at 30^C 
for 30 minutes, after which the reaction was stopped 
by the addition of 0.1 ml of 50% Tricarboxylic Acid, 
to precipitate the protein.
9. The tritium-labelled water produced by the reaction was 
was obtained by standard distillation methods.
10. Assessment of the tritium-content of the water was 
by means of adding 0.8 ml of the distilled water to 
10 ml of Aqua Luma scintillation cocktail and counting 
on a 3-scintillation counter. By subtracting the 
counts per minute (C.P.M) produced by the experimental 
blank from that produced in each experimental tube 
containing bone homogenate, a measure of the collagen 
Prolyl hydroxylase activity in each sample was obtained
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Results :
A (i) Results obtained when homogenates of bone from patients 
suffering from osteoporosis were assayed for collagen 
prolyl hydroxylase activity. In each case the volume 
of bone homogenate assayed is given and the C.P.M./ml 
produced,
TABLE 4A (i)
PATIENT VOL. OF BONE HOMOGENATE 
IN ASSAY (pi)
C.P.M./ml
A.K. 300 620
150 1360
E.R. 300 1023
150 2753
J.M. 300 863
150 1513
100 1986
50 10820
E.D. 300 896
150 2440
100 2550
50 6920
T.W. 300 763
100 710
50 1580
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A (il) Mean values and standard deviations, for the
levels of collagen prolyl hydroxylase activity 
produced by homogenates of bone from patients 
with osteoporosis, and the volume of homogenate 
present in each assay.
TABLE 4A (ii)
VOL. OF BONE HOMOGENATE
IN ASSAY x + S (C.P.M)
( Pl)
300 833 + 151
150 2016 + 6 85
100 1748 + 943
50 6440 H- 4639
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B (i). Results obtained when homogenates of bone from 
patients suffering from renal osteodystrophy 
were assayed for collagen prolyl hydroxylase 
activity. In each case the volume of bone 
homogenate assayed is given and the C.P.M./ml 
produced.
TABLE 4B (i)
PATIENT VOL. OF BONE HOMOGENATE 
. IN ASSAY (pi)
C.P.M/ml
M.H. 300 1836
150 2666
100 6710
50 6620
M.R. 300 3393
150 1246
100 3610
50 -
G.R. 300 1120
150 3327
100 5240
50 8360
J.B. 300 210
150 366
100 420
50 1900
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B (ii) Mean values and standard deviations, for the level 
of collagen prolyl hydroxylase activity produced 
by homogenates of bone from patients with renal 
osteodystrophy, and the volume of homogenate present 
in each assay.
TABLE 4B (ii)
VOL. OF BONE HOMOGENATE
IN ASSAY 
........(yi)
x + S (C.P.M)
300 1640 + 1345
150 1901 + 1342
100 3995 + 2699
50 5627 + 3343
C. Results obtained when homogenates of bone from a 
patient suffering from osteomalacia were assayed 
for collagen prolyl hydroxylase activity. In each 
case the volume of bone homogenate assayed is given 
and the C.P.M./ml produced.
TABLE 4C
PATIENT VOL OF BONE HOMOGENATE 
IN ASSAY 
(yi)
C.P.M./ml
J.S. 300 1200
150 1633
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D. Results obtained when homogenates of bone from a
patient suffering from primary hyperparathyroidism were 
assayed for collagen prolyl hydroxylase activity. In 
each case the volume of bone homogenate assayed is 
given and the C.P.M,/ml produced.
TABLE 4D
PATIENT VOL. OF BONE HOMOGENATE
IN ASSAY C.P.M./ml
. (yi)
M.D. 300 413
150 626
100 1380
50 2800
E. Results obtained when the C.P.M./ml for all patients 
suffering from metabolic bone disease studied were 
averaged; the volume of bone homogenate in each case 
is also given.
TABLE 4E
VOL. OF BONE HOMOGENATE
IN ASSAY X + S (C.P.M)
(yi)
300 1121 + 867
150 1793 + 969
100 2826 + 2225
50 5371 + 3543
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FIGURE 4C
Results illustrating the level of collagen 
prolyl hydroxylase activity, in C.P.M./ml, 
found with each bone disorder, using 
different volumes of bone homogenate. The 
level of activity would seem to increase 
with increasing dilution of homogenate.
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Discussion :
In this study of the enzyme collagen prolyl hydroxylase 
it was hoped that the level of activity of the enzyme could 
be assessed in homogenates of bone from patients suffering 
from metabolic bone disease. However, due to circumstances 
beyond the control of the author, it was not possible to 
continue using this assay beyond initial exploratory 
experiments. Those results which were obtained serve only 
to show that collagen prolyl hydroxylase activity can be 
detected in human bone homogenates, but it was not possible 
to proceed with enzyme kinetic studies to find the maximum 
activity ( foi" the enzyme for different patients. The 
one interesting point to note is that, from those results 
obtained here, the - activity of the enzyme seems to 
increase as the bone homogenate becomes more dilute. Hutton, 
et al. (1966) found, using pure enzyme preparations, that 
the activity produced, in C.P.M. increased as the amount 
of enzyme increased; it could be that there is some kind 
of non-competitive inhibitor of the enzyme present in the 
bone homogenate which is gradually diluted as the homogenate 
becomes more dilute, but no conclusions can be made without 
further experiment.
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CHAPTER FIVE. CREATINE KINASE IN MUSCLE FROM PATIENTS 
SUFFERING FROM METABOLIC BONE DISEASE
All forms of human muscle; smooth muscle, cardiac 
muscle and striated muscle, contain abundant stores of the 
high-energy phosphate compound creatine phosphate 
(Conn and Stumpf, 1967; Yudkin and Offord,1971; Wood, 
1975). This compound plays an important role in muscle 
contraction, during which it is degraded to creatine and 
inorganic phosphate, providing energy for the formation 
of another high-energy compound; adenosine triphosphate 
(ATP). The enzyme which catalyses the breakdown of 
creatine phosphate to form ATP is creatine kinase.
Creatine kinase is found in decreasing order of 
activity in the following human organs; skeletal muscle, 
cardiac muscle, cerebral cortex, smooth muscle, thyroid 
gland, kidney and liver (Forster, et al. 1974). It is 
plentiful in tissues which require a lot of energy for 
their efficient functioning. Normal human serum has no, 
or very little, creatine kinase activity (Wilson, 1965), 
however the serum level can rise with such conditions as 
hypothyroidism, severe physical exercise, muscular trauma, 
epileptic fits and primary hyperparathyroidism. Forster 
(1967) found that a rise in serum creatine kinase also 
occurred with progressive muscular dystrophy and coma, 
where muscle is inactive and muscle wealcness is a 
prominent feature.
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As it was seen that tissue creatine kinase levels 
are low in tissues which require less energy and serum 
creatine kinase levels rise under similar conditions, 
creatine kinase, levels in tissue from metabolic bone 
diseases were studied. Many metabolic bone diseases 
cause such pain and disfigurement that movement becomes 
difficult and patients become less active or even totally 
immobile.
As Goto (1974) has indicated that creatine kinase 
increases in serum originate from skeletal muscle, it 
was decided to compare levels of creatine kinase in muscle 
homogenates, prepared according to Oliver (1955), of 
skeletal muscle of patients suffering from metabolic bone 
disease. As well as studying muscle creatine kinase 
levels in relation to metabolic bone disease, sex-differences 
were also studied. Wiesmann, et al. (1966) have previously 
shown that a higher serum creatine kinase level can be 
found in male serum than in female serum. Further studies, 
by Smith, et al. (1979) and Thomson and Smith (1980), have 
shown that pregnancy is accompanied by an increase in 
female serum creatine kinase levels, suggesting a strong 
link, possibly inhibition of creatine kinase, by oestrogen, 
which falls during pregnancy. Variations of muscle 
creatine kinase levels with age were also studied.
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Materials and Methods:
1. Some striated muscle fragments from the vastus 
lateralis were found attached to through and through 
Meunier trephine biopsies of the anterior iliac crest. 
These fragments were frozen immediately after removal 
from the patient. Shortly before each assay was to 
be performed, the frozen muscle was homogenised in
6 volumes of 0.1 molar potassium chloride solution 
(KCl) at 6000 r.p.m. on a TRI-R STIR-R homogeniser 
(Model S63C. TRI-R Instruments, Rockville Centre,
New York) for 5 minutes on ice.
2. Lowry protein estimations were made by means of the 
standard method laid down by Lowry, et al. (1951).
A standard graph was prepared using varying 
concentrations of bovine serum albumin (BSA)
(FIGURE 5A), from which the protein concentration of 
the muscle homogenates could be assessed. For every 
muscle sample studied, the following dilutions of 
muscle homogenate in distilled water were prepared.
3
25 X 10 p.p.m. in 1 ml.
3
50 X 10 p.p.m. in 1 ml.
3
100 X 10 p.p.m. in 1 ml.
200 X 10^ p.p.m. in 1 ml.
1 ml. of distilled water. (p.p.m = parts per million) 
In the final analysis, only one concentration of muscle
3
homogenate was used, that of 25 x 10 p.p.m.
3. Creatine kinase estimation. The following dilutions of 
muscle homogenate were prepared from each muscle biopsy, 
using distilled water:
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FIGURE 5A
Standard curve of protein concentration versus 
optical density, used in the calculation of 
protein concentration following the Lowry test.
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2.5 X 10 p.p.m. in 1 ml,
3
5.0 X 10 p.p.m. in 1 ml.
10.0 X 10^ p.p.m. in 1 ml.
3
20.0 X 10 p.p.m. in 1 ml.
1 ml of distilled water.
Smaller concentrations of muscle homogenate were 
used in the creatine kinase analysis, as initial studies 
showed concentrations similar to those used in the Lowry 
protein estimation were too high to allow the level of 
creatine kinase to be calculated accurately.
The reaction mechanism for creatine kinase analysis 
is outlined in FIGURE 5B. The method for assay is 
based on that developed by Oliver (1955) and ultimately
results in the measurement of NADPH, another high-energy
molecule, but is performed using a Spinchem kit on an 
LKB autoanalyser. The Spinchem kit uses N-acetyl cysteine 
(NAG) as an activator, a modification of Oliver's method, 
which used glutathione as an activator. This method 
was developed for measuring serum creatine kinase, but 
has been found to be successful in measuring creatine 
kinase levels in muscle homogenates.
Each creatine kinase result was determined empirically 
and did not involve the calculation of a standard curve. 
All appropriate quality control methods were used. Only 
one concentration of muscle homogenate was used in the
3
final analysis, that of 2.5 x 10 p.p.m.
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FIGURE 5B
The mechanism involved in the assay of creatine kinase
(a) To enable this reaction to be measured on the 
LJCB 8600 auto-analyser, it is linked to two 
further reactions. The ATP formed in this 
reaction reacts with glucose.
(b) ATP formed in the previous reaction used in 
the conversion of glucose to glucose-6- 
phosphate by hexokinase.
(c) The glucose formed in the previous reaction 
acts as a substrate for glucose-6-dehydrogenase.
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Results:
1. As a result of the Lowry protein estimations it was 
possible to obtain a measure of the protein present 
in each muscle homogenate in yg protein per ml of 
homogenate. From the creatine kinase assays, a 
result in ng creatine kinase per litre of homogenate 
was obtained. From these two results a measure of 
the amount of creatine kinase, in ng. per mg of 
protein was calculated and all results are shown 
in TABLE 5A.
FT.B. C.K = Creatine kinase.
1° HYPERPARA. = Primary hyperparathyroidism
R.O. = Renal osteodystrophy.
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TABLE 5A
PATIENT, DISORDER, 
AGE AND SEX
|jg PROTE IN/ml ng CK/L ng CK/mg 
(x 105) (x 104) p r o t e i n
OSTEOPOROSIS M. J. E) 62) 2.6 7.9 0. 3
M.M. F) 53) 1.5 7.8 0. 52
T.W. M) 51) 1.9 13.4 0. 68
E.M. F) 58) 2.3 5.8 0. 25
E.R. F) 1.9 6.5 0. 34
E.D. F) 64) 3.7 3.4 0. 34
I.E. F) 1.0 6.0 0. 16
C.B. F) 58) 1.9 1.2 0. 06
A.B. F) 59) 1.5 2.6 0 17
M.B. F) 66) 2.9 3.7 0. 13
A . M. F) 50) 4.0 3.6 0. 09
E.L. F) 53) 0.8 5.7 0 08
J.M. M) 52) 0.9 3.0 0 35
J.M. F) 74) 1.1 6.8 0 62
L.M. F) 1.6 12.9 0 81
M.H. F) 81) 5.9 35.6 0 61
1° HYPERPARA M.D. F) 66) 3.0 13.7 0 .47
J.R. F) 72) 1.2 3.6 0 .3
J.C. F) 65) 0.2 0.5 0 .25
A.A. F) 55) 1.5 29.4 0 .2
M. J. F) 69) 0.9 3.3 0 .36
OSTEOMALACIA I.K. F) 48) 1.4 5.2 0 .37
J.D. F) 30) 2.1 0.8 0 .04
M.G. F) 19) 2.1 13.1 0 .62
J.B. M) 54) 2.0 17.5 0 .85
R.O. E.M. F) 2.0 8.8 0 .44
J.B. M) 64) 2.7 11.8 0 .44
B.M. M) 1.4 5.7 0 .41
R.K. M) 2.5 2.8 0 .11
G.R. M) 53) 3.5 29.9 0 .86
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2, Students t-tests comparing the muscle levels of 
ngCK/mg Protein in each disorder.
TABLE 5B.
DISORDERS COMPARED P
OSTEOPOROSIS
OSTEOPOROSIS
0.34+0.24
0.34+0.24
1° HYPERPARA­
THYROIDISM 
OSTEOMALACIA
0.32+0.1
0.47+0.35
NSD
NSD
OSTEOPOROSIS 0.34+0.24 C.R.F. 0.45+0.27 NSD
1° HYPERPARA­
THYROIDISM 0.32+0.1 OSTEOMALACIA 0.47+0.35 NSD
1° HYPERPARA­
THYROIDISM
0.32+0.1 C.R.F. 0.45+0.27 NSD
OSTEOMALACIA 0.47+0.35 C.R.F. 0.45+0.27 NSD
Results here show no significant difference in the levels 
of ng creatine kinase/mg protein in muscle for each of 
the different metabolic bone diseases studied.
3. Comparison of levels of ng creatine kinase/mg protein 
in muscle from males and females.
The level of creatine kinase in striated muscle from 
male patients showed an average of 0.5 + 0.275 ng 
creatine kinase/mg protein, while in female patients 
the level was 0.33 + 0.21 ng creatine kinase/mg protein 
FIGURE 5C shows the results grouped according to sex 
and the means are significantly different at p <0.05.
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FIGURE 5C
Results in ng creatine kinase per mg of 
muscle protein for each male and female 
patient studied.
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4. Correlation between the level ‘of creatine kinase
per mg of protein and the age of the patient studied.
For females, the correlation co-efficient (r) 
between levels of creatine kinase in striated muscle 
homogenates and age is 0.81, which is significant in 
the range -1 to +1 for all correlation co-efficients.
For males, the correlation co-efficient (r) 
between the levels of creatine kinase in striated 
muscle homogenates and age is 0.7, which is also 
significant in the range -1 to +1 for all correlation 
co-efficients.
126.
Discussion :
Most of the creatine kinase in striated muscle is 
contained within the cell cytoplasm, with some in the 
mitochondria, therefore complete homogenisation of 
muscle is necessary to obtain a measure of the total 
creatine kinase present. The whole horaogenate was 
used in this study, rather than the supernatant, but Oliver 
(1955) showed that either can be used to produce accurate 
results. Methodology is important in the determination 
of creatine kinase. Potassium chloride solution has 
been shown to be effective (Oliver, 1955) in retarding 
any inactivation of the enzyme through the action of an 
inhibitor, as demonstrated by Von Rotthauwe (1967).
Students t-tests performed between the four groups 
of patients in this study, each group suffering from a 
different metabolic bone disease, showed no significant 
difference in the levels of creatine kinase in homogenates 
of their striated muscle (TABLE 5B). Previous studies, 
looking at serum creatine kinase levels in different 
disorders, showed that they became raised with hypothyroidism, 
primary hyperparathyroidism (Wilson, 1965) and muscular 
dystrophy (Forster, 1967; Smith, 1979). However changes 
in creatine kinase levels are easier to detect in human 
serum, where there is normally little present (Wilson,
1965), than in human striated muscle, which is abundant 
in the enzyme. A large change in serum creatine kinase
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would result from only a very small change in the level 
in the muscle, meaning that a result of no significant 
difference between levels of creatine kinase in muscle 
from any disorder would be expected.
However, comparisons made between the levels of 
creatine kinase in male and female patients showed that 
males have a higher striated muscle creatine kinase 
level than female; the difference is significant at 
p <0.05. Wiesmann, et al. (1966) showed that adult males 
have a higher serum creatine kinase level than adult 
females, with Smith, et al. (1979) and Thomson and Smith 
(1980) finding that low levels of serum creatine kinase 
are linked with high levels of blood oestrogen. The 
comparison of creatine kinase levels in male and female 
muscle would seem to support these results and show that 
lower levels of serum creatine kinase in females reflects
lower levels in the muscle itself.
Looking at any possible correlation between the
level of muscle creatine kinase and age, it was found that
a strong relationship existed with both males and females. 
The level of muscle creatine kinase would seem to increase 
with age, as one might expect through increased inactivity, 
as found with coma and muscular dystrophy (Forster, 1967). 
For female patients the correlation between age and muscle 
creatine kinase levels is stronger than that for males, 
which may reflect the dependence of serum creatine kinase 
levels on oestrogen levels, as oestrogen decreases with
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age and becomes greatly reduced at the menopause and 
thereafter.
From this study of creatine kinase in striated 
muscle homogenates, we can see that the levels in muscle 
from males and females reflect those already found in 
their serum, while no relationship can be found between 
muscle creatine kinase levels and different metabolic 
bone diseases.
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CHAPTER SIX. BONE CELL CULTURE .
The various types of cells which can be found in bone 
have already been described in the introductory chapter, 
showing us the different role each plays in the formation 
and maintenance of normal bone. As with mouse calvaria 
providing a model system for looking at the effects of 
substances on bone as a whole, isolated bone cells in 
culture also provide the opportunity to test the effects of 
such substances on the different cells themselves. In 
1964 Peck, et al. developed a method by which collagenase, 
an enzyme capable of degrading bone matrix, was used to 
isolate bone cells and that method has been used in many 
studies (Yu, et al. 1976; McPartlin et al. 1976; Peck, 
et al. 1976; East, et al. 1977; Felix, et al. 1978), 
although others have preferred to use the proteolytic 
enzyme trypsin (Binderman, et al. 1974; Harell, et al, 
1976), making it fairly easy to isolate bone cells to 
study the many aspects of bone metabolism.
To show, initially, that the cells in culture are bone 
cells, various studies concerning calcification, matrix 
formation and the appearance of bone-related enzymes have 
been pursued. Collagen synthesis by osteoblast-like 
cells in culture has been demonstrated by Binderman, et al. 
(1974) and Scott, et al. (1980), while the formation of 
other bone matrix components has been noted by Martin, et al 
(1971), among others. The most important sign of bone
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formation is, of course, mineralisation and work by Rose, 
et al. (1964), Binderman, et al. (1974) Harell, et al.
(1976) and Williams, et al. (1980) has shown that 
osteoblast-like•cells, isolated in tissue culture, are 
very capable of forming bone.
The effects of various hormones and metabolites on 
bone metabolism have been studied looking at these isolated 
cells in culture (Peck, et al. 1964; Rosenbusch, et al. 
1967; Park, et al. 1967; Binderman, et al. 1972; Peck, 
et al. 1973; Peck, et al. 1974; Peck, et al. 1976;
Yu, et al. 1976; Miller, et al. 1976; Wong, et al. 1977; 
Luben, et al. 1977; Harell, et al. 1977; Fast, 1977;
Burns, et al. 1978; Goldring, 1978; Smith, 1979; Wong, 
1980), showing that bone cells in culture, like bone itself, 
respond to calcitonin, parathyroid hormone, vitamin D 
metabolites, oestrogen and prostaglandins, among others.
Some interesting work by Howard, et al. (1981) has also 
suggested that osteoclasts in culture are capable of 
producing l,25(0H)^Dg and 24,25(0H)2Dg, in much the same 
way, they suspect, as osteoclasts of patients with chronic 
renal failure synthesise these metabolites.
In this particular study it is hoped that, by using 
bone cells isolated from mouse calvaria and human bone 
biopsies, using the method of Peck, et al. (1964), the 
effects of various bone-related substances, such as 
oestrogen, P T H , CT and fluoride, as well as human serum 
from patients with metabolic bone disease, on alkaline
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phosphatase and Ca^ ^ levels in the culture medium and 
alkaline phosphatase within the cells themselves may be 
studied. In addition to this biochemical study it is 
also hoped to study any bone formation which may take 
place under the influence of these substances.
Materials and Methods:
2
1. Sterile 25cm tissue culture flasks (Falcon Plastics, 
Becton, Dickinson and Co. Cockeysville, M.D. USA) 
were prepared by coating the culture surface with a 
thin layer of sterile 0.1% gelatin solution. These 
flasks were then stored at 4°C.
2. Culture medium was prepared by the same means as 
described in previous chapters, using either Medium 199 
or BGJb Original medium, with 15% foetal calf serum
or 15% human serum, as specified.
3. Mouse cell cultures were prepared using calvaria 
removed from mice aged 5-21 days and human bone biopsies 
of the iliac crest provided the material for human
cell culture. All bones used were washed carefully 
in Medium 199 solution immediately after removal to 
clean off any blood, then placed in sterile enzyme 
solution.
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4. Enzyme solution was made according to Peck, et al.
(1964), with collagenase as the main active component.
For 10 calvaria or one iliac crest Meunier trephine 
biopsy :
4.0 ml Tris-bufiered saline (pH 7.4)
Glucose to 5 ymoles/ml
Penicillin-Streptomycin solution to 50 units/ml 
(Gibco Bio-Cult Ltd., Paisley)
Crude collagenase to 0.1-6.0 mg/ml (Sigma).
5. The enzyme solution plus bone was then shaken 90 times
per minute for 1.5 hours at 37°C on a rotary shaker
(Luckham Ltd., Sussex), by which time there was virtual
disappearance of calvaria and disintegration of the 
biopsies, forming a suspension.
6. The resultant cell suspension was then spun at 3000 
r.p.m. for 5 minutes on a bench centrifuge, forming 
a pellet.
7. 1 ml of the supernatant formed was added to flasks 
each containing 9 ml of fresh culture medium.
8. In Order to release more free cells from the pelleted 
digest, the pellet was resuspended in 5 ml of fresh 
culture medium and spun at 5000 r.p.m. for 5 minutes 
on a bench centrifuge. The supernatant was removed 
and the pellet resuspended; the supernatant was
made into 1 ml aliquots and placed in culture as before
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9. The cell pellet was suspended and washed in fresh
culture medium a total of three times, the final 
suspension being divided into 0.2 ml aliquots and 
added to prepared tissue culture flasks, each 
containing 9.8 ml of fresh culture medium.
10. All flasks were then gassed with 5% COg in air and 
incubated at 37^C on a rotating tray (Luckham Ltd.,
Sussex), rotating 5 times per minute.
11. Cultures were observed at intervals under a Leitz- 
Diavert inverted objective phase contrast microscope.
12. Culture medium was changed at intervals of about one
week, removing old medium by means of a sterile pipette
and replacing with fresh medium. Old medium was
2 +assayed for alkaline phosphatase and Ca
13. Staining cells:
To fix cells for staining within the tissue culture 
flasks themselves, culture medium was removed and replaced 
by 80% alcohol. To fix cells for staining on histological 
slides, the cells were removed from the tissue culture 
flasks by trypsinisation and placed in specially- 
prepared petri dishes; these petri dishes contained 
gelatinised sterile coverslips and culture medium, 
incubation of the cells in these dishes would allow 
the cells to attach to the coverslips, which were 
then attached to histological slides, after fixation 
in the dishes with 80% alcohol. After fixation, all 
cells were dehydrated in two changes of absolute 
alcohol, two hours each, and cleared in toluene for 
12-18 hours.
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A. Cells were stained for alkaline phosphatase activity 
using Goracri’s cobalt method, sites of activity
were indicated by black cobalt deposits.
B. Standard haemalum and eosin staining was used to 
show cell nuclei and cytoplasm, which stained blue 
and pink, respectively.
C. Giemsa stain was used to show erythrocytes, 
eosinophilic granules, basophilic granules, 
neutrophilic granules cytoplasm and thrombocytes, 
pale red, brown, blue, violet, blue and blue, 
respectively.
14. Trypsinisation:
A sterile trypsin solution was made and stored at
4^0 :
Trypsin 0.025%
EDTA Nag 1 mM
Chick serum 1% ^/u.
in PBS (Ca^^ and Mg^* free)
.To remove all attached cells, remove culture medium 
and replace with 5 ml of phosphate-buffered saline (PBS) 
wash over the cells and remove. Add 0.3 ml of trypsin 
solution to the flask and wash over the adherent cells, 
shaking the flask as you do so, removing any attached 
cells; this proceeds more quickly at 37^C and should 
be observed under a microscope, in this case a Leitz- 
Diavert inverted objective phase contrast microscope.
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When all cells are detached, add 10 ml of culture 
medium and resuspend.
15. Alkaline phosphatase assays on culture medium were 
performed using Boehringer-Mannheim diagnostic kits 
for total alkaline phosphatase.
16. Ca^ *** was measured using a Nova 2 ionised calcium
analyser (American Hospital Supplies Ltd.).
Results :
In initial mouse cell cultures, it was noted that 
after only six days the cells became strongly adherent to 
the tissue culture flasks, assuming elipsoid form, with large 
round nuclei. Changing culture medium produced no change 
in the condition of the cells, remaining adherent throughout; 
throughout the culture period the medium removed was assayed 
for alkaline phosphatase and Ca^^ (FIGURE 6A). After nine 
weeks of culture, two of the original flasks now contained a 
confluent monolayer of cells, originating from about 15 cells
which had been seeded to the flasks; the density of cells in
the flasks was similar to that in FIGURE 6 B , similar to those
described by Burks, et al. 1978).
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FIGURE 6A
2 4"Results of alkaline phosphatase and Ca 
assays performed on the culture medium 
supporting cells in culture.
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Embryonic rat cells grown to confluence in vitro. 
(From Science, 199 (4328), 542-544, Burks J K, 
Peck W A. Permission has been given to use 
photograph.
FIGURE 6C
Embryonic rat calvaria cells grown in culture 
and stained for alkaline phosphatase activity, 
using Gomori's cobalt method. Sites of 
alkaline phosphatase activity are indicated by 
black cobalt deposits. (From Science, 199 
(4328), 542-4. Burks J K, Peck W A). Permission 
has been given to use photograph.
Footnote: It was not possible to use the author’s own
photographs of alkaline phosphatase activity 
in neonatal mouse cells in culture as the 
negatives were lost, beyond the author's control
50 um
Sub-culturing, or passaging, was attempted on the 
confluent cell monolayers after the cells had been in 
culture for 11 weeks, using trypsinisation. It was 
found that cells successfully detached and entered suspension 
with fresh culture medium; new cell cultures were prepared 
by aliquoting this cell suspension into prepared tissue 
culture flasks, as before.
After 12 weeks in culture all cell cultures were fixed 
and stained for alkaline phosphatase, showing that some, 
but not all, cells in culture contained traces of the 
enzyme (FIGURE 6C). Results of alkaline phosphatase and 
Ca^ **' assays performed on the culture medium supporting 
the cells are shown in FIGURE 6A, along with results for 
control culture medium which was incubated without cells. 
These results suggest that the cells in culture took up 
Ca^ *** from the medium, as the level in medium incubated with 
cells lower than in that incubated without cells; alkaline 
phosphatase levels suggest no patterns, only a lot of 
fluctuation.
Further attempts at mouse cell culture were successful 
in as much as cells were obtained, which replicated very 
slowly, but they tended to die before confluence was 
obtained. These cells were stained for alkaline phosphatase 
activity, using Gomori's cobalt method, and it was generally 
found that about 30% of the cells exhibited alkaline 
phosphatase activity in their cytoplasm, perhaps indicating 
the presence of osteoblasts.
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Initial attempts at preparing bone cell cultures from 
samples of human bone proved to be quite interesting.
Bone obtained through the course of operations in the 
hospital's orthopaedic theatre was treated in the same way 
as mouse calvaria: placed in collagenase solution,
incubated and shalien (Peck, et al. 1964), resulting in 
tissue culture flasks containing many spherical bodies 
of uniform site, 80% of which adhered within 48 hours. 
Fixation and staining of these bodies with haemalum and 
eosin showed that they were spheres of cytoplasm with no 
apparent nuclei. Further attempts at human bone cell 
culture produced similar results, but with, occasionally, 
adherent elongate cells with nuclei, which proved to 
stain positive for alkaline phosphatase.
A few subsequent cultures of human cells terminated
by day 2, with all cells dying, prompting me to change the
medium after day 1 to remove any possible lingering effects 
of enzyme solution. At the same time, the effects of 
shaking the bone in the enzyme solution for 0.5 hours, 
as opposed to 1.5 hours, were compared and showed that 
fewer cells were obtained on the shorter exposure to 
collagenase and that longer incubation with the enzyme 
solution does not affect the numbers or viability of the 
cells.
It became increasingly apparent that the spherical
bodies of cytoplasm isolated in culture were probably
erythrocytes. Previously there had been some doubt as to 
the nature of the bodies as they seemed to increase in
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number while in culture, not a feature of erythrocytes; 
it is now thought that the other, elongate, cells were 
responsible for the increase in numbers and caused confusion 
by becoming detached and rounded during cell division. 
Attempts were made to stain the spherical bodies for the 
characteristic erythrocyte colour produced with Giemsa 
stain, but this proved ineffective as this stain was 
developed for blood smears and not erythrocytes alone.
As an alternative the cells were suspended in culture 
medium and spun down on a centrifuge, producing a red 
pellet, indicative of erythrocytes.
Subsequent attempts at human bone cell culture involved 
repeated washing and re-spinning of the cell suspension to 
remove any erythrocytes, but few cells were isolated.
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Discussion :
As a result of the inability to isolate and culture 
large numbers of bone cells, studies of bone cell by­
products in culture medium were not possible ; the 
results in FIGURE 6A represent assays performed on 
culture medium supporting relatively few cells, only 
reaching confluence after 9 weeks, of mixed character.
Had the cell cultures produced greater cell numbers it 
may have been possible to separate all cell types: 
osteoblasts, osteoclasts and osteocytes, for study of 
their individual biochemical characteristics.
Human bone cell cultures also produced too few bone 
cells, but an abundance of erythrocytes. Erythrocytes 
in culture did not pose a problem as far as mouse cell 
cultures were concerned, as the blood supply to the wafer- 
thin calvaria was minimal, compared to the rich blood 
supply to human trabecular bone, but proved to be a regular 
hazard in the preparation of human cell cultures. Another 
problem in trying to isolate bone cells from human bone is 
related to the density of the bone: most bone supplied
from the orthopaedic theatre was in the form of chips of 
cortical bone, too dense to allow easy access to any 
collagenase solution, making the isolation of cells through 
the breakdown of bone very difficult. It should be 
realised that there is a thin line between the concentration 
of an enzyme solution which will digest bone matrix and 
an enzyme solution which will also digest bone cells, this
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happy medium was not, unfortunately, found in this study and 
culture of bone cells was unsuccessful.
If it had been possible to successfully culture large 
amounts of human bone cells, it was hoped that bone may have 
formed in 3-dimensional culture, using Cytodex tissue 
culture beads. These beads would have provided an array 
similar to that found within bone itself, where cells are 
separated by matrix and sit within small cavities or lacunae, 
or on the outside layers of the 'trabecular' bone, involved 
in bone turnover. This, however, was not possible, but it 
would have allowed us to see how various substances related 
to bone metabolism, as well as serum from patients with 
various metabolic bone diseases, have their effects on bone.
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CHAPTER SEVlilN. A STUDY OF THE EFFECTS OF ALUMINIUM ON
ALKALINE PHOSPHATASE AND IONISED CALCIUM 
LEVELS IN CULTURE MEDIUM SUPPORTING 
•NEONATAL MOUSE CALVARIA
Studies by several other groups have suggested that
aluminium may play some role in influencing calcium and
phosphorus metabolism. Initial and more recent studies
(Fauley, et al. 1941; Freeman, et al. 1941; Kirsner,
et al. 1943; Lotz, et al. 1968; Spencer, et al. 1978)
have noted that excessive or prolonged use of aluminium-
containing antacids in the management of peptic ulcers
resulted in the formation of insoluble phosphate complexes
within the intestine, resulting in inhibition of phosphate
absorption within the gut, decreased urinary phosphate
and increased urinary calcium. Spencer, et al. (1978)
showed that, while the administration of aluminium-containing
antacids increased urinary and faecal calcium, intestinal
4 7absorption of calcium, as determined by an oral Ca method, 
remained unchanged. This, along with results from Baylink, 
et al. (1971), suggested that calcium loss during the phosphate 
depletion would be through increased bone resorption.
More recently, attention has again been focused on 
aluminium, but with particular reference to the high levels 
found in the brain and bone of patients on regular haemo- 
dialysis therapy for chronic renal failure. These high 
aluminium concentrations may be associated with dialysis 
dementia, a mental disorder and dialysis osteomalacia
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(Bloom, et al. 1960; Berlyne, et al. 1970; Stanbury, 1972; 
Platts, et al. 1973; Alfrey, et al. 1976; Malluche, et al. 
1976; Flendrig, et al. 1976; Platts, et al, 1977; Elliot, 
et al. 1978; McDermott, et al. 1978; Rozas, et al. 1978; 
Dunea, et al. 1978; Ellis, et al. 1979; Parkinson, et al. 
1979; Wing, et al. 1980; Shore, et al. 1980; Boyce, et 
al. 1981; Prior, et al. 1982). The source of the 
increased aluminium levels found in these patients is thought 
to be the dialysate water used in artificial kidney machines, 
with the incidence of osteomalacia and dialysis dementia 
increasing in those areas where the local water has a higher 
than average aluminium content (Platts, et al. 1977;
Drueke, 1980; Boyce, et al. 1981); oral phosphate-binding 
gels have also been implicated (Alfrey, et al. 1978;
Boyce, et al. 1981).
Ellis, et al. (1979) studied the relationship between 
aluminium and osteomalacia. Takirg samples of bone from 
the iliac crests of patients suffering from chronic renal 
failure, they studied their aluminium content and compared 
them with levels found in equivalent bone samples from 
normal patients. Results showed that while on regular 
dialysis.the aluminium content of the bone had significantly 
increased. In a further animal study, they administered 
intraperitoneal injections of aluminium chloride to rats 
for periods of up to 3 months, finding that osteomalacia 
developed with increasing concentrations of aluminium, 
disappearing eventually after treatment had ceased, which
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reflected results found in the patient studies. Le Fevre, 
et al (1980) also found evidence that aluminium became 
incorporated into the bone.
Boyce, et al. (1981) found that once the concentration 
of aluminium within bone rises above a certain level it 
inhibits mineralisation, but not bone matrix formation, i.e. 
osteomalacia develops where calcification is inhibited. It 
is thought likely that aluminium acts by inhibiting one or 
more of the enzymes concerned with mineralisation, probably 
involving alkaline phosphatase. This latest work has 
formed the basis for this study. Already within this thesis 
attempts have been made to try to elucidate the relationship 
between alkaline phosphatase and bone calcification and by 
studying the effect of aluminium on this system it is 
hoped to clarify the relationship further.
144.
Materials and Methods :
1. Neonatal mouse calvaria cultures were prepared in the 
same manner as described in previous chapters, using 
Medium 199 supplemented with 15% foetal calf serum 
and glutamine.
2. Aluminium chloride solution, sterilised using an 
0.22 ym filter (Falcon Plastics; Becton, Dickinson 
and Co.), was added to various cultures to 
concentrations ranging from 0.031 to 7.44 mMoles.
The volume of aluminium chloride solution added was 
kept constant at 0.1 ml, making a total volume of
0.6 ml in each well of each tissue culture dish.
Control cultures were also prepared, with no added 
aluminium in the culture medium.
3. Culture medium was removed and replaced with fresh 
medium of the same type on days 1, 3 , 5  and 7.
4. On each occasion when the culture medium was removed 
it was assayed either for alkaline phosphatase 
content, using a Boehringer-Mannheim diagnostic kit
for total alkaline phosphatase (Boehringer Diagnostics),
O  ^
or for Ca , using a Nova 2 ionised calcium analyser 
(American Hospital Supplies), as specified.
5. In addition to control cultures containing no added 
aluminium chloride in their culture medium, other 
frozen-dead control calvaria were placed in culture 
and treated as normal.
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As in a previous chapter, mice were prelabelled with 
45Ca by subcutaneous injection at 2 days old and
47placed in culture with medium supplemented with C a . 
In addition to the ^^Ca and ^^Ca, in this case, 
aluminium chloride solution was added to the culture 
medium at a concentration of 0.372 nûi, to test the 
effect of aluminium on calcium exchange by bone in 
culture. Control cultures, where no aluminium 
was added to the culture medium, were also prepared. 
Medium was replenished each day, with the medium 
removed from culture being assessed for ^^Ca and ^^Ca 
activity in the usual way.
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Results:
1. Alkaline phosphatase levels in culture medium supporting 
neonatal mouse calvaria, in the presence of aluminium 
chloride.
TABLE 7A
U/L Alkaline Phosphatase
mM Aluminium in culture DAY 1 DAY 3 DAY 5 DAY 7
0.000 LIVE n 4 4 4 4
X 113 60 37 13
S 25 25 11 6
DEAD n 2 2 2 2
X 247 135 49 7
S 140 42 11 6
0.031 LIVE n 4 3 3 3
X 92 26 18 10
S 71 9 5 1
DEAD n 3 3 3 3
X 330 108 25 16
S 87 63 18 15
0.062 LIVE n 4 4 4 4
X 78 39 10 12
S 20 18 4 5
DEAD n 3 3 3 3
X 350 153 38 9
S 135 77 30 0
147.
TABLE 7A (continued) ...
mM Aluminium in culture DAY 1,
U/L Alkaline Phosphatase 
DAY 3 DAY 5 DAY 7
0.093 LIVE n 4 4 4 4
X 52 50 8 15
S 10 20 2 8
DEAD n 3 3 3 3
X 280 81 11 20
S 13 49 5 1
0.186 LIVE n 4 4 4 4
X 98 46 23 6
S 6 16 2 1
DEAD n 3 3 3 3
X 327 97 35 10
S 48 47 10 2
0.310 LIVE n 4 4 4 4
X 51 23 11 14
S 11 5 4 2
DEAD n 3 3 3 3
X 303 51 17 16
S 102 28 7 2
0.372 LIVE n 4 4 4 4
X 54 18 20 10
S 22 4 12 3
DEAD n 3 3 3 3
X 307 85 36 7
S 78 58 4 4
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TABLE 7A (continued) ...
mM Aluminium in culture
U/L Alkaline 
. DAY 1 . DAY 3
Phosphatase 
DAY 5 DAY 7
0.558 LIVE n 3 4 4 4
X 33 26 22 9
S 8 10 8 8
DEAD n 3 3 3 3
X 292 84 27 6
. S 41 42 6 1
0.620 LIVE n 4 4 4 4
X 48 13 5 13
S 5 5 3 1
DEAD n 3 3 3 3
X 328 129 25 20
S 56 78 21 7
Û.93Ù LIVE n 4 4 4 4
X 48 26 8 9
S 7 19 4 3
DEAD n 3 3 3 3
X 284 125 19 21
S 128 36 6 7
1.240 LIVE n 4 4 4 4
X 71 15 16 12
S 23 11 6 4
DEAD n 3 3 3 3
X 382 76 22 5
S 54 48 9 2
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TABLE 7A (continued)
U/L Alkaline Phosphatase
mM. Aluminium in culture. DAY 1. DAY 3 . DAY 5 DAY 7
1.860 LIVE n 3 4 4 4
X 88 28 22 11
S 6 12 5 6
DEAD n 3 3 3 3
X 421 127 40 12
S 85 50 17 7
3.720 LIVE n 4 4 4 4
X 82 42 25 10
S 57 14 10 3
DEAD n 3 3 3 3
X 315 91 38 6
j 8 91 39 14 5
5.580
7.440 NO RESULTS
Standard culture medium contains no alkaline phosphatase.
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FIGURE 7A
Levels of alkaline phosphatase found when 
mouse calvaria are cultured in the presence 
of various concentrations of aluminium 
chloride.
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2. Students t-tests comparing alkaline phosphatase levels 
in culture medium to which aluminium has been added to 
levels in culture medium with no added aluminium.
TABLE 7B
mM concentrations of aluminium compared p
DAY 3 None
+ 0. 031 (92 + 71) NSD
+ 0, 062 (78 + 20) NSD
+ 0. 093 (52 + 10) 0.01
+ 0 186 (98 + 6) NSD
+ 0. 310 (51 + 11) 0.01
+ 0 372 (54 + 22) 0.02
+ 0 558 (33 + 8) 0.001
+ 0 620 (48 + 5) 0.01
+ 0 930 (48 + 7) 0.01
+ 1 240 (71 + 23) 0.01
+ 1 .860 (88 + 3) NSD
+ 3 720 (82 + 57) NSD
+ 0 031 (26 + 9) NSD
+ 0 .062 (39 + 18) NSD
+ 0 .093 (50 + 20) NSD
+ 0 .186 (46 + 16) NSD
+ 0 .310 (23 + 5) 0.05
+ 0 .372 (18 + 4) 0.02
+ 0 .558 (26 + 10) 0.05
+ 0 .620 (13 + 5) 0.02
+ 0 .930 (26 + 19) NSD
+ 1 .240 (15 + 11) 0.02
+ 1 .860 (28 + 12) NSD
+ 3 .720 (42 + 14) NSD
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TABLE 7B (continued)
mM concentrations of aluminium compared P
DAY 5 None (37 + 11) + 0.031 (18 + 5) 0.05
+ 0.062 (10 + 4) 0.01
+ 0.093 (8 + 4) 0.01
+ 0.186 (23 + 2) 0.05
+ 0.310 (11 + 4) 0.01
+ 0.372 (20 + 12) NSD
+ 0.558 (22 + 8) NSD
+ 0.620 ( 5 + 3) 0.002
+ 0.930 ( 8 + 4) 0.01
+ 1.240 (16 + 6) 0.02
+ 1.860 (22 5) 0.05
+ 3.720 (25 + 10) NSD
DAY 7 None (13 Î G) + 0.031 (10 + 1) NSD
+ 0.062 (12 + 5) NSD
+ 0.093 (15 + B) NSD
+ 0.186 (6 + 1) 0.01
+ 0.310 (14 + 2) NSD
+ 0.372 (10 + 3) NSD
+ 0 .558 ( 9 + 8) NSD
+ 0.620 (13 + 1) NSD
+ 0.930 ( 9 + 3) NSD
+ 1.240 (12 + 4) NSD
+ 1.860 (11 + 6) NSD
+ 3.720 (10 + 3) NSD
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3. Students t-tests comparing alkaline phosphatase levels 
in culture medium supporting living and frozen dead 
calvaria in the presence of the same concentration of 
aluminium.
TABLE 7C
Cultures Compared P
1 OmM living (113+25) + dead (247+140) NSD
0.031mM living (92+71) + dead (330+87) 0.01
0.062mM living (78+20) + dead (350+135) 0.01
0 .093mM living (52+10) + dead (280+13) 0.001
0.186mM living (98+6) + dead (327+48) 0.001
O.SlOmM living (51+11) + dead (303+102) 0.01
0.372mM living (54+22) ■h dead (307+78) 0.002
0.558mM living (33+8) + dead (292+41) 0.001
0.620mM living (48+5) + dead (328+56) 0.001
0.930mM living (48+7) 4- dead (284+128) 0.02
1.240mM living (71+23) + dead (382 +54) 0.001
1.860mM living (88+6) + dead (421+85) 0.001
3.72OmM living (82+57) dead (315+91) 0.01
2 OmM living (60+25) + dead (135+42) 0.05
0.031mM living (26+9) + dead (108+63) NSD
0 .062mM living (39+18) + dead (153+77) 0.05
0.09 3mM living (50+20) + dead (81+49) NSD
O.lSemM living (46+16) + dead (97+47) NSD
O.SlOmM living (23+5) + de ad (51+28) NSD
0.372mM living (18+ 4 ) + dead (85+58) NSD
0.558mM living (26+10) + de ad (84+42) NSD
0.620mM living (13+5) + dead (129+78) 0.05
0.930mM living (26+19) + dead (125+36) 0.01
1.240mM living (15+11) + dead (76+48) NSD
1.86OmM living (28+12) + dead (127+50) 0.02
3.72OmM living (42+14) + dead (91+39) NSD
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TABLE 7C (continued)
Cultures Compared P
DAY 5 OmM living 37+11) + dead 49+11) NSD
O.OSlmM living 18+5 ) + dead 25+18) NSD
0,062mM living 10+4) + dead 38+30) NSD
0 .093mM living 8+2) + dead 11+5) NSD
0.186mM living 2 3+2) dead 35+10) NSD
O.SlOmM living 11+4) + dead 17 +7) NSD
0.372mM living 20+12) + dead 36+4) NSD
0.558mM living 22+8) + dead 27+6) NSD
0.62OmM living (5+3) + dead 25+21) NSD
0.930mM living (8+4) + dead 19+6) 0.05
1.240mM living 16+6) + dead 22+9) NSD
1.860mM living 22+5) + dead 40+17) NSD
3.72OmM living 25+10) + dead 38+14) NSD
DAY 7 OmM living 13+6) + dead (7+6) NSD
O.OSlmM living 10 + 1) + de ad 16+15) NSD
0.062mM living 12+5) + dead (9+0)
0.093mM living 15+8) + dead 20 + 1) NSD
0.186mM living 6 + 1) + dead 10+2) 0.05
O.SlOmM living 14+2) + dead 16+2) NSD
0.372mM living 10+3) + dead 7+4) NSD
0.558mM living (9 + 8) + de ad 6 + 1) NSD
0.620mM living 13+1) + de ad 20 + 7) NSD
0.930mM living (9+3) + dead 21+7) 0.02
1.240mM living 12+4) + dead 5+2) NSD
1.86OmM living 11+6) + dead 12+7) NSD
3.720raM living 10+3) + dead 6+5) 0.05
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FIGURE 7B
The effects of killing mouse calvaria by 
freezing and thawing on the release of 
alkaline phosphatase into the calvaria 
culture medium. No aluminium chloride 
has been added to any of the cultures 
studied here.
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The first and most noticeable feature of this experiment
was the effect of the 5.58mM and the 7.44m^d concentrations
of aluminium on the mouse calvaria in culture. When
added to the culture medium, within 24 hours these solutions had
resulted in fragmenting of the calvaria in culture, with
small particles of bone floating freely in the culture
medium; these cultures were subsequently abandoned.
Results here, in TABLE 7 A and FIGURE 7A, shoiv that any 
concentration of aluminium in culture medium causes a 
decrease in the level of alkaline phosphatase in the culture 
medium. The effect of aluminium on the alkaline phosphatase 
levels does not seem to be dose-dependent or related to 
concentration, although there is a lot of variation in the 
amount of inhibition exhibited. Alkaline phosphatase 
levels in all of the cultures, with or without added
aluminium,fall as the cultures proceed and eventually
reach the same low level. It is important to remember that
fresh standard culture medium, as used here, has no alkaline
phosphatase present before it is placed in culture with the 
calvaria and any alkaline phosphatase present at any time 
during the culture period comes from the bone itself.
An interesting point to note is that dead calvaria 
in culture release more alkaline phosphatase into the 
culture medium than the live calvaria. This phenomenon 
probably reflects the breakdown of the bone as a result 
of the death and damage due to freezing and thawing, 
explaining perhaps the initially high levels of alkaline 
phosphatase produced when live calvaria have just been 
dissected-out and placed in culture.
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To see whether we could detect calvaria dying in the 
course of culture by a similar rise in alkaline 
phosphatase level in the culture medium, sample 
calvaria were killed at intervals throughout the 
culture period and replaced in culture, the alkaline 
phosphatase levels in their culture medium measured 
as normal.
TABLE 7D
DAY CULTURE ALKALINE PHOSPHATASE LEVEL (U/L)
KILLED DAY 1 DAY 3 DAY 5 DAY 7 DAY 9
0 n 4 4 4 4 4
X 331 96 23 7 15
S 62 41 15 3 5
1 n 2 2 2 2 2
X 41 124 22 10 11
S 24 40 12 8 1
3 n 3 3 3 3 3
X 73 44 111 22 16
S 20 30 48 8 8
7 n 3 3 3 3 3
X 45 53 14 4 98
S 33 9 2 4 10
— n 3 3 3 3 3
X 40 25 15 29 10
S 26 4 13 12 1
The results in this table (TABLE 7D) show that following
the death of any calvaria by freezing is followed by a steep
rise in the level of alkaline phosphatase in the culture
medium on the following day, complementin g results by
Lenaers- Claeys, et al. (1976) who found that freezing and
thawing to produce dead explants always resulted in a rise
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in the alkaline phosphatase level in their culture 
medium. As well as confirming that it is always the 
case that dead explants of bone release more alkaline 
phosphatase than live explants, not a feature of adding 
aluminium, we also have a competent yardstick by which 
we can assess the inability of those calvaria which we 
hope to maintain alive.
5. Alkaline phosphatase, as the name suggests, works 
generally in alkaline conditions of up to pH 9.8; 
the culture medium used here is neutral, as indicated 
by phenol red, but became more acidic on addition of 
the aluminium chloride solution. It was thought that, 
perhaps, the decreased level of alkaline phosphatase 
found in the presence of aluminium chloride may be 
an effect of the pH rather than the aluminium itself.
To test whether the decreased levels of the enzyme 
reflected a pH or aluminium effect, the pH of the culture 
medium was raised using 0.IM NaOH, 1 drop in each well 
producing an alkaline pH, as indicated by the phenol 
red. More accurate determinations of the pH of the 
culture medium seemed inappropriate as after a short 
period of incubation the pH would change again. Results 
of this experiment are shown in TABLE 7E and FIGURE 7C, 
where the alkaline phosphatase levels produced in the 
new, higher, pH are compared with those at the lower 
pH, in the presence of the same concentration of 
aluminium.
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TABLE 7E
iM Aluminium present
U/L Alkaline 
DAY 1 DAY 2
Phosphatase 
DAY 3 DAY '
0.000 n . 3 3 3 3
X 2 32 79 25 19
S 25 22 8 6
0.031 n 4 4 4 4
X 248 75 21 13
S 25 9 6 3
0.062 n 4 4 4 4
X 162 39 21 14
S 23 2 8 1
0.093 n 3 4 3 3
X 165 71 17 10
S 51 31 5 1
0.186 n 4 4 4 4
X 122 52 16 10
S 26 7 2 0
0.310 n 4 4 4 4
X 131 50 16 10
" S 11 7 3 2
0.372 n 4 4 4 4
X 143 47 13 13
S 17 2 1 2
Disregarding the artificially high level of alkaline 
phosphatase recorded &r each type of culture on day 1, the 
result of damage during the dissection procedure, we can
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FIGURE 7C
Comparing the effects of an alkaline or 
an acid pH on the release of alkaline 
phosphatase from calvaria, in the 
presence of aluminium chloride.
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see that increasing the pH decreases the level of
alkaline phosphatase recorded. From these results
we can see that the aluminium, therefore, decreases
the alkaline phosphatase levels slightly beyond those
which we already found, but the trends are the same, with
no significant differences.
2 +Ionised calcium (Ca ) levels in culture medium supporting 
neonatal mouse calvaria, in the presence of aluminium 
chloride.
TABLE 7E. „
mM Ca
mM Aluminium in culture DAY 1 DAY 3 DAY 5 DAY 7
0.000 LIVE n 3 3 3
- 0.370 0.597 0.569
S 0.172 0.074 0.071
DEAD n 3 3 3
X 1.254 1.412 1.180
S 0.051 0.012 0.058
0.031 LIVE n 3 3 3 3
X 1.374 1.781 1.95 1.839
S 0.120 0.212 0.151 0.102
DEAD n 3 3 3 3
X 1.196 1.658 1.485 1.563
S 0.017 0.184 0.086 0.353
0.062 LIVE n 3 3 3 3
X 1. 444 2.117 2.244 2.043
S 0.073 0.346 0.028 0.138
DEAD n 3 3 3 3
X 1.045 1.323 1.27,1 1.151
S 0.127 0.543 0.065 0.474
0.093 LIVE n 3 3 3
X 1,51 1. 834 1.853
S 0.199 0.297 0.329
0.186 LIVE n 3 3 3
X 1.45 1.854 2.05
S 0.038 0.214 0.225
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FIGURE 7D
Levels of Ca^ "** found in culture medium 
supporting mouse calvaria, in the presence 
of various concentrations of aluminium 
chloride.
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mM Aluminium in culture DAY 1 DAY 2 DAY 3 DAY 4
0.310 LIVE n 3 3 3
X 1.48 2.042 2.103
• S 0.020 0 .062 0.066
0.372 LIVE n 3 3 3
X 1.48 1.684 1.716
S 0.051 0.294 0 .538
2 +standard culture medium has a 1.1 mM concentration of Ca
Students t-tests, comparing the levels of Ca^^ in 
culture medium supporting mouse calvaria in the presence 
of aluminium with those where no aluminium is present, 
show that levels in the presence of aluminium are 
significantly greater (from p <0.01 to p <0.001). T-tests 
comparing the levels of Ca^^ in culture medium supporting 
living and dead calvaria, in the presence of aluminium
show that, in general, as time proceeds, the level of 
2 +Ca in the presence of dead calvaria is significant 1; 
lower than that in the presence of live calvaria.
The main purpose of this study of the effect of
2 +aluminium on the levels of alkaline phosphatase and Ca 
in mouse calvaria culture medium was to see if we could 
learn more about the possible relationship between the 
two parameters. The following table lists the alkaline 
phosphatase (A.P) and Ca^^ levels in equivalent cultures 
on each day of culture and in the presence of different 
concentrations of aluminium.
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TABLE 7G
U/L
Average A.P. and Ca^^ (mM) on each day
mM Aluminium present
A.P.
DAY 1 
, +
DAY 3
9 +
A.P. Ca A.P
DAY 5
Ca^ '*'
0 113 0.370 60 0.598 37 0.569
0.031 92 1.374 50 1.781 20 1.950
0.062 78 1.444 39 2.117 10 2 .244
0.093 52 1.510 50 1.834 8 1.853
0.186 98 1.450 46 1.854 23 2 .050
0.310 51 1.480 23 2.042 11 2 .103
0 .372 54 1.480 18 1.684 20 1.716
Taking all Ca^^ amd A.P . pairs in the above table we
find a strong correlation between the two parameters 
(r = - 0.835), showing that as alkaline phosphatase 
levels in culture decrease the ionised calcium levels 
increase.
161,
FIGURE 7E
2 +The relationship between Ca and alkaline
phosphatase levels found in culture medium
in the presence of aluminium chloride ;
each pair of results was found with the
same concentration of aluminium chloride.
A correlation co-efficient of -0.835 was
2 +found to exist between Ca"" and alkaline 
phosphatase levels in culture, with a 
line of regression: y = 0.0076 x + 2.1.
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EIGURE 7F
45Levels of Ca In culture medium in the
presence of aluminium chloride. The 
45release of Ca from the pre-labelled 
bone indicates the level of bone 
resorption.
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9. As the aluminium has any effect inside the bone itself, 
it was suggested that it may have been more relevant to 
study the alkaline phosphatase content of the bone in 
culture, not the alkaline phosphatase in the medium. By 
setting up two sets of cultures, one set with 0.093 mM 
aluminium solution and one without and removing two sample 
calvaria from each set of culture each day, homogenising 
them in 5 ml of culture medium and assaying their homogenate 
for alkaline phosphatase, it was possible to test if 
decreases in alkaline phosphatase culture medium containing 
aluminium reflected changes within the bone itself. The 
results obtained are shown in TABLE 71 and FIGURE 7 H .
TABLE 71
ALKALINE PHOSPHATASE (U/L) + DAY OF CULTURE
DAY 1 DAY 2 DAY 5 DAY 6
CONTROL X 38 24 22 24
S 8.5 2.8 2.2 5
ALUMINIUM X 33 10 7 7
ADDED S 1.4 0 0 0
S.D. 0 0.01 0.01 0.001
These results show that as well as reducing the alkaline
phosphatase levels in bone culture medium, aluminium 
significantly lowers the level of alkaline phosphatase 
in the bone itself.
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FIGURE 7H
Looking at the levels of alkaline phosphatase 
within the bone itself in the presence of 
aluminium chloride solution, as well as in 
the presence of control medium, which 
contains no aluminium.
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DISCUSSION:
Ellis, et al. (1979) and Boyce, et al. (1981) found 
that the continued administration of aluminium in vivo leads 
to osteomalacia, through the inhibition of calcification as a 
result of, perhaps, as Boyce, et al. (1981) suggests, the 
inhibition of enzymes involved in calcification, such as 
A.P. Both of these groups, along with Le Eevre, et al. 
(1980), have shown that aluminium is readily incorporated 
into bone in vivo. The basis of this study was the 
effect of aluminium on bone mineralisation in vitro, looking 
specifically at A.P. and Ca^^, with a view, in general, of 
looking at the relationship between these two parameters 
as well as their reaction to aluminium.
Firstly, the effects of aluminium on A.P. release by 
bone in vitro was studied, adding aluminium in varying 
concentrations to the culture medium and assessing the 
effect on the enzyme. Note that fresh culture medium 
contains no A.P. and any enzyme activity present can only 
have originated from the bone itself. Results in TABLE 7A, 
7B and FIGURE 7A suggest that aluminium has some effect on 
decreasing the amount of A.P. released by bone; results 
in TABLE 71 and FIGURE 7H suggest that this may be through 
decreasing enzyme activity within the bone itself and not 
by inhibiting its release from bone in culture. Comparisons 
made between the levels of A.P. in culture medium supporting 
living and dead calvaria, in the presence of aluminium 
(TABLE 70), show that A.P. is released in abundance from
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bones, but that the amount available for release is less
in the presence of aluminium than when none is present ;
metabolic controls which are influencing A.P. become
ineffective when the bone dies and the enzyme is freely
released (TABLE 7D, FIGURE 7B).
If, as is suggested, aluminium inhibits calcification
one would expect that the presence of the element in
culture medium supporting mouse calvaria would either
prevent or reduce the uptake of calcium from the culture
medium, which normally has a 1,1 mM concentration of Ca^^.
As before, aluminium was added to culture medium supporting
neonatal mouse calvaria, in varying concentrations, and the
2 +effect on the Ca levels in the culture medium assessed.
Looking at results in TABLE 7F, FIGURE 7D, we can see quite
2 +clearly that while the Ca level in culture medium with
no added aluminium is quite low compared to the original
concentration of 1.1 mM, probably as a result of calcium
uptalie for mineralisation, the levels of Ca^^
presence of aluminium are all higher than 1.1 mM, probably
as a result of resorption releasing calcium, with no
uptake for mineralisation. These results would strongly
suggest that aluminium acts by inhibiting calcification.
As was stated earlier, one of the main quests of
this thesis is to find out more about the relationship
between A.P. activity and calcification. It has been
seen that aluminium causes decreased A.P. activity, with
2 +an accompanying increase in the Ca levels in the culture
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2 +
medium. Looking at levels of A.P. and Ca in the 
presence of the same concentration of aluminium (TABLE 7G. 
FIGURE 7E) we can see the strong relationship between the 
two parameters, producing a correlation co-efficient of 
-0.835, and suggesting that the enzyme A.P. is, beyond 
doubt, involved in mineralisation.
Adding strength to the conclusion that aluminium 
acts on A.P. and decreases the uptake of calcium for 
mineralisation are results in TABLE 7H and FIGURES 7F, 7G, 
using ^^Ca and ^^Ca labels, that uptake of calcium in 
the presence of aluminium is noticeably decreased.
These results would suggest, then, that aluminium 
inhibits the activities of the enzyme A.P. in relation to 
the calcification of bone. From these results it cannot 
be concluded at which concentration, within the range 
used, aluminium has its effect, that would require further 
and more specific studies, but its action on calcification 
would seem to be convincing.
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GENERAL DISCUSSION AND CONCLUSIONS
Metabolic bone diseases are a widespread and 
complicated group of disorders affecting bone, with various 
problems related to bone pain and fractures, as well as the 
less obvious problems concerned with hyper and hypocalcaemia 
and bone loss. As a group they are probably among the most 
widespread and least appreciated of diseases, having none of 
the more usual and distressing symptoms normally associated 
with disease, with their characteristics generally being 
accepted as those accompanying old age, but their almost 
universal occurrence makes their control and treatment 
important with today's continually increasing population.
The control and treatment of these disorders cannot however 
be successfully attained without a full or, at least, 
comprehensive understanding of how these disorders occur 
and how they develop. All of the studies contained within 
this thesis have been performed in an attempt to understand 
more about metabolic bone diseases.
0%gan culture preparations of neonatal mouse calvaria 
have been used many times in studies associated with bone 
metabolism (Goldhaber, 1958; Susi, et al. 1966 ; Nisbet ,
1968; Nisbet, et al. 1969; Reynolds, et al. 1970 ; Nisbet , et al( 197* 
Stern, et al. 1970; Messer, et al. 1973; Minkin, 1973;
Maria, et al. 1977; Messer, 1977; Herrmann-Erlee, et al.
1978) and proved invaluable in this study. However it 
was also hoped to study human bone in organ culture, the 
3-dimensional integrity of human bone being nearer to the
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true structure of bone than the wafer-thin layer of cartilage 
in calvaria, also allowing the in vitro study of bone from 
patients suffering from metabolic bone disease. It was the 
complex structure of human bone which proved to be the 
stumbling block as far as its in vitro culture was concerned. 
Where mouse calvaria cultures are easily reproducible, human 
bone cultures are not. Calvaria from an average litter of 
six days old are of a fairly uniform size, but human bone 
fragments, of mature calcified bone, may often appear to 
be of the same size, but they can vary greatly in the degree 
of calcification, the number of cells and even the amount of 
bone present ; the severity of bone disease may also vary 
between bones within the same individual. As all studies 
involving bone cultures were comparative, results produced 
from human bone in culture could not be compared with 
confidence and such cultures were not pursued. Attempts 
at preparing cultures of human bone cells also proved 
difficult, but with continued attempts it should be possible 
to culture all kinds of bone cells successfully, as has been 
found with other cell types.
Human serum was studied in culture with mouse calvaria
and proved more fruitful than studies of human bone in
culture. By preparing standard cultures of mouse calvaria,
45with bone prelabelled with Ca and culture medium containing 
47Ca, it became possible to look at the effects of human 
serum, from a variety of metabolic problems, on bone 
turnover in vitro. Many groups have studied bone resorption
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45in culture, looking at the release of Ca from prelabelled
bone, under the influence of specific bone-related test
substances. Studies have helped to show that PTH
stimulates bone resorption in vitro, after initially
inhibiting resorption, (Raisz, et al. 1967, 1969; Stern,
1969; Parsons, et al. 1971; MacIntyre, et al. 1971;
Engracio, et al. 1972; Minkin, 1973), CT inhibits bone
resorption (Raisz, et al. 1967; Reynolds, et al. 1968;
Raisz, et al. 1968; Nisbet, et al. 1968; Mittleman, et al.
1968; Binderman, et al. 1972; Gozariu, et al. 1973; Luben,
et al. 1976; Geusens, et al. 1980; Maier, et al. 1980;
Stevenson, et al. 1981), oestrogen inhibits bone resorption
(Atkins, et al. 1972; Robin, et al. 1980; Wink, et al.
1980) and vitamin D metabolites promote bone strength
(Mittleman, et al. 1968; Raisz, et al. 1974; Boyle, 1974;
Stern, etal. 1976; Peacock, et al. 1976; DeLuca, 1977;
Wong, et al, 1977; Cohen, et al. 1980). As the pattern of
bone resorption under the influence of these substances is
45so well known, they were placed in culture with the Ca
47labelled bone, to measure resorption, and the Ca labelled
culture medium, as a measure of calcification, to see if
bone resorption occurred as normal, without interference 
47from the Ca, and to see what effect these substances 
may have on bone formation.
Results obtained showed that as in previous studies , 
over the 4 day culture period, PTH inhibits bone resorption 
before stimulating it, CT inhibits bone resorption, oestrogen 
decreases bone resorption, while the vitamin D metabolites 
inhibited bone resorption where they were expected to 
stimulate it, this however would still have the effect of
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increasing bone strength. The trends suggested that the 
47uptake of Ca from the culture medium, and its possible 
re-release by the bone in culture, did not seem to 
interfere with the assay of bone resorption and could 
possibly be providing a fairly accurate representation of 
the effects of these same test substances on bone formation. 
The effects of PTH, CT, oestrogen and the vitamin D 
metabolites on bone formation would seem to be that PTH 
stimulates bone formation, as in vivo; CT normalises 
b o n e  formation, which is interesting when compared to 
previous studies which have only suggested its involvement 
in bone resorption; oestrogen stimulates the uptake of 
calcium, which may help to explain why the loss of oestrogen 
with the menopause causes such devastating bone loss; while 
the vitamin D metabolites, according to this study, have 
no effect on calcification, where previous results have 
shown that they promote bone turnover. This last result 
is interesting, but no definite conclusions may be drawn 
without repeating the experiment several times to check 
the result, which time did not allow for here.
The duplication of results concerning bone resorption 
found in previous studies by this system meant that the 
effects of new substances, which have not previously been 
assessed, could be studied with a degree of confidence, 
involving the investigation of the effects of sera from 
patients suffering from a variety of metabolic disorders.
In general, the results have suggested that serum from 
patients suffering from these metabolic bone disorders acts
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on bone in vitro to produce similar patterns of bone 
turnover to those found in vivo.
Osteoporotic serum acts to increase bone resorption 
and decrease calcification, as compared with normal human 
serum, which mirrors the accumulated bone loss found with 
osteoporosis (Albright, et al. 1948). The treatment of 
one osteoporotic patient with oestrogen had the effect 
of reducing bone resorption and increasing calcium uptake, 
bringing bone turnover nearer to that found in normal 
individuals and suggesting that oestrogen is effective 
in the control of osteoporosis.
Osteomalacic/ricketic serum acts on bone in vitro to 
enhance bone resorption and decrease mineralisation, which 
would lead to the osteomalacic/ricketic condition of soft, 
mainly osteoid bone (Smith, 1979). These conditions, 
one the adult form and one the juvenile form, are often 
treated using 25(0H)Dg and l,25(0H)2Dg (DeLuca, 1977;
Kanis, et al. 1977; Frame, et al. 1978; Ahmed, et al. 1979; 
Offerman, et al. 1979) and these metabolites, in culture 
with ^^Ca and ^^Ca, have been shown to decrease bone 
resorption, which would indeed help the osteomalacic 
condition, while their effects on mineralisation are unclear.
The condition of 1° hyperparathyroidism is recognised 
by increased bone turnover, particularly resorption, through 
the action of PTH (Rosenbach, et al. 1967; Vaes, 1968; 
Harris, et al. 1969; Shubina, et al. 1969; Byers, et al. 
1971; Chu, et al. 1971; Messer, et al. 1973a; Minkin, 1973;
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Peck, et al. 1976; Reeve, et al. 1976; Langeland, 1977; 
Wong, et al. 1977; Luben, et al. 1977; Maria, et al. 1977; 
Ibbotson, et al. 1978; Krieger, et al. 1980; Malluche, 
et al. 1981). accompanied by increased bone formation. 
Hyperparathyroid serum acts on bone in vitro to increase 
bone resorption, as compared to normal human serum, but 
decreases the uptake of calcium, which is not indicative 
of bone formation.
Hypoparathyroidism, where patients have no, or very 
little serum PTH, exhibits decreased bone resorption through 
the lack of available PTH. Serum from such patients acts 
on bone in vitro to decrease calcium uptake from the culture 
medium, while results concerning bone resorption are 
inconclusive; it could be that the decreased formation of 
bone is to counteract the decreased bone resorption and 
keep the level of bone as normal as possible. One hypo- 
parathyroid patient studied was treated with la (OH)Dg 
which, as far as this study is concerned, seems to have 
little effect on bone turnover.
Paget's disease of bone is recognised by increased bone 
turnover, which leads to the deposition of disorganised 
woven bone, as opposed to normal lamellar bone (Nagant de 
Deuxchaînes, et al. 1964; Singer, 1977) and the deforming 
of skull and limb bones (Smith, 1979; Krane, 1980). It 
is thought by some to be caused by a viral inclusion found 
within the nucleus of osteoclasts of such patients (Rebel, 
et al. 1980; Singer, 1980) and so it was interesting to
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note the effects of the serum from P,D. patients. Serum 
from patients suffering from P.D. of bone caused increased 
bone resorption in vitro, with decreased mineralisation, as 
compared to normal human serum. The latter, lack of 
calcium upt alee, indicative of a lack of bone formation, was 
unexpected as P.D. is characterised by both increased 
formation and resorption. Treatment of P.D. with C.T, 
as in the case of one patient studied, acted to decrease 
bone resorption and 'normalise’ calcification, showing 
that it can be effective in treating P.D. of bone.
Sample sera from patients suffering from malignant 
hypercalcaemia acted on bone in vitro to increase bone 
resorption and decrease calcium uptake, suggesting that the 
excess serum calcium came from the bone. As a comparison, 
though, serum from patients with carcinoma but with no 
elevated serum calcium produced the same effect, which may 
suggest the presence of some factor in the malignant patient's 
serum which causes bone resorption in vitro but not in vivo, 
further study would be required.
A family, all of whom had taken a massive overdose 
of 25(0H)Dg, provided two samples for the study of the effects 
of serum from patients suffering from hypervitarainosis D on 
bone turnover in vitro. This serum caused decreased bone 
resorption, in the same way as the two test vitamin D 
metabolites, although calcium uptake was less than expected, 
as compared to normal human serum and the two metabolites.
As the serum Ca and AP in both cases was normal, we 
see serum acting differently in vivo and in vitro.
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stimulating bone resorption only in the latter.
Hypophosphataemic serum, from patients suffering from
the rare disorder where the individuals have little or no
45serum AP, was studied in culture with Ca-labelled bone 
47and Ca-labelled culture medium, causing decreased 
mineralisation, with no effect on resorption. As AP is 
thought to be important in mineralisation, this result is 
important in supporting this supposition, with no AP 
leading to decreased mineralisation. A test substance such 
as this, where bone formation is affected more than bone 
resorption, shows the value of this system in showing aspects 
of bone turnover.
On the whole, this study of bone turnover in vitro, 
under the influence of different sera has been interesting, 
showing how both bone resorption and formation can be 
affected. Although there are other and more accurate ways 
of diagnosing metabolic bone diseases, this method of 
studying bone turnover could be useful in assessing the 
development of any disorder. Many metabolic bone diseases 
are diagnosed by means of histological study of sections 
of iliac crest bone biopsies, which are useful in as much 
as the condition of the bone can be seen, but inaccurate 
in that the severity of a disorder may vary between bones 
in the same patient, there cannot be repeated sampling 
from the same site, as well as taking into account the 
fact that changes occur slowly in bone, different disorders 
taking years to manifest or treat. Using serum from 
such patients, serum which can be sampled repeatedly
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without affecting the result, unlike bone, and which is 
more dynamic than bone, adapting to changés more quickly, 
changes in a patient's condition can be assessed. The 
effects of drug therapy may be seen more quickly, as has 
already been seen in those cases where the serum used 
came from patients who had already received some kind of 
drug therapy. The latter is probably the most important 
aspect of this study; by constant monitoring of serum 
biochemistry and bone turnover in vitro, it may also be 
possible to understand the effects of particular drug 
ther spies in more detail.
The enzyme alkaline phosphatase (AP) has stimulated 
a lot of interest over the years concerning its role in 
the mineralisation of bone. In the first half of this 
century Robison (1923, 1932) pioneered the study of this 
enzyme, finding that AP was always to be found in areas 
where calcification would soon occur and leading him to 
suggest that it was responsible for a localised increase 
in phosphate esters, which would precipitate with calcium, 
forming calcium phosphate and mineralising bone. Further 
studies by Bachra, et al. (1959) also provided evidence 
that AP acts locally, but suggested that the enzyme itself 
was involved in mineralisation. Khairi, et al. (1973) 
and Franck, et al. (1974) related increased AP activity 
with increased osteoblastic activity and increased 
mineralisation, when studying Paget's disease of bone.
The level of AP in human serum is used as a diagnostic 
index of the degree of mineralisation in several metabolic
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bone diseases, the level varying with different disorders 
(Rasmussen, et al. 1974; Smith, 1979), although no 
studies have been performed to show that the level of 
serum AP relates directly to the level of AP in bone 
itself. Alkaline phosphatase is not exclusive to bone, 
it is also found in gastro-intestinal mucosa, placenta and 
liver (Smith, 1979), although the bulk of the enzyme derives 
from bone and liver. It was important, then, that a study 
should be made to see if serum AP can be associated with 
bone AP, as an index of mineralisation and bone disease.
Using sample iliac crest bone biopsies from patients 
suffering from several metabolic bone disorders, homogenates 
of bone were prepared and assayed for AP content ; the 
serum AP level in the serum of each patient, as near to the 
day of biopsy as possible, was also noted. By looking at 
bone and serum AP levels, it was found that a strong 
correlation exists between bone AP and serum AP levels, 
with a correlation co-efficient of 0.893, indicating that 
serum AP levels closely reflect AP levels within bone.
This result was encouraging, with the correlation being 
stronger than expected, the AP from other sources not 
interfering signifi.cnntly with the result.
Many studies were carried out for this thesis using
in vitro cultures of mouse calvaria, assaying the culture
2 +medium for changes in AP and Ca , which are thought to 
reflect levels in bone itself. One particular study 
involved the investigation of the effects of aluminium 
on AP and mineralisation of bone. Many patients suffering
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from chronic renal failure (C.R.P) have been found to 
have high levels of aluminium concentrated in both 
their brain and bone tissue, which are thought to be 
associated with the conditions of dialysis dementia and 
dialysis osteomalacia, which often accompany long-term 
kidney dialysis (Bloom, et al. 1960; Berlyne, et al.
1970; Stanbury, 1972; Platts, et al. 1973; Alfrey, 
et al. 1976; Malluche, et al. 1976; Flendrig, et al.
1976; Platts, et al, 1977; Elliot, et al. 1978;
McDermott, et al. 1978; Rozas, et al. 1978; Dunea, 
et al. 1978; Ellis, et al. 1979; Parkinson, et al. 1979; 
Wing, et al. 1980; Shore, et al. 1980; Boyce, et al.
1981; Prior, et al. 1982) and are thought to be associated 
in turn, with levels of aluminium in dialysate water or 
oral phosphate-binding gels (Platts, et al. 1977; Alfrey, 
et al. 1978; Drueke, 1980; Boyce, et al. 1981).
Ellis, et al. (1979) and Le Fevre, et al. (1980) 
found that aluminium is easily incorporated into bone, 
with osteomalacia developing as the aluminium concentration 
within bone increased. Increasing concentrations of 
aluminium were also found to be linked with the inhibition 
of mineralisation, probably by inhibiting AP (Boyce, 
et al, 1981). This finding formed the basis of this 
particular study into the effects of aluminium, looking 
at its effects on AP and Ca^* levels in vitro when placed 
in culture with neonatal mouse calvaria.
When compared with cultures where no aluminium has
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been added, it can be seen that aluminium does decrease 
the amount of AP released into culture medium by bone in 
culture (TABLES 7A, 7B, FIGURE 7k), which was found to 
reflect decreased levels of AP within the bone itself, 
found by homogenising bone which had been exposed to 
aluminium and assaying for AP (TABLE 71, FIGURE 7H).
These results supported the idea that aluminium causes 
dialysis osteomalacia by inhibiting AP activity within 
the bone; they also suggest that, as with serum AP 
and bone AP levels, levels of AP in culture medium reflect 
those in cultured bone.
If, as is suspected, AP is involved in mineralisation,
it was also of interest to look at the effects of
aluminium on Ca^^ levels in culture medium, which are
normally high, around l.lmM. From the results (TABLE 7F,
2 +FIGURE 7D) obtained when Ca assays were carried out in 
culture medium in the presence of aluminium, it is clear 
that the presence of aluminium, enhancing decreased AP 
levels, causes Ca^^levels in the culture medium to remain 
high, where they fall if no aluminium is present. This 
result supports the strong link between high levels of 
aluminium, low levels of A P , decreased mineralisation and the 
occurrence of dialysis osteomalacia.
As one of the main interests of this thesis was to 
find out more about the relationship between bone AP and 
mineralisation, the relationship between AP and Ca^^levels 
in the face of aluminium inhibition was studied (TABLE 7G, 
FIGURE 7E), showing a correlation co-efficient of -0.835.
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This result shows the strong relationship between AP and
mineralisation, calcium levels remaining high while AP
45levels are low and vice versa. Using Ca-labelled bone and 
47Ca-labelled culture medium, the relationship between A P ,
2 +Ca and aluminium was again exhibited, when aluminium
caused the uptake of calcium from the culture medium to
be decreased (TABLE 7H, FIGURES 7F, 7G).
It would seem then that aluminium does inhibit
mineralisation through inhibiting A P , which in turn has a
strong influence on Ca^^ levels in culture, high levels
2 +of the enzyme causing Ca levels to fall as mineralisation 
occurs, although from this study it is not possible to tell 
whether AP facilitates mineralisation or takes part in it 
itself.
As with the bone turnover studies, it was hoped to
study the effects of human sera, from a variety of metabolic
bone diseases, on AP and Ca^* levels in culture medium,
but this proved to be difficult. Human serum has its own
inherent AP and Ca^ **" content, making it difficult to use
these parameters as a measure of the effects of the serum
on mineralisation, the ^^Ca, ^^Ca system proved more
successful. Preliminary studies, however, using foetal
calf serum gave indications of a strong relationship between 
2 +AP and Ca levels in culture, which was later confirmed by 
the aluminium studies.
Other studies related to metabolic bone disease involved 
the assay of two different and unrelated enzymes :
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collagen prolyl hydroxylase and creatine kinase.
Collagen is the main structural component of bone and 
as such any changes in bone metabolism, such as in the 
various metabolic bone diseases, may be reflected in 
changes in collagen metabolism. In this case collagen 
metabolism was to be studied by looking at the activity 
of the enzyme collagen prolyl hydroxylase in different 
disorders. Proline represents 20% of all of the amino 
acids in collagen and any failure in its hydroxylation 
prevents the formation of the characteristic triple helix 
shape found in collagen. The assay for this enzyme was 
developed by Hutton, et al. (1966), where activity is
3
measured by means of assay of the H^O formed at the end 
of the experiment. Various co-factors and conditions 
essential to this assay have already been described 
(Mitamo, et al. 1959; Fujiraoto and Tamiya, 1962;
Flanagan and Nichols, 1962; Prockop, et al. 1963, 1964, 
Juva and Prockop, 1964, 1966; Meister, et al. 1964, 
Peterkofsky and Udenfriend, 1965; Hurych and Chvapil, 
1965; Hutton, et al. 1966, 1967).
Here the assay was performed using homogenates 
prepared from slivers of bone cut from biopsies of the 
iliac crest, but the assay did not pass the developmental 
stage of seeing if the assay was working, caused by many 
technical hitches beyond the control of the author. No 
comparative studies could be made, although what results 
were obtained did suggest that increasing the dilution of
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the bone homogenate increased the enzyme activity 
detected> perhaps suggesting the presence of an inhibitor. 
It is unfortunate that this assay could not be developed 
further as it showed promise in the study of metabolic 
bone disease.
The assay of muscle creatine kinase was more 
successful. Creatine kinase, the enzyme involved in the 
breakdown of the high energy molecule creatine phosphate 
to form ATP, is found in many human tissues, but is most 
abundant in skeletal muscle (Forster, et al, 1974), a 
tissue which requires a lot of energy for normal 
functioning. Normal human serum has little or no 
creatine kinase activity (Wilson, 1965), but this can rise 
with such disorders as hypothyroidism, severe physical 
exercise, muscular trauma, epileptic fits and primary 
hyperparathyroidism, as well as in coma and progressive 
muscular dystrophy (Forster, 1967). As many metabolic 
bone disorders can affect movement, through increased bone 
pain and disfigurement, it was decided to see if creatine 
kinase, levels vary with different metabolic bone diseases.
The assay for creatine kinase used here is based on 
that determined by Oliver (1955), using homogenates 
prepared from fragments of the vastus lateralis, the 
muscle found attached to Meunier trephine biopsies of 
the iliac crest. Most of the creatine kinase in striated
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muscle is found within the cell cytoplasm and so 
complete homogenisation is necessary to obtain a true 
measure of the enzyme present. Lowry protein assays 
were also performed to allow a measure of creatine kinase 
in ng creatine kinase/mg protein to be obtained.
Results of these assays showed little difference 
between creatine kinase levels in muscle from patients 
suffering from different metabolic bone disease and, in 
retrospect, it would probably have been of interest to 
compare the levels of the enzyme found in these patients 
with that found in muscle from a normal individual.
Changes in serum creatine kinase levels, as found in 
previous studies, are easier to detect as normal serum 
contains no creatine kinase; homogenates of skeletal 
muscle, however, contain an abundance of creatine kinase, 
making subtle changes difficult to detect. Comparisons 
made between levels of creatine kinase in muscle from 
male and female patients showed that males have a higher 
content in skeletal muscle than females, reflecting 
results for serum creatine kinase levels found by Wiesmann, 
et al (1966). Work by Smith, etal. (1979) and Thomson 
and Smith (1980) linked low levels of serum creatine 
kinase in females to the inhibition of the enzyme by 
oestrogen; the levels rise during pregnancy, as oestrogen 
falls. Looking at the effect of age on muscle creatine 
kinase levels, the levels rise in both male and female
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subjects, but most noticeably in females, probably related 
to the decline of oestrogen with the menopause.
From these studies concerning bone metabolism in 
metabolic bone disease, various conclusions can be drawn, 
with indications of lines for further study.
Organ cultures of neonatal mouse calvaria continue 
to provide invaluable assistance in the study of bone 
metabolism. The use of pre-labelled calvaria and pre-labelled 
culture medium in the study of the effects of substances 
on bone turnover shows promise in many further studies, 
concerned with drug therapies and other treatments for 
metabolic bone diseases. Results concerning the effects of 
human sera on bone turnover proved interesting, with more 
studies, using larger numbers of samples, being required to 
discern any particular effects of different sera.
The importance of the enzyme alkaline phosphatase in 
mineralisation has been further emphasised by these studies, 
perhaps suggesting that an alkaline phosphatase ’substitute' 
could be used in the treatment of bone loss. The relationship 
between serum alkaline phosphatase and bone alkaline 
phosphatase has also been determined, meaning that serum 
alkaline phosphatase,unless additional information suggests 
to the contrary, is a good index of bone metabolism.
Creatine kinase levels in skeletal muscle bear no 
relation to metabolic bone disease and further study is not 
required, unless it is to look at serum creatine kinase 
levels in the different disorders. The study of collagen
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prolyl hydroxylase levels in human bone continues to be 
of interest, as does the culture of human bone cells, 
with further studies doubtless producing interesting 
results in the study of metabolic bone diseases.
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CHAPTER EIGHT. APPENDIX: ADDITIONAL REVIEW OF RECENT LITERATURE
In the main text of the thesis, the origin, development and 
activities of the main bone cell types were discussed. Osteoclasts, 
the bone-resorbing cells, were found to originate from 
circulating monocytes (Mundy, et. al. 1977, 1978) and more 
recent studies by Bonnuci (1981) would seem to support this, 
with monocytes becoming macrophages and giant multinucleate cells, 
as are osteoclasts, in vitro (Sutton, et. al. 1972). Biochemical 
changes produced in the cells under the influence of various bone- 
resorbing agents, such as PTH, 1, 25(0H)2 Dg, prostaglandins and 
osteoclast-activating factor, produced by lymphocytes, have been 
found to include increases in levels of hyaluronate and acid 
phosphatase activity (Luben, et. al. 1976; Wong, et. al. 1977; 
Raisz, et. al. 1981; Simmons, et. al. 1982). Physical changes 
include increased activity in the ruffled border of the osteoclasts, 
which accommodates enzyme-rich vacuoles (Rifkin, et. al. 1980; 
Bonnuci, 1981), and the discharge of enzymes into the extra­
cellular space. The ruffling effect produces pseudopodia, which 
indeed make the cells motile in vitro (Chambers, et. al. 1982), 
the production of which is halted by calcitonin (CT), a potent 
inhibitor of bone resorption, apparently via a reduction in serum 
calcium, perhaps suggesting a role for pseudopodia in the mechanism 
of bone resorption. Osteoclasts are also found to undergo a 
continuous loss and incorporation of nuclei in the maintenance 
of their activity (Young, 1962).
It seems likely that osteoclasts do not have receptors for 
PTH, which stimulates bone resorption, but it is probable that they 
have CT receptors (Chambers, et. al. 1982), Parathyroid hormone
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may influence osteoclastic bone via its effect on osteoblasts
(Rodan, et. al, 1981) and the adenylate cyclase system (Luben,
et.al, 1975; Braidman, et. al, 1981).
Osteoblasts, as well as osteoclasts, are influenced by PTH,
prostaglandins and l,25(0H>2Dg (Rodan, et. al* 1981; Walters,
et. al. 1982), In their studies of the role of osteoblasts in
bone resorption, Rodan, et, al. (1981) have found that PTH,
generally a bone-resorbing agent, affects osteoblasts, bone-
forming cells, in several ways : increasing adenylate cyclase
activity to increase cyclic AMP (cAMP), the activation of cAMP-
dependent protein kinase, the inhibition of collagen synthesis,
inhibition of AP activity, stimulation of Ca-uptake, production
of cell-shape changes resulting in a more relaxed arrangement of
osteoblasts. It would seem that these changes are communicated
chemotactically to osteoclasts, which are attracted to the site
and proceed to breakdown the bone matrix using their projections
and the enzymes contained inside. Ramp, et, al. (1982) have found
that PTH generally causes an increase in the level of cAMP within
the skeleton and suggest a role for it as the secondary messenger
involved in bone resorption.
Peck, et. al. (1981) showed that the cAMP increase associated
with the stimulation of osteoblasts by PTH is directly linked to
2+increases in extracellular Ca concentrations, which in turn
2+increase the activity of PTH. The results suggest that Ca is
2+also involved in communicating the influence of PTH, with Ca in 
effect controlling the cAMP response to PTH stimulation of osteoblasts 
and therefore the activity of adenylate cyclase, which acts on ATP 
to produce cAMP, or by inhibiting the use of cAMP.
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The more general effects of PTH, CT and l,25(0H)2Dg involve 
the control of serum calcium levels. Ramp, et, al. (1982) looked
at the action of PTH on bone and found that it affects both bone
formation and resorption, with high levels stimulating bone
resorption and then bone formation, and lower levels influencing
mainly bone formation; two sides to PTH activity, as found in 
45 47Ca, Ca studies in the main text. The release of calcium from 
bone via osteoclastic bone resorption is, however, slow and PTH has 
been found to be responsible for speedy increases in the level of 
serum calcium, the suggestion now being that it acts on bone extra­
cellular fluid, which somehow compels the prompt release of calcium 
from bone.
Various studies have shown that CT increases bone formation, 
although it has no direct effect on collagen formation or mineralisation 
CRaisz, et. al. 1981), but Weiss, et. al. (1981) have found that the 
administration of CT following a period of bone formation actually 
suppresses any further bone formation, meaning that CT also has a 
dual effect on bone metabolism. Where PTH stimulates the release 
of calcium into bone extracellular fluid, CT acts to inhibit that 
release (Ramp, et. al. 1982), which would seem to be important 
in the control of hypercalcaemia during feeding.
Vitamin D and its metabolites are known to have great 
influence on bone metabolism and calcium homeostasis, allowing the 
release of calcium from bone (Putkey, et. al. 1982; Ramp, et. al.
1982), with l,25(0H)2Dg, for example, stimulating osteoclastic bone 
resorption and inhibiting bone collagen synthesis. In cases of 
severe vitamin D deficiency, bone fails to mineralise normally and 
there is a decrease in osteoclastic activity, however the 
administration of vitamin Dg to such patients manifests itself in
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the resumption of calcification, while no detectable change in 
Serum calcium levels are found. The lack of change in serum 
calcium levels on the application of vitamin suggests that it 
too, like PTH and CT, somehow acts directly on bone in times of 
calcium crisis (Putkey, et. al. 1982), Interestingly, although 
PTH has been shown to act directly on bone, it cannot do so in 
vitamin D-deficient animals (Crowell, et. al. 1981).
It has been suggested that a lack of exposure to vitamin D 
in the environment, either from the sun or the diet, may be 
responsible for the expression of rickets and osteomalacia in 
certain communities, as discussed in the main text of the thesis. 
However, Sasson, et. al. (1982) maintain that phytate contained in 
the unleavened bread of Bedouins is responsible for their mineral 
defects; the argument will, doubtless, continue.
Many of the studies concerning the effects of various 
factors on bone metabolism have used in vitro cell and organ 
cultures as their experimental model, the importance of which have 
already been discussed earlier in the thesis. More recently, 
several groups have concentrated on the characterisation of the ' 
cells grown in culture and the isolation of specific cell types.
Parry, et. al. (1981) isolated cells from a human iliac crest 
bone biopsy of a 12 year old girl. Once established in culture 
the cells produced alkaline phosphatase levels lOx those found 
in the medium of comparable skin cells, collagen of the type 
associated with bone-forming cells was also detected; when 
cultured in chambers grown inside mammalian peritoneal cavities, 
the cells were found to have produced an amorphous calcium deposit. 
These results compare well with results following the isolation of 
living cells, successfully achieved by Bard, et. al. in 1972. It
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is more common to isolate cells from calvaria of rodents, as 
attempted and described in the main text. Aubin, et. al. (1982) 
obtained many clones of cells on digestion of foetal rat calvaria 
and found cells responsive to PTH and prostaglandin E^, the clones 
also produced type I (bone) and type III collagen as well as matrix 
components in the form of glycosaminoglycans.
Simmons, et. al. (1982) also cultured bone cells in the 
peritoneal cavities of mice, finding that osteoblast-like cells 
formed mineralised bone in proportion to AP activity, detected in 
the environs, and in association with type I collagen. Wong (1982) 
has been working on the separation of osteoblast-like (OB) and 
osteoclast-like (OC) cells using sedimentation techniques, producing 
cells of different sizes in 4 fractions, which were further 
characterised, following 6 days in culture, using biochemical 
criteria. These results indicate promise in the growth of bone 
from cells in vitro and more intricate experimentation concerning 
bone metabolism in vitro in the future.
The growth of bone from bone rudiments has been attempted 
for many years, with Rajan, et. al, (1970) placing the intact 
digits of 12-16 week human embryos in culture and growing the 
cartilagenous rod in culture until it had increased significantly 
in length, within 6 days. Recent attempts by Tenenbaum et. al, 
(1982), using periostea from 17-day-old emryonic chick calvaria, 
folded and grown in culture on plasma clots, produced osteoid 
tissue between the folds, which subsequently mineralised in the 
presence of the AP substrate beta-glycerophosphate.
Perhaps the formation of bone in vitro could be assessed 
using the new staining method developed by Kimmel, et. al. (1981), 
which stains bone and cartilage specifically and gives results 
within a few days. This stain could also be used, perhaps, to judge
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the effects of metabolites on in vitro bone cultures, as it has 
been developed for use particularly with young bone.
Diphosphonates were mentioned in chapter seven and are 
generally thought to be inhibitors of bone turnover. Further 
studies looking at the possible uses of both naturally-occurring 
and synthetic diphasphonate compounds have produced promising 
results. The diphosphonates disodium ethylidine-l-hydroxy-1,1- 
diphosphonate (EHDP) and dichloromethylene diphosphonate (CI^MDP), 
have been shown to inhibit soft tissue calcification and bone 
resorption, but McGuire, et. al. (1982) suggest a possible role for 
it in preventing inflammation which produces arthritis. However, 
a study by Boyce, et. al. (1982) has shown that while EHDP does 
reduce mineralisation, but at the doses required to reduce the 
increased bone resorption found in Paget*s Disease, the decrease 
in mineralisation is so dramatic as to result in osteomalacia, 
therefore strict control of the drug dosage is required. A study 
of the activity of EHDP has also shown that it affects all bone 
cell types and not one specifically (Felix, et. al. 1981).
The main interest in this thesis concerned osteoporosis, a 
bone disorder found most commonly in post-menopausal women. A 
common factor thought to be the cause of the decrease in bone mass 
found in these individuals is the notable decrease in serum 
oestrogen levels, consequently oestrogen has been used in the 
treatment of this post-menopausal bone loss. Nevertheless, a 
recent survey by Boyle (1982) shows that many general practitioners 
prescribe vitamin D, on its own or in association with oestrogen, 
as treatment, suggesting that vitamin D deficiency may also play a 
part in this disorder. The use of eostrogen in the treatment of 
bone loss would also seem to be inadvisable following the work by
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Raisz, et. al. (1981) which shows that oestrogen actually decreases 
bone growth and that formation of bone at the menopause is actually 
maintained, even increased. They found that there are no oestrogen 
receptors in bone and that it has no particular effect on collagen 
synthesis or bone resorption. Results did suggest that oestrogen 
may act on vitamin D, indicating perhaps that the G.P.'s are correct 
in their treatment, that it may increase muscle mass and so increase 
bone mass by mechanical stress, but that resorption of bone at the 
menopause probably increases as a result of some osteoblastic 
defect.
An interesting paper by Mazess (1982) shows that there is no 
history of sustained loss of trabecular bone following the menopause, 
that minimal changes in the mineral content of bone, alone, may in 
effect greatly alter the strength of bone, making it liable to 
pseudofractures, or decreases in the circulation may reduce the 
amount of energy available to sustain the bone, leading to a 
reduction in mechanical strength. Mazess (1982) also shows that 
men also lose bone as they'get older, although less than women, 
and that the loss is slow and progressive, but accelerated in 
women at the menopause. Oestrogen does inhibit the loss of bone 
at the menopause, but its effectiveness as a preventive agent 
decreases again, perhaps indicating that, after a while, the loss 
of oestrogen is no longer a factor in ageing bone loss.
Another possible *cure* or treatment of osteoporosis, which, 
although it may not be caused solely by the loss of oestrogen, is 
still a dominant feature in the elderly, has been studied by Dent, 
et. al. (1980). They looked at a microcrystalline calcium hydroxy- 
apatite compound (MCHC), a bone mineral compound, in association 
with dihydrotachysterol, and found that the treatment improved the 
calcium balance in patients with osteogenesis inperfecta, although
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it produced no obvious changes in the bone itself, and they hope 
that it may be used for osteoporotic patients. Clearly, though, a
greater understanding of the causes and effects of bone disorders 
and disorders of calcium metabolism is needed before any great 
steps can be made in their eradication.
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